{
 "updated": "2026-11-09",
 "counts": {
  "total": 100,
  "endures": 51,
  "fails": 49
 },
 "claims": [
  {
   "id": "ablative-laser-pih-dark-skin",
   "layer": "endures",
   "domain": "光电",
   "part": "面部",
   "claim": "剥脱性点阵激光后的色素异常风险，在Fitzpatrick III型及以上、肤色较深的人群明显更高。",
   "plain": "肤色越深，表皮黑色素越多，热损伤后的炎症反应越容易转成色素沉着。剥脱性点阵激光去表皮、热作用深，亚洲人做完出现反黑和色沉的报告明显多于白种人，所以参数要更保守、术前术后防晒要更严。",
   "evidence": [
    {
     "year": 2010,
     "type": "队列研究",
     "grade": "中",
     "label": "亚洲人剥脱性点阵二氧化碳激光的临床研究记录了色素沉着等不良反应",
     "ref": "PMID:20976801"
    },
    {
     "year": 2011,
     "type": "队列研究",
     "grade": "弱",
     "label": "1550nm点阵激光在亚洲人中的不良反应以炎症后色素沉着为主",
     "ref": "PMID:22151942"
    },
    {
     "year": 2013,
     "type": "系统综述",
     "grade": "强",
     "label": "深肤色激光治疗综述指出色素改变是主要风险，需按肤色调整参数",
     "ref": "PMID:24098905"
    },
    {
     "year": 2017,
     "type": "系统综述",
     "grade": "强",
     "label": "亚洲人点阵治疗综述明确剥脱性治疗的主要并发症是色沉与黄褐斑反跳",
     "ref": "PMID:27605303"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "剥脱性点阵激光治疗黄褐斑的Meta分析记录了一过性色沉与疱疹等不良反应",
     "ref": "PMID:38379033"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "中",
     "label": "深肤色III型及以上患者剥脱性点阵激光后色素沉着发生率约两成至四成",
     "ref": "PMID:40820662"
    }
   ],
   "first_year": 2010,
   "last_year": 2025,
   "n_evidence": 6,
   "scope": "浅肤色人群风险较低但并非没有；黄褐斑就医者做剥脱性治疗更容易反黑，通常不作为首选。",
   "ask": [
    "我的Fitzpatrick分型是几型？",
    "这个参数在亚洲人里的反黑概率大概多少？",
    "术前要不要先做小面积测试？"
   ],
   "status": "verified"
  },
  {
   "id": "laser-hair-removal-cycle",
   "layer": "endures",
   "domain": "光电",
   "part": "全身",
   "claim": "激光脱毛的效果取决于毛囊是否处于生长期、毛发颜色和部位；生长期含黑色素的毛囊对光热更敏感，休止期毛囊基本不受影响，所以需要按毛发周期分次治疗。",
   "plain": "毛发周期分生长期、退行期和休止期，只有生长期毛囊含较多黑色素、与毛球供血相连，激光的热量才能破坏它。动物实验显示生长期毛囊对694纳米激光敏感，退行期和休止期毛囊抵抗。不同部位周期长度不同，所以治疗间隔和次数要按部位定，单次治疗只能覆盖当时处于生长期的毛囊。",
   "evidence": [
    {
     "year": 1998,
     "type": "队列研究",
     "grade": "弱",
     "label": "小鼠模型显示生长期含黑色素的毛囊对694纳米激光敏感，退行期和休止期毛囊抵抗",
     "ref": "PMID:9665395"
    },
    {
     "year": 2008,
     "type": "指南",
     "grade": "强",
     "label": "激光与强脉冲光毛发减少指南要求按毛发周期安排多次治疗，并规范使用长期毛发减少一词",
     "ref": "PMID:18688107"
    },
    {
     "year": 2013,
     "type": "系统综述",
     "grade": "强",
     "label": "激光脱毛综述指出不同波长适用于不同肤色，需多次治疗获得长期毛发减少",
     "ref": "PMID:23332016"
    },
    {
     "year": 2019,
     "type": "系统综述",
     "grade": "强",
     "label": "低能量家用设备单次脉冲即可诱导毛囊进入退行期，说明周期状态影响反应",
     "ref": "PMID:30681170"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "脱毛方法综述指出激光和强脉冲光属于暂时性脱毛，效果受毛发颜色和皮肤类型限制",
     "ref": "PMID:34524781"
    }
   ],
   "scope": "白色、灰色和浅金色毛发缺少黑色素，激光效果差；妊娠、激素异常和某些药物引起的多毛要先查原因。",
   "ask": [
    "我的毛发颜色和肤色适合哪种波长？",
    "这个部位的治疗间隔是多久？",
    "大概需要几次才能达到稳定减少？"
   ],
   "status": "verified",
   "first_year": 1998,
   "last_year": 2021,
   "n_evidence": 5
  },
  {
   "id": "ipl-erythema-rosacea",
   "layer": "endures",
   "domain": "光电",
   "part": "面部",
   "claim": "强脉冲光改善玫瑰痤疮的红斑与毛细血管扩张有低到中等强度的证据；对炎症性痤疮的作用较弱，多作为辅助治疗。",
   "plain": "强脉冲光是宽谱光，血红蛋白吸收后转为热，封闭扩张的毛细血管、减轻面部潮红。按GRADE评级的系统综述里，激光和强脉冲光改善玫瑰痤疮红斑与毛细血管扩张的证据为低到中等强度；与脉冲染料激光相比，两者在五成以上清除率上无差异，强脉冲光在更高清除率上略占优。对炎症性痤疮，Meta分析显示强脉冲光不如光动力，多作为联合治疗。",
   "evidence": [
    {
     "year": 2010,
     "type": "系统综述",
     "grade": "强",
     "label": "综述梳理强脉冲光在血管病变、色素、痤疮和光老化中的参数选择与适应证",
     "ref": "PMID:20166155"
    },
    {
     "year": 2019,
     "type": "系统综述",
     "grade": "强",
     "label": "152项随机对照试验、20944人的系统综述按GRADE评级，激光与强脉冲光改善红斑和毛细血管扩张的证据为低到中等强度",
     "ref": "PMID:30585305"
    },
    {
     "year": 2020,
     "type": "系统综述",
     "grade": "强",
     "label": "8项随机对照试验450人的Meta分析显示强脉冲光对炎症性痤疮的改善不如对照和光动力，亚洲人群更差",
     "ref": "PMID:32623823"
    },
    {
     "year": 2022,
     "type": "系统综述",
     "grade": "强",
     "label": "42项研究的综述评估强脉冲光用于痤疮、玫瑰痤疮等炎症性皮肤病，证据质量不一",
     "ref": "PMID:35913536"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "4项研究141人的Meta分析显示强脉冲光与脉冲染料激光在五成清除率上无差异，七成五以上清除率略优，疼痛更高",
     "ref": "PMID:39240125"
    }
   ],
   "scope": "对单纯潮红、红斑毛细血管扩张型更适用；丘疹脓疱型需联合药物，深肤色和近期暴晒者要调整参数。",
   "ask": [
    "我的玫瑰痤疮是哪一型，适合做强脉冲光吗？",
    "做几次能看出效果，间隔多久一次？",
    "做完以后潮红和反黑的风险怎么管理？"
   ],
   "status": "verified",
   "first_year": 2010,
   "last_year": 2024,
   "n_evidence": 5
  },
  {
   "id": "melasma-lowfluence-laser",
   "layer": "endures",
   "domain": "光电",
   "part": "面部",
   "claim": "黄褐斑的光电治疗中，高能量、高密度更容易诱发炎症后色素沉着；低能量、大光斑的方案相对更稳。",
   "plain": "黄褐斑的黑色素细胞本来就活跃，热损伤一大，炎症后色素沉着和反黑的风险就上来。低能量、大光斑、拉长间隔的做法靠累积效应起效，单次反应轻，更适合亚洲皮肤；高能量打法短期看着有效，一旦反黑反而更难处理。",
   "evidence": [
    {
     "year": 2012,
     "type": "系统综述",
     "grade": "强",
     "label": "综述梳理黄褐斑治疗从高能量转向低能量、大光斑的思路演变",
     "ref": "PMID:22640433"
    },
    {
     "year": 2017,
     "type": "系统综述",
     "grade": "强",
     "label": "亚洲皮肤点阵治疗综述建议低密度、多次、长间隔以降低色素沉着风险",
     "ref": "PMID:27605303"
    },
    {
     "year": 2021,
     "type": "队列研究",
     "grade": "中",
     "label": "随机对照显示深肤色IV至V型做激光后色素沉着与反黑发生率高",
     "ref": "PMID:33002283"
    },
    {
     "year": 2021,
     "type": "指南",
     "grade": "强",
     "label": "《中国黄褐斑诊疗专家共识（2021版）》给出分型与治疗原则，激光列为联合手段",
     "ref": "DOI:10.35541/cjd.20200900"
    },
    {
     "year": 2022,
     "type": "系统综述",
     "grade": "强",
     "label": "低能量Q开关激光治疗黄褐斑的系统综述提示疗效与复发并存",
     "ref": "PMID:35888655"
    }
   ],
   "first_year": 2012,
   "last_year": 2022,
   "n_evidence": 5,
   "scope": "稳定期、表皮型黄褐斑更适用；活动期、炎症明显或近期暴晒后应先控制诱因。",
   "ask": [
    "我的黄褐斑是活动期还是稳定期？",
    "这次治疗的能量密度大概在什么范围？",
    "做完后反黑的风险有多高，怎么处理？"
   ],
   "status": "verified"
  },
  {
   "id": "fractional-laser-acne-scar-evidence",
   "layer": "endures",
   "domain": "光电",
   "part": "面部",
   "claim": "点阵激光是痤疮瘢痕治疗中研究较多的一类，证据以中小样本随机对照为主；剥脱性点阵比非剥脱更有效，但恢复期和色素异常风险更高，联合方案通常优于单用。",
   "plain": "点阵激光在皮肤上打出微小热损伤带，靠胶原重塑改善痘坑。26项研究的综述显示剥脱性点阵改善幅度约26%至83%，非剥脱约26%至50%，剥脱性红斑和色沉更明显。Cochrane综述提醒整体证据质量不高，研究多为短期、评估标准不统一；后来的Meta分析显示联合治疗排名更靠前。",
   "evidence": [
    {
     "year": 2012,
     "type": "系统综述",
     "grade": "强",
     "label": "26项研究的综述显示剥脱性点阵激光改善痘坑26%至83%，非剥脱26%至50%，剥脱性色沉更多",
     "ref": "PMID:22296284"
    },
    {
     "year": 2016,
     "type": "系统综述",
     "grade": "强",
     "label": "Cochrane综述认为痘坑治疗整体缺少高质量证据，研究方法和评估标准不统一",
     "ref": "PMID:27038134"
    },
    {
     "year": 2023,
     "type": "系统综述",
     "grade": "强",
     "label": "7项研究的Meta分析显示点阵皮秒与其他点阵激光疗效无显著差异，但色沉和疼痛更少",
     "ref": "PMID:37310182"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "39项比较研究的系统综述显示剥脱性激光对萎缩性瘢痕更有效，疼痛和恢复期也更长",
     "ref": "PMID:40515775"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "68项随机对照试验的网状Meta分析显示激光联合PRP或填充排名靠前",
     "ref": "PMID:41081097"
    }
   ],
   "scope": "冰锥型、车厢型和滚动型痘坑反应不同；深肤色、活动期痤疮和瘢痕体质者要降低能量并先控制炎症。",
   "ask": [
    "我的痘坑以哪种类型为主？",
    "选剥脱还是非剥脱，恢复期差多久？",
    "需要几次治疗，联合什么方案？"
   ],
   "status": "verified",
   "first_year": 2012,
   "last_year": 2025,
   "n_evidence": 5
  },
  {
   "id": "isotretinoin-laser",
   "layer": "endures",
   "domain": "光电",
   "part": "面部",
   "claim": "非剥脱点阵激光与口服异维A酸之间不存在固定的六个月停药禁忌；剥脱性治疗的保守要求仍更严格。",
   "plain": "早期基于瘢痕风险的说法被后来的系统评价修正：非剥脱点阵激光和微针在服药期间做，风险没有明显升高；全剥脱激光和机械磨削仍然不推荐在服药期间进行。是否停药、停多久，要按治疗方式和个体情况定。",
   "evidence": [
    {
     "year": 2017,
     "type": "指南",
     "grade": "强",
     "label": "ASDS共识按治疗方式分级，认为非剥脱激光与微针在服药期间可谨慎进行",
     "ref": "PMID:28498204"
    },
    {
     "year": 2017,
     "type": "系统综述",
     "grade": "强",
     "label": "系统综述与共识建议：全剥脱激光和机械磨削不推荐在异维A酸治疗期间进行",
     "ref": "PMID:28658462"
    },
    {
     "year": 2017,
     "type": "指南",
     "grade": "强",
     "label": "标准诊疗指南按操作类型给出异维A酸使用者的处理建议",
     "ref": "PMID:29491653"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "中",
     "label": "深肤色患者服异维A酸期间做剥脱性点阵激光，色素沉着反而低于未服药组",
     "ref": "PMID:40820662"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "综述汇总异维A酸与操作相关的皮肤并发症报告，提示风险与操作类型相关",
     "ref": "PMID:39568321"
    }
   ],
   "first_year": 2017,
   "last_year": 2025,
   "n_evidence": 5,
   "scope": "全剥脱激光、机械磨削、有瘢痕体质或近期有皮肤感染的人，仍应推迟或调整方案。",
   "ask": [
    "我做的是剥脱还是非剥脱？",
    "服药情况需要提前告诉操作医生吗？",
    "如果坚持要做，风险和替代方案是什么？"
   ],
   "status": "verified"
  },
  {
   "id": "rf-microneedling-complications",
   "layer": "endures",
   "domain": "光电",
   "part": "面部",
   "claim": "射频微针的并发症以红斑、水肿和疼痛等短暂反应为主；也可能出现色素改变、纹理异常、脂肪萎缩、瘢痕和烧伤，风险与能量设置、肤色和操作经验有关。",
   "plain": "射频微针靠微针把射频能量送入真皮，热损伤深度和能量设置决定反应轻重。系统评价里多数不良反应是短暂红斑和水肿，但监管数据库的报告显示，纹理改变、色素异常和脂肪萎缩也会发生，面部、颈部和腹部都有记录。深肤色、能量过高、重复治疗和操作不熟练会增加风险。",
   "evidence": [
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "42项高质量研究的综述认为射频微针可重复、安全使用，也可用于深肤色人群",
     "ref": "PMID:33577211"
    },
    {
     "year": 2026,
     "type": "系统综述",
     "grade": "强",
     "label": "22项研究的系统综述显示不良反应以短暂红斑和水肿为主，未见严重并发症",
     "ref": "PMID:41947517"
    },
    {
     "year": 2026,
     "type": "队列研究",
     "grade": "中",
     "label": "FDA器械不良事件数据库中114份报告含224个事件，纹理改变、色素异常和脂肪萎缩最常见",
     "ref": "PMID:41886649"
    },
    {
     "year": 2026,
     "type": "队列研究",
     "grade": "中",
     "label": "2020至2025年86份报告含145个不良事件，脂肪萎缩、瘢痕和炎症后红斑最多，FDA已发出警告",
     "ref": "PMID:42430734"
    },
    {
     "year": 2026,
     "type": "队列研究",
     "grade": "中",
     "label": "随机分面对照显示射频微针比点阵二氧化碳激光恢复更快、色素事件更少",
     "ref": "PMID:42312398"
    }
   ],
   "scope": "能量过高、同一部位反复治疗、深肤色或近期暴晒的人风险更高；出现持续凹陷、色沉或瘢痕要尽早复诊。",
   "ask": [
    "这次治疗的能量和遍数是多少？",
    "我的肤色出现色沉或脂肪萎缩的风险有多高？",
    "术后红斑、结痂一般持续多久？"
   ],
   "status": "verified",
   "first_year": 2021,
   "last_year": 2026,
   "n_evidence": 5
  },
  {
   "id": "tattoo-removal-color-depth",
   "layer": "endures",
   "domain": "光电",
   "part": "全身",
   "claim": "文身去除的效果取决于墨水颜色、颗粒大小、色素深度、皮肤类型和激光波长；黑蓝色反应较好，黄绿红等颜色需要匹配波长，部分颜色难以清除。",
   "plain": "激光把墨水颗粒打碎，再由巨噬细胞和淋巴系统慢慢清走。黑色和蓝黑色对1064纳米和755纳米激光反应较好；红色、橙色要532纳米，绿色和黄色更难匹配。动物实验显示1064纳米对黑文身效果最好，色素颗粒大小和巨噬细胞募集与清除效果相关；文身越深、颜色越杂、层次越多，需要的次数越多。",
   "evidence": [
    {
     "year": 2015,
     "type": "系统综述",
     "grade": "强",
     "label": "文身去除综述把影响因素分为激光、文身和宿主三类，包括大小、深度、颜色和免疫反应",
     "ref": "PMID:25949018"
    },
    {
     "year": 2022,
     "type": "系统综述",
     "grade": "强",
     "label": "文身去除综述指出532、1064、694和755纳米各有适用颜色，皮秒激光正在增加",
     "ref": "PMID:35604505"
    },
    {
     "year": 2022,
     "type": "队列研究",
     "grade": "弱",
     "label": "大鼠文身模型显示1064纳米对黑文身效果最好，色素颗粒直径和巨噬细胞募集与疗效相关",
     "ref": "PMID:35289435"
    },
    {
     "year": 2026,
     "type": "系统综述",
     "grade": "强",
     "label": "综述指出波长、脉宽、色素化学和深度共同决定效果，785纳米只适合部分冷色墨水",
     "ref": "PMID:42548855"
    }
   ],
   "scope": "黄绿色、浅色和含金属成分的墨水反应差；瘢痕体质、深肤色和近期暴晒会增加色沉与瘢痕风险。",
   "ask": [
    "我的文身是什么颜色、多深？",
    "用哪个波长，预计几次？",
    "出现色沉或瘢痕怎么处理？"
   ],
   "status": "verified",
   "first_year": 2015,
   "last_year": 2026,
   "n_evidence": 4
  },
  {
   "id": "blepharoplasty-technique-recurrence",
   "layer": "endures",
   "domain": "手术",
   "part": "眼周",
   "claim": "重睑术式各有适用范围；埋线、小切口与切开在适应证、复发率和修复难度上不同，埋线法皱襞变浅或消失的风险更高。",
   "plain": "埋线靠缝线把皮肤和睑板或提上睑肌腱膜固定，创伤小、恢复快，但线结松动后皱襞会变浅或消失；切开法去皮去脂、固定更牢，恢复期长，修复时组织已经改变，难度更大。选择要看眼皮厚度、脂肪量、皮肤松弛度和既往手术史，不能只按恢复期长短决定。",
   "evidence": [
    {
     "year": 2009,
     "type": "队列研究",
     "grade": "弱",
     "label": "51例连续埋线法长期随访，作者指出传统埋线法复发率高，改良后未见皱襞消失",
     "ref": "PMID:19421810"
    },
    {
     "year": 2018,
     "type": "队列研究",
     "grade": "弱",
     "label": "切开法改良技术的研究记录了术后复发和缝线外露的风险",
     "ref": "PMID:30191281"
    },
    {
     "year": 2020,
     "type": "系统综述",
     "grade": "强",
     "label": "亚洲重睑术并发症综述把皱襞、高度、缝线和外形问题分类列出",
     "ref": "PMID:33368082"
    },
    {
     "year": 2022,
     "type": "队列研究",
     "grade": "弱",
     "label": "埋线法改良研究指出缝线松动是皱襞回退或消失的常见原因",
     "ref": "PMID:34896040"
    },
    {
     "year": 2023,
     "type": "系统综述",
     "grade": "强",
     "label": "亚洲上睑修复综述指出多次并发症后组织有限，修复方案需要按成因设计",
     "ref": "PMID:36396250"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "中",
     "label": "138例重睑相关投诉分析显示不对称是最常见原因，原发手术投诉最多",
     "ref": "PMID:39998431"
    }
   ],
   "scope": "眼皮薄、脂肪少、皮肤不松的人更适合埋线；皮肤松弛明显、脂肪厚或既往修复者，切开或小切口更稳，但仍可能出现不对称。",
   "ask": [
    "我的眼皮条件和脂肪量适合哪种术式？",
    "埋线后如果变浅，多久可以修复？",
    "修复时原来的线会影响手术吗？"
   ],
   "status": "verified",
   "first_year": 2009,
   "last_year": 2025,
   "n_evidence": 6
  },
  {
   "id": "thread-lift-durability",
   "layer": "endures",
   "domain": "手术",
   "part": "面部",
   "claim": "埋线提升的维持时间与线材、埋置层次和病例选择有关，公开证据以短期随访为主。",
   "plain": "线的倒刺抓住组织，靠异物反应和纤维包裹形成支撑，不是把组织重新固定到骨膜上。系统评价发现多数研究随访短、效果有限，少数报告效果好的研究由厂商资助。把它看成几个月到一年左右的过渡手段，比当成手术替代更贴合现有证据。",
   "evidence": [
    {
     "year": 2010,
     "type": "系统综述",
     "grade": "强",
     "label": "早期综述认为倒刺线提升的证据以短期、小样本研究为主",
     "ref": "PMID:20618559"
    },
    {
     "year": 2010,
     "type": "队列研究",
     "grade": "中",
     "label": "29例埋线后并发症与早期复发的发生情况被记录",
     "ref": "PMID:20100265"
    },
    {
     "year": 2018,
     "type": "系统综述",
     "grade": "强",
     "label": "系统综述认为十年间没有实质证据支持埋线的疗效与安全性，多数研究提升效果有限",
     "ref": "PMID:29481392"
    },
    {
     "year": 2019,
     "type": "系统综述",
     "grade": "强",
     "label": "综述把埋线称为双刃剑，列出线材相关并发症与再手术问题",
     "ref": "PMID:30893160"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "综述梳理可吸收线材的降解周期与组织反应，维持时间受线材与层次影响",
     "ref": "PMID:33469333"
    },
    {
     "year": 2023,
     "type": "撤稿",
     "grade": "强",
     "label": "声称埋线效果持久的论文已被撤稿，提示该领域证据质量存疑",
     "ref": "PMID:36762403"
    }
   ],
   "first_year": 2010,
   "last_year": 2023,
   "n_evidence": 6,
   "scope": "皮肤明显松弛、脂肪堆积为主的人，单靠埋线改善有限，通常需要手术或其他方式。",
   "ask": [
    "用的线材是什么材质、能维持多久？",
    "随访计划是多长时间？",
    "如果效果不满意，取出或修复的难度大不大？"
   ],
   "status": "verified"
  },
  {
   "id": "liposuction-serious-complications",
   "layer": "endures",
   "domain": "手术",
   "part": "全身",
   "claim": "抽脂不是小手术；脂肪栓塞、肺栓塞、深部感染、内脏穿孔和麻醉相关并发症都可能致命，风险与抽吸量、麻醉方式和场所资质有关。",
   "plain": "抽脂要先把大量含麻药的液体打进皮下，再负压吸出，液体负荷、麻醉和脂肪进入血管都可能出问题。德国五年72例严重并发症的分析里有23例死亡，感染、出血、内脏穿孔和肺栓塞是主要死因，多数在术后24小时内出现。抽吸量越大、联合手术越多，风险越高。",
   "evidence": [
    {
     "year": 2005,
     "type": "系统综述",
     "grade": "强",
     "label": "抽脂、腹壁整形与拉皮的死亡和并发症文献综述指出各研究统计口径差异大",
     "ref": "PMID:16029697"
    },
    {
     "year": 2008,
     "type": "队列研究",
     "grade": "中",
     "label": "德国1998至2002年72例严重并发症中含23例死亡，感染、出血、穿孔和肺栓塞为主要原因",
     "ref": "PMID:18520866"
    },
    {
     "year": 2008,
     "type": "系统综述",
     "grade": "强",
     "label": "抽脂后脂肪栓塞综合征的综述指出诊断困难、无特异治疗，重点在预防和早期识别",
     "ref": "PMID:18509699"
    },
    {
     "year": 2019,
     "type": "系统综述",
     "grade": "强",
     "label": "24项安全性研究的系统综述显示肿胀麻醉局部麻醉相对最安全，全身麻醉和联合手术风险更高",
     "ref": "PMID:30702445"
    },
    {
     "year": 2026,
     "type": "系统综述",
     "grade": "强",
     "label": "41项研究的系统综述显示感染、脂肪栓塞和血肿是最常见并发症，臀部脂肪移植栓塞率约7.77%",
     "ref": "PMID:41091202"
    }
   ],
   "scope": "小范围、肿胀麻醉、单次手术风险较低；大容量抽脂、全身麻醉、多部位联合和术后长途旅行会放大风险。",
   "ask": [
    "计划抽多少毫升，用什么麻醉？",
    "手术在哪里做，有没有抢救和转诊条件？",
    "术后出现气短、胸痛或发热怎么办？"
   ],
   "status": "verified",
   "first_year": 2005,
   "last_year": 2026,
   "n_evidence": 5
  },
  {
   "id": "rhinoplasty-material-tradeoffs",
   "layer": "endures",
   "domain": "手术",
   "part": "鼻部",
   "claim": "鼻整形材料没有一种适合所有人；硅胶、膨体与自体软骨在感染、移位、吸收和修复难度上各有代价。",
   "plain": "硅胶假体易雕刻、取出相对容易，但长期可能出现移位、透光和包膜问题；膨体固定性好，感染后处理更麻烦；自体软骨没有排异，感染和穿出率低，但要取肋或耳软骨，存在吸收、变形和供区问题。系统评价显示自体软骨感染风险更低，硅胶的二次手术率更高，选择要看鼻部条件和既往手术史。",
   "evidence": [
    {
     "year": 2011,
     "type": "系统综述",
     "grade": "强",
     "label": "鼻背处理综述显示自体组织和合成材料均有可接受结果，合成材料移位和穿出更多",
     "ref": "PMID:22030516"
    },
    {
     "year": 2018,
     "type": "系统综述",
     "grade": "强",
     "label": "53项研究的Meta分析显示自体肋软骨总并发症率约14%，多用于修复病例，膨体并发症率约6%",
     "ref": "PMID:29705398"
    },
    {
     "year": 2022,
     "type": "系统综述",
     "grade": "强",
     "label": "1233例的Meta分析显示自体软骨满意度更高、并发症和二次手术率低于硅胶",
     "ref": "PMID:35365029"
    },
    {
     "year": 2022,
     "type": "系统综述",
     "grade": "强",
     "label": "3803例的Meta分析显示合成材料鼻背增高的总并发症率约2.75%，修复率约6.4%",
     "ref": "PMID:35451637"
    },
    {
     "year": 2026,
     "type": "系统综述",
     "grade": "强",
     "label": "28项研究的系统综述显示自体软骨感染和穿出更低，合成材料长期感染和穿出更高",
     "ref": "PMID:42499483"
    }
   ],
   "scope": "皮肤薄、既往感染或多次修复的人，自体材料通常更稳；皮肤厚、鼻背需要大量填充的人，材料选择要权衡供区和外形。",
   "ask": [
    "我的鼻部皮肤厚度适合哪种材料？",
    "这个材料感染或移位后怎么处理？",
    "如果以后要修复，取出难度大不大？"
   ],
   "status": "verified",
   "first_year": 2011,
   "last_year": 2026,
   "n_evidence": 5
  },
  {
   "id": "fat-graft-retention",
   "layer": "endures",
   "domain": "手术",
   "part": "面部",
   "claim": "自体脂肪移植的体积保留率受处理方式、注射层次和受区血供影响；长期保留率低于早期文献报告的水平。",
   "plain": "移植的脂肪要先经历吸收，再靠受区建立血供活下来，所以打进去不等于留下来。系统评价汇总的客观测量结果多在五成上下，年轻、受区血供好的人保留更多；早期文献里九成以上的说法，多来自主观估计和短期随访。",
   "evidence": [
    {
     "year": 2013,
     "type": "队列研究",
     "grade": "中",
     "label": "比较不同采集与处理方式对脂肪活性的影响，处理方式影响移植效果",
     "ref": "PMID:23584621"
    },
    {
     "year": 2014,
     "type": "队列研究",
     "grade": "中",
     "label": "客观体积测量显示长期保留率约三成至五成，年龄与受区条件影响结果",
     "ref": "PMID:25028738"
    },
    {
     "year": 2018,
     "type": "队列研究",
     "grade": "中",
     "label": "三维体积分析比较三种脂肪处理方式，保留率存在差异",
     "ref": "PMID:29327032"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "系统综述与Meta分析汇总面部脂肪移植平均保留率约47%，区间41%至53%",
     "ref": "PMID:31940073"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "中",
     "label": "五年随访显示保留率与体重变化相关，常需再次移植",
     "ref": "PMID:39938464"
    }
   ],
   "first_year": 2013,
   "last_year": 2025,
   "n_evidence": 5,
   "scope": "瘢痕区、放疗后、血供差的受区保留率更低；体重大幅变化也会干扰对保留率的判断。",
   "ask": [
    "我的受区血供条件怎么样？",
    "脂肪是怎么处理的，用哪种注射层次？",
    "有没有客观测量手段能随访保留率？"
   ],
   "status": "verified"
  },
  {
   "id": "lower-blepharoplasty-fat-handling",
   "layer": "endures",
   "domain": "手术",
   "part": "眼周",
   "claim": "眼袋手术的效果取决于脂肪怎么处理，单纯切除与脂肪复位的适应证不同，不能一概而论。",
   "plain": "眼袋的膨出多半是眶隔脂肪移位加上皮肤与支持结构松弛，把这部分脂肪切掉，短期平了，年纪再大一点可能出现凹陷。脂肪复位把脂肪挪回眶缘后方固定，保留容积，适合以膨出为主、皮肤弹性还行的人。选择要看脂肪量、皮肤松弛度和既往手术史。",
   "evidence": [
    {
     "year": 2016,
     "type": "系统综述",
     "grade": "强",
     "label": "经结膜入路下睑成形术的综述，说明该入路适用于以脂肪膨出为主、皮肤松弛轻的人",
     "ref": "PMID:27499473"
    },
    {
     "year": 2019,
     "type": "队列研究",
     "grade": "中",
     "label": "改良下睑成形联合脂肪复位的病例系列，报告术后轮廓与并发症情况",
     "ref": "PMID:30734070"
    },
    {
     "year": 2021,
     "type": "队列研究",
     "grade": "中",
     "label": "脂肪复位与游离脂肪移植两种方式在下睑成形中的对比研究",
     "ref": "PMID:33595637"
    },
    {
     "year": 2024,
     "type": "队列研究",
     "grade": "中",
     "label": "经结膜脂肪复位成形术的回顾，讨论脂肪膨出程度与适应证的关系",
     "ref": "PMID:37220233"
    },
    {
     "year": 2026,
     "type": "队列研究",
     "grade": "中",
     "label": "经皮入路下睑成形中脂肪复位联合深层脂肪切除的技术报告与结果",
     "ref": "PMID:41051496"
    }
   ],
   "scope": "皮肤明显松弛、需要去皮的人，单做经结膜入路改善有限；既往做过眼袋手术的人组织已改变，修复难度更高。",
   "ask": [
    "我的眼袋是脂肪膨出为主，还是皮肤松弛为主？",
    "这个方案是切除脂肪还是复位固定？",
    "如果几年后出现凹陷，还能怎么修？"
   ],
   "status": "verified",
   "first_year": 2016,
   "last_year": 2026,
   "n_evidence": 5
  },
  {
   "id": "facelift-plane-durability",
   "layer": "endures",
   "domain": "手术",
   "part": "面部",
   "claim": "面部提升的维持时间与分离层次、筋膜处理和皮肤切除量有关；深平面与SMAS技术的差异，现有比较研究的结论并不一致。",
   "plain": "拉皮手术把松弛的软组织重新复位，效果按年计。深平面在骨膜下或深筋膜层分离，理论上的提升更持久，但并发症报告更高；SMAS折叠或切除创伤小，满意度也高。系统评价显示两种术式都能维持一年以上，深平面满意度略高、并发症也略多；长期随访研究多来自单一术者，证据等级有限。",
   "evidence": [
    {
     "year": 2016,
     "type": "队列研究",
     "grade": "中",
     "label": "25年1089例面部提升的观察显示随访超过3年困难，术式与病例选择共同影响持久性",
     "ref": "PMID:27348643"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "21项研究2896例的Meta分析显示深平面满意度94.4%、SMAS 87.8%，并发症分别为17.2%和10.3%",
     "ref": "PMID:40801931"
    },
    {
     "year": 2026,
     "type": "系统综述",
     "grade": "强",
     "label": "45项研究10784例的Meta分析显示深平面总体并发症率6.6%，未见长期面神经损伤",
     "ref": "PMID:42576065"
    },
    {
     "year": 2026,
     "type": "队列研究",
     "grade": "中",
     "label": "569例、16年随访的骨膜下中面部提升报告结果稳定、并发症少",
     "ref": "PMID:42009921"
    }
   ],
   "scope": "皮肤量多、筋膜松弛明显的人，提升层次比单纯去皮更重要；瘢痕体质、吸烟和高血压会增加并发症，不能只按术式名称判断。",
   "ask": [
    "手术在哪个层次分离，怎么处理筋膜？",
    "效果大概能维持几年，随访怎么安排？",
    "深平面和SMAS在我脸上各自的风险是什么？"
   ],
   "status": "verified",
   "first_year": 2016,
   "last_year": 2026,
   "n_evidence": 4
  },
  {
   "id": "ha-delayed-nodule-biofilm",
   "layer": "endures",
   "domain": "注射填充",
   "part": "面部",
   "claim": "玻尿酸填充后的迟发红肿与结节，机制上更接近低度感染和生物膜相关炎症；处理以溶解填充物为主，抗生素不作为首选。",
   "plain": "迟发结节多在注射后数月才出现，能培养出细菌的比例不高，但生物膜一旦形成，很难靠抗生素清除。临床路径是先判断有没有感染，再用透明质酸酶把填充物溶掉，必要时加用激素；没有感染证据就上抗生素，往往解决不了问题，还容易反复。",
   "evidence": [
    {
     "year": 2013,
     "type": "系统综述",
     "grade": "强",
     "label": "综述梳理填充物相关炎性结节的病因与病理，区分感染、异物反应与迟发炎症",
     "ref": "PMID:24037757"
    },
    {
     "year": 2015,
     "type": "队列研究",
     "grade": "中",
     "label": "单中心23例迟发结节，中位4个月出现，用激素与透明质酸酶处理有效",
     "ref": "PMID:26166260"
    },
    {
     "year": 2016,
     "type": "系统综述",
     "grade": "强",
     "label": "感染性并发症综述指出填充物表面生物膜难以清除，预防靠无菌操作和减少组织创伤",
     "ref": "PMID:27152101"
    },
    {
     "year": 2019,
     "type": "队列研究",
     "grade": "中",
     "label": "不同交联度玻尿酸的迟发结节发生率不同，用病灶内激素加透明质酸酶处理",
     "ref": "PMID:30789508"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "迟发结节综述提出用超声、病理和炎症指标区分炎症与感染，避免长期盲目用药",
     "ref": "PMID:34840652"
    },
    {
     "year": 2023,
     "type": "队列研究",
     "grade": "中",
     "label": "临床标本与体外实验显示生物膜形成是迟发并发症的风险因素",
     "ref": "PMID:38260874"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "共识建议确认感染后才用抗生素并做培养，炎症性结节按个体情况处理",
     "ref": "PMID:38907876"
    }
   ],
   "first_year": 2013,
   "last_year": 2024,
   "n_evidence": 7,
   "scope": "急性红肿热痛、脓性分泌物或全身发热提示真感染，需先引流和培养，不能只按炎症处理。",
   "ask": [
    "这个结节做过超声或细菌培养吗？",
    "处理方案里会不会先用透明质酸酶溶解？",
    "如果考虑生物膜，抗生素要用多久、依据是什么？"
   ],
   "status": "verified"
  },
  {
   "id": "overfilled-face",
   "layer": "endures",
   "domain": "注射填充",
   "part": "面部",
   "claim": "面部反复、大量填充会改变软组织力学与轮廓；过度填充的修整比初次填充更困难。",
   "plain": "填充物不会完全按预期待在一个层次，反复叠加会改变面部各层的厚度和滑动关系，出现面中部变宽、表情不自然。修整时要判断哪些是填充物、哪些是组织变化，还要面对粘连和血管风险，难度明显高于第一次注射。",
   "evidence": [
    {
     "year": 2013,
     "type": "系统综述",
     "grade": "强",
     "label": "影像学综述记录填充物在面部长期存留及并发症的影像特征",
     "ref": "PMID:22837310"
    },
    {
     "year": 2020,
     "type": "队列研究",
     "grade": "中",
     "label": "解剖研究提出面部横向筋膜隔与过度填充后的轮廓改变有关",
     "ref": "PMID:31688233"
    },
    {
     "year": 2021,
     "type": "队列研究",
     "grade": "弱",
     "label": "磁共振影像显示玻尿酸在面部可长期存留并移位",
     "ref": "PMID:33002985"
    },
    {
     "year": 2022,
     "type": "系统综述",
     "grade": "强",
     "label": "综述描述过度填充面部的临床特征与成因",
     "ref": "PMID:35691292"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "综述把过度填充归因于产品选择、注射层次和反复追加",
     "ref": "PMID:37977678"
    },
    {
     "year": 2024,
     "type": "队列研究",
     "grade": "中",
     "label": "解剖与力学分析解释过度填充后轮廓失真的机制",
     "ref": "PMID:38369859"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "综述讨论长期反复填充者的管理策略与修整难点",
     "ref": "PMID:40997064"
    }
   ],
   "first_year": 2013,
   "last_year": 2025,
   "n_evidence": 7,
   "scope": "少量、按解剖层次分次注射的人风险较低；已经出现变形时，单纯溶解未必能恢复原貌。",
   "ask": [
    "我脸上现在有几层填充物，分别是什么？",
    "修整前会不会先做超声定位？",
    "如果溶解后仍不对称，下一步怎么处理？"
   ],
   "status": "verified"
  },
  {
   "id": "injection-infection-setting",
   "layer": "endures",
   "domain": "注射填充",
   "part": "面部",
   "claim": "医美注射相关的感染风险与无菌操作、注射层次和场所资质有关；非正规场所的风险更高。",
   "plain": "注射把材料送进皮下甚至更深，消毒不严、层次不对、材料来源不明，都可能把细菌带进去。非正规场所的注射多由无资质人员操作，用的也常是未获批产品，文献里的分枝杆菌感染暴发和异物反应多与此有关。",
   "evidence": [
    {
     "year": 2002,
     "type": "监管文件",
     "grade": "强",
     "label": "《医疗美容服务管理办法》规定注射等医疗美容项目须在取得许可的医疗机构、由具备资格的医师实施",
     "ref": "卫生部令第19号 https://www.gov.cn/zhengce/2002-01/22/content_5713757.htm"
    },
    {
     "year": 2008,
     "type": "队列研究",
     "grade": "中",
     "label": "中胚层注射后出现分枝杆菌持续性脓肿暴发",
     "ref": "PMID:18200353"
    },
    {
     "year": 2010,
     "type": "队列研究",
     "grade": "中",
     "label": "美容注射相关偶发分枝杆菌皮肤感染暴发被报道",
     "ref": "PMID:19840199"
    },
    {
     "year": 2016,
     "type": "系统综述",
     "grade": "强",
     "label": "综述指出填充物表面生物膜与慢性感染相关，预防靠无菌操作和减少组织创伤",
     "ref": "PMID:27152101"
    },
    {
     "year": 2020,
     "type": "队列研究",
     "grade": "中",
     "label": "合法与非法填充物对比研究显示非法产品和未受训操作者的不良反应更多",
     "ref": "PMID:32418301"
    },
    {
     "year": 2022,
     "type": "队列研究",
     "grade": "中",
     "label": "7659例注射填充回顾分析记录严重不良事件，包括感染与血管并发症",
     "ref": "PMID:35170541"
    }
   ],
   "first_year": 2002,
   "last_year": 2022,
   "n_evidence": 6,
   "scope": "正规机构也可能出现感染，风险高低还取决于产品、操作者和术后护理，不等于有资质就零风险。",
   "ask": [
    "注射环境是不是按无菌操作来做的？",
    "用的产品有没有正规注册信息？",
    "出现红肿热痛时，机构怎么处理？"
   ],
   "status": "verified"
  },
  {
   "id": "tear-trough-filler-delayed-complications",
   "layer": "endures",
   "domain": "注射填充",
   "part": "眼周",
   "claim": "泪沟与眶下区域注射后的迟发问题比其他部位更常见，剂量和层次都要保守，宁少勿多。",
   "plain": "眶下皮肤薄、活动多、淋巴回流慢，同样的材料打在这里更容易出现丁达尔现象、迟发水肿和结节。系统综述里这类迟发反应的报告集中在泪沟和眶下区域，处理上常要溶解甚至手术修整。所以这个部位普遍建议低剂量、深层、分次，而不是一次填满。",
   "evidence": [
    {
     "year": 2012,
     "type": "系统综述",
     "grade": "强",
     "label": "泪沟解剖与治疗选择的综述，指出该区域皮肤薄、血管与淋巴分布特殊，注射风险高于面颊",
     "ref": "PMID:22523096"
    },
    {
     "year": 2022,
     "type": "系统综述",
     "grade": "强",
     "label": "泪沟填充的系统综述汇总适应证、材料与并发症，提示迟发反应并不少见",
     "ref": "PMID:34192769"
    },
    {
     "year": 2022,
     "type": "系统综述",
     "grade": "强",
     "label": "专门针对泪沟填充迟发并发症的系统综述，把结节、水肿、变色列为主要问题",
     "ref": "PMID:34666405"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "把泪沟填充后的静态与动态变形分开描述，提出按类型处理的路径",
     "ref": "PMID:38727846"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "眶周透明质酸填充并发症的大型综述，认为该区域需要更保守的剂量与更深层次",
     "ref": "PMID:40963300"
    },
    {
     "year": 2026,
     "type": "系统综述",
     "grade": "强",
     "label": "泪沟解剖与临床管理的最新综述，强调术前评估凹陷类型与皮肤条件",
     "ref": "PMID:42150047"
    }
   ],
   "scope": "结构性凹陷伴明显皮肤松弛的人，单纯填充改善有限，可能需要手术；既往注射过的人修整难度更高。",
   "ask": [
    "我这个泪沟是凹陷为主，还是皮肤松弛为主？",
    "计划打多少量，分几次打？",
    "如果出现迟发水肿或结节，怎么处理，费用谁承担？"
   ],
   "status": "verified",
   "first_year": 2012,
   "last_year": 2026,
   "n_evidence": 6
  },
  {
   "id": "hyaluronidase-specific-to-ha",
   "layer": "endures",
   "domain": "注射填充",
   "part": "面部",
   "claim": "透明质酸酶能降解透明质酸类填充物；对非透明质酸类填充物，它没有降解作用。",
   "plain": "透明质酸酶只切断透明质酸的糖苷键，对羟基磷灰石、聚左旋乳酸这类材料不起溶解作用，所以用之前要先确认注射的是什么。不同品牌、不同交联度的玻尿酸对酶的敏感度也不一样，用量和注射方式要按情况调整。",
   "evidence": [
    {
     "year": 2015,
     "type": "系统综述",
     "grade": "强",
     "label": "综述指出不同玻尿酸产品对酶敏感度不同，血管并发症需大剂量冲洗",
     "ref": "PMID:26618463"
    },
    {
     "year": 2019,
     "type": "系统综述",
     "grade": "强",
     "label": "综述总结透明质酸酶的临床应用范围，明确其作用底物",
     "ref": "PMID:31482503"
    },
    {
     "year": 2021,
     "type": "队列研究",
     "grade": "中",
     "label": "体外与尸体动脉实验显示硫代硫酸钠对羟基磷灰石溶解有限，该类填充物仍缺合适拮抗剂",
     "ref": "PMID:33544840"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "综述指出透明质酸酶仅对玻尿酸类有效，急诊需立即使用",
     "ref": "PMID:38231537"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "综述比较可降解填充物的降解途径，永久性材料未见降解证据",
     "ref": "PMID:39649762"
    },
    {
     "year": 2024,
     "type": "队列研究",
     "grade": "弱",
     "label": "非透明质酸填充物血管并发症的缓解来自解除血管痉挛，而非溶解材料",
     "ref": "PMID:38955457"
    }
   ],
   "first_year": 2015,
   "last_year": 2024,
   "n_evidence": 6,
   "scope": "注射物不明时先做超声或问清产品；酶本身也可能引起过敏，急救场景不能只靠它。",
   "ask": [
    "能不能先确认我打的是哪一类填充物？",
    "溶解酶大概要用多少量、怎么判断够不够？",
    "我对酶过敏的风险有多高，需不需要先做皮试？"
   ],
   "status": "verified"
  },
  {
   "id": "filler-vascular-emergency",
   "layer": "endures",
   "domain": "注射填充",
   "part": "面部",
   "claim": "面部注射的血管栓塞是急症；透明质酸类填充物有针对性拮抗剂，其他填充物没有。",
   "plain": "填充物打进动脉会堵住供血，皮肤先发白、再淤青，之后可能坏死；眼底动脉受累还会失明，处理窗口以小时计。玻尿酸可以用透明质酸酶溶掉，其他材料没有对应的溶解剂，只能靠扩血管、热敷和对症处理，所以预防与早期识别更重要。",
   "evidence": [
    {
     "year": 2012,
     "type": "队列研究",
     "grade": "中",
     "label": "病例系列报告面部填充后视网膜动脉阻塞导致视力损害",
     "ref": "PMID:22835509"
    },
    {
     "year": 2021,
     "type": "队列研究",
     "grade": "中",
     "label": "体外与尸体动脉实验显示羟基磷灰石类填充物缺乏合适拮抗剂",
     "ref": "PMID:33544840"
    },
    {
     "year": 2023,
     "type": "队列研究",
     "grade": "中",
     "label": "玻尿酸注射相关血管并发症的回顾性研究，提出缺乏统一救治方案",
     "ref": "PMID:37580566"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "综述明确透明质酸酶是玻尿酸并发症的关键处理手段，急诊需立即使用",
     "ref": "PMID:38231537"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "综述比较各类填充物降解途径，永久性材料植入后长期留存",
     "ref": "PMID:39649762"
    }
   ],
   "first_year": 2012,
   "last_year": 2024,
   "n_evidence": 5,
   "scope": "已发生组织坏死或视力下降时，单靠溶解酶往往不够，需眼科、皮肤科等多科联合处理。",
   "ask": [
    "出现发白、剧痛或视力变化，多久内能得到处理？",
    "机构有没有常备透明质酸酶和急救流程？",
    "我打的是不是玻尿酸，能不能被溶解？"
   ],
   "status": "verified"
  },
  {
   "id": "filler-danger-zones",
   "layer": "endures",
   "domain": "注射填充",
   "part": "鼻部",
   "claim": "鼻部、眉间和鼻唇沟是面部注射的高危区域，与动脉走行和吻合支分布有关。",
   "plain": "这几个部位皮下组织薄，面动脉、滑车上动脉、鼻背动脉的分支就在附近，而且眼动脉与面动脉之间存在吻合。针头一旦进入血管，材料可以逆流到眼动脉。知道血管在哪一层、多深，比记住所谓安全点位更有用。",
   "evidence": [
    {
     "year": 2012,
     "type": "队列研究",
     "grade": "中",
     "label": "视网膜动脉阻塞病例分析把鼻部、眉间列为栓塞高风险注射部位",
     "ref": "PMID:22835509"
    },
    {
     "year": 2017,
     "type": "队列研究",
     "grade": "中",
     "label": "解剖研究显示眼动脉栓塞与注射路径和血管吻合有关",
     "ref": "PMID:28749836"
    },
    {
     "year": 2017,
     "type": "队列研究",
     "grade": "中",
     "label": "滑车上动脉解剖分析给出眉间注射的危险区与深度",
     "ref": "PMID:27530765"
    },
    {
     "year": 2019,
     "type": "队列研究",
     "grade": "中",
     "label": "眶下动脉解剖研究标出鼻唇沟与眶下区的危险区",
     "ref": "PMID:30327185"
    },
    {
     "year": 2024,
     "type": "队列研究",
     "grade": "中",
     "label": "三维解剖测量显示面动脉在鼻唇沟附近的位置与深度变异大",
     "ref": "PMID:38872060"
    }
   ],
   "first_year": 2012,
   "last_year": 2024,
   "n_evidence": 5,
   "scope": "有手术史、外伤史或既往填充史的人局部解剖已改变，风险判断要个体化。",
   "ask": [
    "这几个区域的血管走行你们怎么评估？",
    "会不会用钝针或超声引导？",
    "出现异常时机构的急救预案是什么？"
   ],
   "status": "verified"
  },
  {
   "id": "permanent-filler-late-complications",
   "layer": "endures",
   "domain": "注射填充",
   "part": "面部",
   "claim": "非降解类填充材料的并发症多在注射数年后出现，材料难以取出，修复常常需要手术。",
   "plain": "硅油、聚甲基丙烯酸甲酯、聚丙烯酰胺这类材料不会被酶分解，注射后可能多年没有症状，之后出现肉芽肿、反复感染、移位和轮廓变形。它们没有对应的溶解酶，只能靠手术清创或切除，取不干净还会复发。现在这类材料多用于严格筛选的病例，随访要按年算。",
   "evidence": [
    {
     "year": 2012,
     "type": "队列研究",
     "grade": "中",
     "label": "不可降解水凝胶类材料用于面部填充后出现感染性并发症，部分病例反复发作",
     "ref": "PMID:22942210"
    },
    {
     "year": 2014,
     "type": "系统综述",
     "grade": "强",
     "label": "影像综述指出磁共振评估非降解填充物并发症存在明显局限",
     "ref": "PMID:24948821"
    },
    {
     "year": 2018,
     "type": "共识",
     "grade": "强",
     "label": "专家共识讨论聚甲基丙烯酸甲酯填充的适应证与并发症处理，强调操作与长期随访",
     "ref": "PMID:29872906"
    },
    {
     "year": 2024,
     "type": "队列研究",
     "grade": "弱",
     "label": "病例报告记录非降解填充材料导致血管闭塞后需要高压氧等综合处理",
     "ref": "PMID:39821769"
    },
    {
     "year": 2026,
     "type": "队列研究",
     "grade": "中",
     "label": "回顾性研究比较非降解填充物取出后不同重建方式的效果",
     "ref": "PMID:42009923"
    }
   ],
   "scope": "已出现明显肉芽肿、反复感染或轮廓变形的人，单纯抗炎往往不够；是否取出要按影像和范围评估。",
   "ask": [
    "我打的材料会不会被身体降解？",
    "如果以后出现硬块，能不能用溶解酶处理？",
    "取出手术的范围和风险大概是什么？"
   ],
   "status": "verified",
   "first_year": 2012,
   "last_year": 2026,
   "n_evidence": 5
  },
  {
   "id": "filler-selection-by-region-plane",
   "layer": "endures",
   "domain": "注射填充",
   "part": "面部",
   "claim": "填充材料的选择要看部位、层次和需要的支撑力；同一种材料在不同层次的表现不一样。",
   "plain": "额部、鼻部、泪沟、唇部和颧部的皮肤厚度、血管密度和表情活动都不同，需要的硬度、支撑力和注射层次也不一样。骨膜上打支撑型材料、浅层打柔软型材料是常见的分法；把一种材料套到所有部位，容易出现丁达尔现象、结节和轮廓不自然。",
   "evidence": [
    {
     "year": 2016,
     "type": "队列研究",
     "grade": "弱",
     "label": "技术文章把聚左旋乳酸的面部注射拆成六步，强调稀释、层次与手法",
     "ref": "PMID:28095577"
    },
    {
     "year": 2017,
     "type": "指南",
     "grade": "强",
     "label": "面部评估与注射指南按上半面部分区给出肉毒素与透明质酸填充剂的选择与层次",
     "ref": "PMID:28746271"
    },
    {
     "year": 2022,
     "type": "系统综述",
     "grade": "强",
     "label": "泪沟填充的系统综述比较不同材料与技术的效果和不良反应",
     "ref": "PMID:34192769"
    },
    {
     "year": 2026,
     "type": "系统综述",
     "grade": "强",
     "label": "综述讨论颞部、鼻部、唇部和下颌线这些高风险区域的材料与技术选择",
     "ref": "PMID:42878425"
    },
    {
     "year": 2026,
     "type": "系统综述",
     "grade": "强",
     "label": "综述按产品类型列出填充剂与胶原刺激剂的适应证、技术与并发症",
     "ref": "PMID:42479576"
    }
   ],
   "scope": "同一部位反复注射过、有瘢痕或解剖变异的人，层次判断要重新做，不能照搬常规方案。",
   "ask": [
    "这个部位适合用哪一类材料？",
    "计划打在哪个层次，为什么？",
    "如果效果不自然，后面怎么调整？"
   ],
   "status": "verified",
   "first_year": 2016,
   "last_year": 2026,
   "n_evidence": 5
  },
  {
   "id": "delayed-nodule-management-sequence",
   "layer": "endures",
   "domain": "注射填充",
   "part": "面部",
   "claim": "迟发结节的处理顺序是先定性：确认材料类型、有无感染和血管受累，再选溶解、抗炎或手术取出。",
   "plain": "结节多在注射后数周到数年出现，先要看打的是什么材料、局部有没有红肿热痛和波动感。透明质酸类可以先做超声，必要时用透明质酸酶；再生类和不可降解类没有对应溶解酶，多靠激素、抗炎或手术取出。穿刺培养能帮上忙，培养阴性也不能排除低度感染。",
   "evidence": [
    {
     "year": 2018,
     "type": "共识",
     "grade": "强",
     "label": "专家共识按发生时间对填充并发症分类，并给出各类情况的处理建议",
     "ref": "PMID:29305643"
    },
    {
     "year": 2021,
     "type": "队列研究",
     "grade": "中",
     "label": "高频超声用于判断填充后触及的结节，可区分材料聚集与其他性质肿块",
     "ref": "PMID:33500791"
    },
    {
     "year": 2024,
     "type": "队列研究",
     "grade": "中",
     "label": "55例胶原刺激类填充物并发症的回顾分析，结节与肉芽肿的处理方式各不相同",
     "ref": "PMID:38693639"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "弱",
     "label": "病例系列整理迟发并发症的处理经验，按炎症与感染分流",
     "ref": "PMID:40257429"
    },
    {
     "year": 2026,
     "type": "系统综述",
     "grade": "强",
     "label": "范围综述把再生类材料结节的预防、诊断与处理整理成一条临床路径",
     "ref": "PMID:42438624"
    }
   ],
   "scope": "快速增大、伴发热或脓性分泌物的结节要按感染处理，先引流和培养，不能只按炎症观察。",
   "ask": [
    "这个结节能不能先做超声看层次？",
    "需不需要穿刺做细菌培养？",
    "如果是再生类材料，处理方式和透明质酸有什么不同？"
   ],
   "status": "verified",
   "first_year": 2018,
   "last_year": 2026,
   "n_evidence": 5
  },
  {
   "id": "filler-ultrasound-role",
   "layer": "endures",
   "domain": "注射填充",
   "part": "面部",
   "claim": "超声能看清填充物的位置、层次和血管受累情况；在并发症判断和透明质酸酶注射里，它是可用的工具。",
   "plain": "超声可以在注射前看血管走行，注射后看材料落在哪一层、有没有压迫或堵住血管。出现发白、剧痛或迟发结节时，高频超声能区分材料聚集、炎症和血管内栓塞；在超声引导下把透明质酸酶打进病灶，比盲打更准。它的限制是依赖操作者经验，目前还没有统一流程。",
   "evidence": [
    {
     "year": 2021,
     "type": "队列研究",
     "grade": "中",
     "label": "高频超声用于判断填充后触及的结节，能区分材料聚集与其他性质的肿块",
     "ref": "PMID:33500791"
    },
    {
     "year": 2021,
     "type": "队列研究",
     "grade": "中",
     "label": "多普勒超声测量面动脉走行与深度的变异，为注射前评估提供依据",
     "ref": "PMID:33171021"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "弱",
     "label": "超声引导下注射透明质酸酶的新手法，用于处理填充相关血管并发症",
     "ref": "PMID:41210390"
    },
    {
     "year": 2026,
     "type": "系统综述",
     "grade": "强",
     "label": "综述给出高风险注射区域的超声图像要点，用于术前与并发症评估",
     "ref": "PMID:41942642"
    },
    {
     "year": 2026,
     "type": "队列研究",
     "grade": "中",
     "label": "100例填充相关血管不良事件的国际多中心研究，总结多普勒超声的表现",
     "ref": "PMID:42279455"
    }
   ],
   "scope": "有经验的超声医生和合适的探头才有这个分辨力；超声不能代替临床判断和细菌培养。",
   "ask": [
    "这个部位注射前会不会先做超声看血管？",
    "出现发白或剧痛时，能不能马上做超声确认？",
    "超声引导下打溶解酶，操作者做过多少例？"
   ],
   "status": "verified",
   "first_year": 2021,
   "last_year": 2026,
   "n_evidence": 5
  },
  {
   "id": "infraorbital-filler-vision-risk",
   "layer": "endures",
   "domain": "注射填充",
   "part": "眼周",
   "claim": "眶下与泪沟区血管吻合丰富，注射误入血管可能造成视力损害，属于面部注射的高危区域。",
   "plain": "眶下动脉、内眦动脉与眼动脉之间存在吻合，填充物一旦进入动脉并逆行，可能到达眼动脉分支造成视力下降甚至失明。这类事件比例不高，但后果不可逆，处理窗口以小时计。所以眶周注射要求回抽、低压、少量、分层，并且机构要备有透明质酸酶和急救流程。",
   "evidence": [
    {
     "year": 2020,
     "type": "系统综述",
     "grade": "强",
     "label": "透明质酸填充相关视力丧失的系统综述，汇总发生部位、处理与转归",
     "ref": "PMID:31822960"
    },
    {
     "year": 2020,
     "type": "系统综述",
     "grade": "强",
     "label": "眶下注射相关并发症的综述，指出该区域血管解剖是主要风险来源",
     "ref": "PMID:33794721"
    },
    {
     "year": 2023,
     "type": "系统综述",
     "grade": "强",
     "label": "眶下凹陷年轻化的综述，把血管并发症列为主要考虑",
     "ref": "PMID:36998744"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "眶周透明质酸填充并发症的大型综述，强调识别早期缺血征象与立即处理",
     "ref": "PMID:40963300"
    }
   ],
   "scope": "既往有眼周手术史、血管变异或凝血异常的人风险更高；出现视力变化属于急症，需要眼科同时介入。",
   "ask": [
    "这个部位注射时会不会做回抽？",
    "机构里有没有透明质酸酶，多久能拿到？",
    "如果术后出现视力变化，你们的处理流程是什么？"
   ],
   "status": "verified",
   "first_year": 2020,
   "last_year": 2025,
   "n_evidence": 4
  },
  {
   "id": "chemical-peel-depth-risk",
   "layer": "endures",
   "domain": "皮肤管理",
   "part": "面部",
   "claim": "化学剥脱按作用深度分为浅层、中层和深层，深度由药剂、浓度、停留时间和皮肤预处理决定，越深并发症风险越高。",
   "plain": "浅层剥脱只到表皮，主要处理色沉、痘印和粗糙；中层到真皮乳头层，深层可达真皮网状层。深肤色人群做中层以上更容易出现炎症后色素沉着和瘢痕，所以参数要保守、术前要判断肤色和屏障状态。术后护理和防晒直接影响结果。",
   "evidence": [
    {
     "year": 1999,
     "type": "队列研究",
     "grade": "中",
     "label": "30例亚洲人用酚剥脱治疗痘坑，记录了色素改变和瘢痕等不良反应",
     "ref": "PMID:9915186"
    },
    {
     "year": 2008,
     "type": "指南",
     "grade": "强",
     "label": "化学剥脱操作指南按表皮和真皮受累范围界定深度，并列出适应证、禁忌证与并发症处理",
     "ref": "PMID:18688104"
    },
    {
     "year": 2016,
     "type": "系统综述",
     "grade": "强",
     "label": "美容操作后炎症后色素沉着的综述指出剥脱和激光后深肤色人群风险更高",
     "ref": "PMID:29452657"
    },
    {
     "year": 2017,
     "type": "系统综述",
     "grade": "强",
     "label": "三氯醋酸剥脱的综述把色素改变、瘢痕和感染列为与深度相关的主要不良反应",
     "ref": "PMID:27931952"
    },
    {
     "year": 2017,
     "type": "队列研究",
     "grade": "弱",
     "label": "803例的中层和深层三氯醋酸剥脱研究显示，深肤色人群因色素和瘢痕顾虑而少用，条带技术用于控制深度",
     "ref": "PMID:28097306"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "中",
     "label": "IV至VI型皮肤做高浓度甘醇酸加三氯醋酸序贯剥脱的回顾性研究记录了疼痛和色素相关不良反应",
     "ref": "PMID:40620441"
    }
   ],
   "scope": "浅层剥脱在规范操作下风险较低；黄褐斑活动期、近期暴晒、口服维A酸或瘢痕体质者需要推迟或降低深度。",
   "ask": [
    "这次剥脱大概到哪一层，用什么药、停留多久？",
    "我的肤色和屏障状态适合做中层以上吗？",
    "出现色沉或结痂时怎么处理？"
   ],
   "status": "verified",
   "first_year": 1999,
   "last_year": 2025,
   "n_evidence": 6
  },
  {
   "id": "topical-retinoid-photoaging",
   "layer": "endures",
   "domain": "皮肤管理",
   "part": "面部",
   "claim": "外用维A酸类改善光老化细纹与色素的证据，在各类外用成分里相对充分；效果与浓度和耐受性管理有关。",
   "plain": "维A酸类药物能促进表皮更新、刺激胶原合成，随机对照研究显示0.02%以上浓度对细纹、粗糙和色素沉着有改善，浓度越高效果和刺激反应都更明显。它需要长期使用，起效以月计，红斑、脱屑和干燥常见，通常从低浓度、隔天使用开始建立耐受。",
   "evidence": [
    {
     "year": 1989,
     "type": "队列研究",
     "grade": "中",
     "label": "随机双盲对照显示0.05%维A酸乳膏用6个月可改善细纹、粗糙、萎黄和色素沉着",
     "ref": "PMID:2674225"
    },
    {
     "year": 2022,
     "type": "系统综述",
     "grade": "强",
     "label": "7项随机对照试验的系统综述显示维A酸对皱纹、斑状色素沉着和色斑有改善，疗程可用至24个月",
     "ref": "PMID:35620028"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "25项研究的系统综述把维A酸列为光老化外用治疗的金标准对照",
     "ref": "PMID:39348007"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "23项随机对照试验的网状Meta分析显示维A酸、异维A酸和视黄醇改善细纹，维A酸安全性较好",
     "ref": "PMID:40707570"
    }
   ],
   "scope": "以细纹、粗糙和色素为主的光老化更适用；对松弛、容量缺失和深层皱纹作用有限，敏感肌和玫瑰痤疮需先控制炎症。",
   "ask": [
    "我适合从什么浓度开始，多久用一次？",
    "出现脱屑和刺痛时应该减量还是停用？",
    "需要用多久才能判断有没有效果？"
   ],
   "status": "verified",
   "first_year": 1989,
   "last_year": 2025,
   "n_evidence": 4
  },
  {
   "id": "topical-ingredient-evidence-gap",
   "layer": "endures",
   "domain": "皮肤管理",
   "part": "面部",
   "claim": "外用抗老成分之间的证据强度差别很大；维A酸类之后，多数成分的研究规模小、时间短，效果也弱于维A酸。",
   "plain": "同样是抗老精华，维A酸有几十年的随机对照数据，烟酰胺、维生素C、肽类更多是短期、小样本研究，结论常停留在保湿和肤色改善。非处方视黄醇产品的双盲试验里，近一半没有做出与基质对照的差异；把成分名字当成效果，容易买错。",
   "evidence": [
    {
     "year": 2017,
     "type": "系统综述",
     "grade": "强",
     "label": "肽类外用的综述指出临床疗效证据常偏弱，吸收受分子量和亲脂性限制",
     "ref": "PMID:27451932"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "9项双盲随机试验中4项视黄醇产品与基质无差异，其余5项证据质量低",
     "ref": "PMID:34980969"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "25项比较研究显示多数成分的疗效不及维A酸，但刺激性更小",
     "ref": "PMID:39348007"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "网状Meta分析中维A酸、异维A酸和视黄醇排名靠前，羟基酸等只在部分终点上有优势",
     "ref": "PMID:40707570"
    }
   ],
   "scope": "烟酰胺、维生素C等对肤色和屏障有支持证据，但抗皱和抗松弛的长期数据不足；不能只按成分表推断效果。",
   "ask": [
    "这个成分有没有随机对照研究，随访多久？",
    "浓度和剂型是什么，透皮吸收有数据吗？",
    "和维A酸相比，它的证据差在哪里？"
   ],
   "status": "verified",
   "first_year": 2005,
   "last_year": 2025,
   "n_evidence": 4
  },
  {
   "id": "sunscreen-photoaging",
   "layer": "endures",
   "domain": "皮肤管理",
   "part": "全身",
   "claim": "在皮肤光老化的各类干预里，防晒的长期证据相对扎实。",
   "plain": "紫外线是光老化的主要外因，防晒直接减少累积暴露，作用机制清楚、可重复验证。随机对照研究显示每天用防晒的人四年后皮肤老化程度低于按习惯使用的人；外用抗氧化、维A类等是补充，不能替代防晒。",
   "evidence": [
    {
     "year": 2008,
     "type": "队列研究",
     "grade": "中",
     "label": "随机对照研究显示含广谱防晒的日霜可减少紫外线引起的皮肤结构改变",
     "ref": "PMID:18410803"
    },
    {
     "year": 2013,
     "type": "队列研究",
     "grade": "强",
     "label": "随机对照试验显示每天用防晒四年可延缓皮肤老化",
     "ref": "PMID:23732711"
    },
    {
     "year": 2015,
     "type": "系统综述",
     "grade": "强",
     "label": "光老化机制与治疗综述把防晒列为基础干预",
     "ref": "PMID:25351668"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "系统综述认为防晒的保护作用证据有限但方向一致，仍作为基础建议",
     "ref": "PMID:34698024"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "光老化综述把防晒与维A类列为证据较充分的预防和治疗手段",
     "ref": "PMID:40072791"
    }
   ],
   "first_year": 2008,
   "last_year": 2025,
   "n_evidence": 5,
   "scope": "防晒解决的是紫外线相关老化，对自然老化、重力性松弛作用有限，不能替代其他治疗。",
   "ask": [
    "我日常的防晒量够不够，要不要补涂？",
    "室内和阴天需不需要防晒？",
    "除了防晒，还有哪些干预有长期证据？"
   ],
   "status": "verified"
  },
  {
   "id": "periorbital-pigmentation-subtypes",
   "layer": "endures",
   "domain": "皮肤管理",
   "part": "眼周",
   "claim": "黑眼圈分色素型、血管型和结构型，成因不同，单一手段很难都解决。",
   "plain": "色素型是皮肤本身的色素沉着，血管型是眼周皮肤薄、静脉透出，结构型是泪沟凹陷投下的阴影。三类的处理方向不一样，色素型靠防晒和美白类手段，血管型对光电与填充反应不一，结构型主要靠填充或手术。先把类型分清，再谈方案，否则容易花了钱没变化。",
   "evidence": [
    {
     "year": 2014,
     "type": "系统综述",
     "grade": "强",
     "label": "眶周色素沉着的病因与分类综述，把色素、血管与结构因素分开讨论",
     "ref": "PMID:24719068"
    },
    {
     "year": 2016,
     "type": "系统综述",
     "grade": "强",
     "label": "眶周色素沉着综合综述，强调诊断分型决定治疗选择",
     "ref": "PMID:26962392"
    },
    {
     "year": 2020,
     "type": "系统综述",
     "grade": "强",
     "label": "基于证据的眶周色素沉着诊断与治疗综述，逐类评估现有手段",
     "ref": "PMID:34078228"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "眶周色素沉着治疗的系统综述，多数干预的证据质量偏低，联合方案更常见",
     "ref": "PMID:32740208"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "光电器械治疗眶周色素沉着的系统综述，适应证与参数差异大",
     "ref": "PMID:37661041"
    }
   ],
   "scope": "三类因素常常同时存在，分型只是抓主要矛盾；甲状腺、过敏性鼻炎、睡眠与贫血等因素也会影响，需要一并评估。",
   "ask": [
    "我的黑眼圈主要是哪一类？",
    "这个方案针对的是色素、血管还是结构？",
    "如果不做治疗，日常能做什么？"
   ],
   "status": "verified",
   "first_year": 2014,
   "last_year": 2024,
   "n_evidence": 5
  },
  {
   "id": "postprocedure-barrier-care",
   "layer": "endures",
   "domain": "皮肤管理",
   "part": "面部",
   "claim": "破皮类项目后的屏障修复，核心是保湿封闭、减少刺激和防晒；具体修复成分能加快恢复，但证据多为短期小样本。",
   "plain": "点阵激光、剥脱和微针之后，角质层不完整，经皮水分丢失上升，红斑和色沉风险随之增加。保湿封闭能促进上皮化，含泛醇、烟酰胺等成分的修复产品在随机试验中显示能降低红斑和水分丢失；但没有哪种产品被证明不可替代，清洁、防晒和避免刺激同样重要。",
   "evidence": [
    {
     "year": 2019,
     "type": "队列研究",
     "grade": "中",
     "label": "随机分面对照显示硅凝胶与凡士林基质在剥脱性点阵激光后愈合无差异，硅凝胶红斑和色沉更少",
     "ref": "PMID:31169354"
    },
    {
     "year": 2021,
     "type": "队列研究",
     "grade": "中",
     "label": "随机双盲试验显示0.5%噻吗洛尔能降低点阵二氧化碳激光后的经皮水分丢失并改善结痂",
     "ref": "PMID:33211352"
    },
    {
     "year": 2025,
     "type": "共识",
     "grade": "强",
     "label": "21位专家的共识给出点阵剥脱性二氧化碳激光的术前准备、术后护理与禁忌",
     "ref": "PMID:39434507"
    },
    {
     "year": 2026,
     "type": "系统综述",
     "grade": "强",
     "label": "系统综述与专家小组建议围操作期使用洁面、保湿、抗氧化和防晒，高质量证据有限",
     "ref": "PMID:41773167"
    },
    {
     "year": 2026,
     "type": "队列研究",
     "grade": "中",
     "label": "88例随机对照显示含烟酰胺、泛醇的方案在皮秒激光后降低水分丢失、改善红斑",
     "ref": "PMID:42686896"
    }
   ],
   "scope": "创面感染、明显渗出或疱疹复发时先处理感染；修复产品不能替代防晒和复诊，深肤色人群色沉风险更高。",
   "ask": [
    "术后多久可以正常清洁和化妆？",
    "修复产品要用到什么程度可以停？",
    "出现渗液、结痂或色沉怎么处理？"
   ],
   "status": "verified",
   "first_year": 2019,
   "last_year": 2026,
   "n_evidence": 5
  },
  {
   "id": "peel-melasma-adjunct",
   "layer": "endures",
   "domain": "皮肤管理",
   "part": "面部",
   "claim": "化学剥脱是黄褐斑的辅助或维持治疗；浅层剥脱有随机对照支持，但单用效果有限、复发常见，深肤色人群要防色素沉着。",
   "plain": "黄褐斑是慢性、易复发的色素病，化学剥脱靠加速表皮更新和去除色素起辅助作用。随机对照显示30%甘醇酸和15%三氯醋酸对表皮型黄褐斑有效，甘醇酸耐受性更好；网状Meta分析里剥脱的疗效排名中等，副作用比例不低。国际共识把剥脱列为联合治疗的一部分，单用难以维持。",
   "evidence": [
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "59项随机对照试验的网状Meta分析显示剥脱疗效排名中等，副作用比例约38%",
     "ref": "PMID:34660626"
    },
    {
     "year": 2021,
     "type": "队列研究",
     "grade": "中",
     "label": "90例随机对照显示30%甘醇酸和15%三氯醋酸对表皮型黄褐斑有效，甘醇酸耐受性更好",
     "ref": "PMID:33372385"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "黄褐斑化学剥脱综述把各类剥脱剂定位为附加或维持治疗",
     "ref": "PMID:37977681"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "中",
     "label": "深肤色黄褐斑序贯剥脱的回顾性研究显示评分改善，但停药12周复发率达70%",
     "ref": "PMID:40620441"
    },
    {
     "year": 2026,
     "type": "共识",
     "grade": "强",
     "label": "38位专家的国际Delphi共识把化学剥脱列为增强外用药疗效的辅助手段",
     "ref": "PMID:40996222"
    }
   ],
   "scope": "表皮型、稳定期黄褐斑更适合；活动期、近期暴晒、深肤色或黄褐斑反跳史者要降低浓度和停留时间。",
   "ask": [
    "我的黄褐斑是表皮型还是混合型？",
    "用哪种剥脱剂、浓度多少？",
    "做完怎么防晒和维持，复发率多高？"
   ],
   "status": "verified",
   "first_year": 2021,
   "last_year": 2026,
   "n_evidence": 5
  },
  {
   "id": "ad-ban-before-after",
   "layer": "endures",
   "domain": "监管",
   "part": "机构",
   "claim": "医疗美容广告不得使用就医者的名义或形象做诊疗前后效果对比，也不得对安全性和功效作保证性承诺。",
   "plain": "这条规定针对的是最常见的一类医美广告：放一张素颜和一张精修，配一句「安全无痛」。按现行执法口径，用就医者的名义或形象做前后对比、对安全性和功效作保证承诺，都属于重点打击的情形。广告主还得先取得医疗广告审查证明，没有证明的广告本身就违法。",
   "evidence": [
    {
     "year": 2002,
     "type": "监管文件",
     "grade": "强",
     "label": "医疗美容服务管理办法要求发布医疗美容广告前取得审查证明，并按核准内容发布",
     "ref": "卫生部令第19号 https://www.gov.cn/zhengce/2002-01/22/content_5713757.htm"
    },
    {
     "year": 2021,
     "type": "监管文件",
     "grade": "强",
     "label": "《医疗美容广告执法指南》把使用就医者形象做前后对比、对安全性功效作保证性承诺列为重点打击情形",
     "ref": "市场监管总局公告2021年第37号 https://www.gov.cn/zhengce/zhengceku/2021-11/04/content_5648772.htm"
    },
    {
     "year": 2023,
     "type": "监管文件",
     "grade": "强",
     "label": "十一部门指导意见明确医疗美容服务属于医疗活动，并对虚假宣传提出综合监管要求",
     "ref": "关于进一步加强医疗美容行业监管工作的指导意见 https://www.gov.cn/lianbo/2023-05/05/content_5754184.htm"
    },
    {
     "year": 2025,
     "type": "监管文件",
     "grade": "强",
     "label": "市场监管总局违法广告典型案例中，医疗美容机构因宣称功效与实际不符被处罚",
     "ref": "市场监管总局2025年违法广告典型案例 https://www.samr.gov.cn/xw/mtjj/art/2025/art_c23be9198eba493c88f860da9d8c297c.html"
    }
   ],
   "scope": "机构按照要求主动公开执业信息、诊疗科目和价格，不具有商业目的，一般不按广告处理；科普内容只要不带机构地址和联系方式，也不属于变相广告。",
   "ask": [
    "这条广告有医疗广告审查证明吗，编号是多少？",
    "广告里的效果描述，有没有对安全性作保证？",
    "宣传材料里出现的对比图，是真实就医者吗，有没有取得同意？"
   ],
   "status": "verified",
   "first_year": 2002,
   "last_year": 2025,
   "n_evidence": 4
  },
  {
   "id": "license-and-scope-public",
   "layer": "endures",
   "domain": "监管",
   "part": "机构",
   "claim": "医美机构必须持有医疗机构执业许可证，并按核准的诊疗科目开展项目，机构资质与诊疗科目都应当可以查到。",
   "plain": "执业许可证管的是「能不能做医疗」，诊疗科目管的是「能做哪一类」。很多纠纷出在后者，机构有证，但做的项目不在核准科目里，或者由不具备相应资格的人操作。就医者可以在机构内查看许可证和科目公示，也可以在当地卫生健康部门的公开渠道核对。",
   "evidence": [
    {
     "year": 2002,
     "type": "监管文件",
     "grade": "强",
     "label": "医疗美容服务管理办法规定开展医疗美容须取得医疗机构执业许可，并按核准的诊疗科目执业",
     "ref": "卫生部令第19号 https://www.gov.cn/zhengce/2002-01/22/content_5713757.htm"
    },
    {
     "year": 2018,
     "type": "监管文件",
     "grade": "强",
     "label": "医疗纠纷预防和处理条例要求医疗机构公开执业信息，完善知情告知与病历管理",
     "ref": "国务院令第701号 https://www.gov.cn/zhengce/content/2018-08/31/content_5318057.htm"
    },
    {
     "year": 2023,
     "type": "监管文件",
     "grade": "强",
     "label": "十一部门指导意见要求强化信息公开和信用约束，把机构与人员的合规信息公示出来",
     "ref": "关于进一步加强医疗美容行业监管工作的指导意见 https://www.gov.cn/lianbo/2023-05/05/content_5754184.htm"
    },
    {
     "year": 2025,
     "type": "监管文件",
     "grade": "强",
     "label": "市场监管总局典型案例中，有机构在未取得执业许可的情况下开展注射类服务被查处",
     "ref": "市场监管总局2025年违法广告典型案例 https://www.samr.gov.cn/xw/mtjj/art/2025/art_c23be9198eba493c88f860da9d8c297c.html"
    }
   ],
   "scope": "许可证和科目公示是机构层面的资质，不覆盖具体操作者的资格；执业医师的注册范围与主诊医师备案需要单独核对。",
   "ask": [
    "这个项目的诊疗科目在你们的执业许可证上吗？",
    "给我做这个项目的医生，执业范围是什么？",
    "主诊医师是谁，能在公示信息里查到吗？"
   ],
   "status": "verified",
   "first_year": 2002,
   "last_year": 2025,
   "n_evidence": 4
  },
  {
   "id": "device-registration-required",
   "layer": "endures",
   "domain": "监管",
   "part": "机构",
   "claim": "注射填充类产品属于药品或者医疗器械，必须有批准文号或者注册证，机构使用未注册产品属于违法。",
   "plain": "玻尿酸填充剂、再生类材料按第三类医疗器械管理，肉毒素按药品管理，都要求有注册证或批准文号，并且经营使用单位要从合法渠道购进、查验资质并留存记录。所谓「水货」「代购」「院内分装」，缺的正是这一环，出问题以后连产品来源都追不到。",
   "evidence": [
    {
     "year": 2002,
     "type": "监管文件",
     "grade": "强",
     "label": "医疗美容服务管理办法要求使用的药品与器械符合国家规定，严禁使用未经批准的产品",
     "ref": "卫生部令第19号 https://www.gov.cn/zhengce/2002-01/22/content_5713757.htm"
    },
    {
     "year": 2008,
     "type": "监管文件",
     "grade": "强",
     "label": "A型肉毒毒素被列入毒性药品管理，采购、储存与使用均有专门要求",
     "ref": "国食药监办〔2008〕405号 https://wsjkw.sh.gov.cn/yzgl4/20180815/0012-60884.html"
    },
    {
     "year": 2021,
     "type": "监管文件",
     "grade": "强",
     "label": "医疗器械监督管理条例规定使用单位应当从合法渠道购进医疗器械并查验注册证与供货资质",
     "ref": "国务院令第739号 https://www.gov.cn/zhengce/content/2021-03/18/content_5593739.htm"
    },
    {
     "year": 2023,
     "type": "监管文件",
     "grade": "强",
     "label": "十一部门指导意见把医疗美容用药品医疗器械纳入综合监管重点事项",
     "ref": "关于进一步加强医疗美容行业监管工作的指导意见 https://www.gov.cn/lianbo/2023-05/05/content_5754184.htm"
    }
   ],
   "scope": "批准文号只说明产品本身合规，不说明适应证选择、注射层次和操作者水平；同一款产品在不同部位的风险差别很大。",
   "ask": [
    "这个产品能不能当着我的面拆封，包装上的注册证号是多少？",
    "机构能不能提供产品的购进凭证？",
    "如果我出现迟发反应，产品批号能不能查到？"
   ],
   "status": "verified",
   "first_year": 2002,
   "last_year": 2023,
   "n_evidence": 4
  },
  {
   "id": "compliance-medical-activity-license",
   "layer": "endures",
   "domain": "监管",
   "part": "机构",
   "claim": "医疗美容属于医疗活动，须在取得《医疗机构执业许可证》的机构内、由具备执业资质的人员实施。",
   "plain": "《医疗美容服务管理办法》把医疗美容界定为运用手术、药物、医疗器械等创伤性或侵入性技术方法对人的容貌和体态进行的修复与再塑，按医疗活动管理。开展这类服务要取得《医疗机构执业许可证》并在核定的诊疗科目内进行，未经执业注册的人员不得从事诊疗服务。生活美容机构不在这个范围里。",
   "evidence": [
    {
     "year": 2002,
     "type": "监管文件",
     "grade": "强",
     "label": "第二条把医疗美容界定为创伤性或侵入性医学技术方法，第八条要求取得《医疗机构执业许可证》后方可执业",
     "ref": "卫生部令第19号 https://www.gov.cn/zhengce/2002-01/22/content_5713757.htm"
    },
    {
     "year": 2021,
     "type": "监管文件",
     "grade": "强",
     "label": "医师须经执业注册，并在注册的执业范围内从事执业活动",
     "ref": "中华人民共和国医师法 https://wjw.jiangsu.gov.cn/art/2023/2/27/art_49492_10770673.html"
    },
    {
     "year": 2023,
     "type": "监管文件",
     "grade": "强",
     "label": "十一部门指导意见要求加强机构与人员准入管理，生活美容机构不得开展医疗美容服务",
     "ref": "关于进一步加强医疗美容行业监管工作的指导意见 https://www.gov.cn/lianbo/2023-05/05/content_5754184.htm"
    }
   ],
   "scope": "已取得许可但由无资质人员操作的仍属违规；纯生活美容护理不在本办法调整范围内。",
   "ask": [
    "给我操作的医生有没有在这家机构办理执业注册？",
    "机构的《医疗机构执业许可证》上核准的诊疗科目有哪些？",
    "这个项目是在医疗机构里做，还是在生活美容场所做？"
   ],
   "status": "verified",
   "first_year": 2002,
   "last_year": 2023,
   "n_evidence": 3
  },
  {
   "id": "compliance-chief-physician",
   "layer": "endures",
   "domain": "监管",
   "part": "机构",
   "claim": "医疗美容实行主诊医师负责制，项目须由主诊医师负责或在其指导下实施。",
   "plain": "《医疗美容服务管理办法》第十一条列了主诊医师的条件：执业医师资格、相应临床工作经历、经过专业培训或进修并合格。第十八条规定医疗美容服务实行主诊医师负责制，项目必须由主诊医师负责或在其指导下实施；不具备这些条件的执业医师只能在主诊医师指导下做技术性工作。",
   "evidence": [
    {
     "year": 2002,
     "type": "监管文件",
     "grade": "强",
     "label": "第十一条列出主诊医师的三项条件，第十八条规定医疗美容服务实行主诊医师负责制",
     "ref": "卫生部令第19号 https://www.gov.cn/zhengce/2002-01/22/content_5713757.htm"
    },
    {
     "year": 2021,
     "type": "监管文件",
     "grade": "强",
     "label": "医师执业须按注册的执业范围进行，超范围执业属于违规",
     "ref": "中华人民共和国医师法 https://wjw.jiangsu.gov.cn/art/2023/2/27/art_49492_10770673.html"
    },
    {
     "year": 2023,
     "type": "监管文件",
     "grade": "强",
     "label": "十一部门指导意见要求加强医疗美容从业人员准入管理",
     "ref": "关于进一步加强医疗美容行业监管工作的指导意见 https://www.gov.cn/lianbo/2023-05/05/content_5754184.htm"
    }
   ],
   "scope": "主诊医师负责制不免除机构的管理义务；多点执业与外出会诊另有备案要求。",
   "ask": [
    "这个项目由哪位主诊医师负责，他的执业注册信息能在哪里核验？",
    "如果由资历较浅的医生操作，主诊医师是否在场指导？",
    "主诊医师的执业范围里有没有医疗美容这一项？"
   ],
   "status": "verified",
   "first_year": 2002,
   "last_year": 2023,
   "n_evidence": 3
  },
  {
   "id": "compliance-project-classification",
   "layer": "endures",
   "domain": "监管",
   "part": "机构",
   "claim": "医疗美容项目按技术难度与风险实行分级准入，不同级别对机构和医师的条件要求不同。",
   "plain": "《医疗美容服务管理办法》第二条写明，根据技术难度和可能发生的医疗风险程度，对医疗美容项目实行分级准入管理；第十六条要求机构在核定的诊疗科目范围内开展项目，不得开展未备案的项目。卫生部办公厅 2009 年印发的《医疗美容项目分级管理目录》把项目分为四级，级别越高，对机构条件与主诊医师资历的要求越严。",
   "evidence": [
    {
     "year": 2002,
     "type": "监管文件",
     "grade": "强",
     "label": "第二条规定对医疗美容项目实行分级准入管理，第十六条要求按核定诊疗科目开展并不得开展未备案项目",
     "ref": "卫生部令第19号 https://www.gov.cn/zhengce/2002-01/22/content_5713757.htm"
    },
    {
     "year": 2009,
     "type": "监管文件",
     "grade": "强",
     "label": "《医疗美容项目分级管理目录》把项目分为一至四级，并对不同级别项目的机构条件与人员资历作出规定",
     "ref": "卫办医政发〔2009〕220号 http://www.szlh.gov.cn/qgbmxxgkml/qwsjkj/gzwj/zcfg/content/post_5066762.html"
    },
    {
     "year": 2023,
     "type": "监管文件",
     "grade": "强",
     "label": "十一部门指导意见要求加强医疗美容项目与机构的准入管理",
     "ref": "关于进一步加强医疗美容行业监管工作的指导意见 https://www.gov.cn/lianbo/2023-05/05/content_5754184.htm"
    }
   ],
   "scope": "分级目录以当时的医疗技术条件为基础，新技术与新项目另有备案或审批要求。",
   "ask": [
    "我要做的这个项目属于第几级？",
    "这家机构有没有开展这个级别项目的资质和抢救条件？",
    "这个项目在卫生健康部门备案过吗？"
   ],
   "status": "verified",
   "first_year": 2002,
   "last_year": 2023,
   "n_evidence": 3
  },
  {
   "id": "compliance-ad-review-certificate",
   "layer": "endures",
   "domain": "监管",
   "part": "机构",
   "claim": "发布医疗美容广告要先取得医疗广告审查证明，内容不得超出审查同意的范围。",
   "plain": "《广告法》第四十六条要求医疗、药品、医疗器械广告在发布前由广告审查机关对内容进行审查，未经审查不得发布。医疗美容广告属于医疗广告，发布时应当标明审查批准文号，内容不得超出审查同意的范围，也不得含有表示功效、安全性的断言。市场监管总局 2021 年的执法指南把未经审查发布列为执法重点。",
   "evidence": [
    {
     "year": 2002,
     "type": "监管文件",
     "grade": "强",
     "label": "第二十七条规定发布医疗美容广告必须按照国家有关广告管理的法律、法规办理",
     "ref": "卫生部令第19号 https://www.gov.cn/zhengce/2002-01/22/content_5713757.htm"
    },
    {
     "year": 2021,
     "type": "监管文件",
     "grade": "强",
     "label": "第四十六条规定医疗、药品、医疗器械广告发布前须经审查，未经审查不得发布",
     "ref": "中华人民共和国广告法 https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/fgs/art/2023/art_5474cf75173c45d6a0379730fb4e8d97.html"
    },
    {
     "year": 2021,
     "type": "监管文件",
     "grade": "强",
     "label": "《医疗美容广告执法指南》把未经审查发布、超出审查范围发布列为执法查处情形",
     "ref": "市场监管总局公告2021年第37号 https://www.gov.cn/zhengce/zhengceku/2021-11/04/content_5648772.htm"
    }
   ],
   "scope": "审查证明只覆盖经审定的内容，擅自改词、换图或跨平台另发都可能构成未审查发布。",
   "ask": [
    "这条广告的医疗广告审查证明编号是多少？",
    "广告里出现的说法和审查通过的内容一致吗？",
    "广告里的前后对比图和出镜者有没有取得授权？"
   ],
   "status": "verified",
   "first_year": 2002,
   "last_year": 2021,
   "n_evidence": 3
  },
  {
   "id": "records-and-consent-evidence",
   "layer": "endures",
   "domain": "监管",
   "part": "机构",
   "claim": "病历与知情同意书是医疗纠纷处理中的核心证据，就医者有权查阅和复制自己的病历资料。",
   "plain": "出问题以后，能不能查清发生了什么，取决于当时有没有记录。条例明确规定就医者可以查阅、复制病历资料，机构不能以「内部资料」为由拒绝。知情同意也不只是签个字，要把术式、风险、替代方案和可能的并发症说清楚，写下来，双方各留一份。",
   "evidence": [
    {
     "year": 2002,
     "type": "监管文件",
     "grade": "强",
     "label": "医疗美容服务管理办法要求实施前向就医者本人或亲属书面告知适应证、风险与注意事项并取得签字同意",
     "ref": "卫生部令第19号 https://www.gov.cn/zhengce/2002-01/22/content_5713757.htm"
    },
    {
     "year": 2018,
     "type": "监管文件",
     "grade": "强",
     "label": "医疗纠纷预防和处理条例规定就医者有权查阅、复制病历资料，医疗机构应当提供",
     "ref": "国务院令第701号 https://www.gov.cn/zhengce/content/2018-08/31/content_5318057.htm"
    },
    {
     "year": 2023,
     "type": "监管文件",
     "grade": "强",
     "label": "十一部门指导意见要求把诊疗活动纳入综合监管重点事项，病历与告知是监管抓手之一",
     "ref": "关于进一步加强医疗美容行业监管工作的指导意见 https://www.gov.cn/lianbo/2023-05/05/content_5754184.htm"
    }
   ],
   "scope": "复制病历的具体范围和流程按条例与机构规定执行，涉及第三方信息的部分会做处理；封存病历要在双方在场的情况下进行。",
   "ask": [
    "术前告知书能不能给我一份留存？",
    "我的病历里会记录哪些内容，术后多久可以复印？",
    "如果需要封存病历，走什么流程？"
   ],
   "status": "verified",
   "first_year": 2002,
   "last_year": 2023,
   "n_evidence": 3
  },
  {
   "id": "dispute-three-routes",
   "layer": "endures",
   "domain": "监管",
   "part": "机构",
   "claim": "医美纠纷的处理途径不止打官司一条，协商、人民调解和诉讼是并列的三条路，行政投诉也是其中一环。",
   "plain": "很多人以为出了事只能起诉，其实条例把协商、人民调解和诉讼并列为处理途径。医患双方可以自愿协商，也可以向医疗纠纷人民调解委员会申请调解，调解不收费，达成协议后可以申请司法确认。涉及虚假宣传、无证行医的，还可以向市场监管和卫生健康部门投诉。",
   "evidence": [
    {
     "year": 2002,
     "type": "监管文件",
     "grade": "强",
     "label": "医疗美容服务管理办法要求机构建立纠纷处理机制并接受卫生行政部门监督",
     "ref": "卫生部令第19号 https://www.gov.cn/zhengce/2002-01/22/content_5713757.htm"
    },
    {
     "year": 2018,
     "type": "监管文件",
     "grade": "强",
     "label": "医疗纠纷预防和处理条例规定协商、人民调解、诉讼三条途径，并明确调解协议可以申请司法确认",
     "ref": "国务院令第701号 https://www.gov.cn/zhengce/content/2018-08/31/content_5318057.htm"
    },
    {
     "year": 2023,
     "type": "监管文件",
     "grade": "强",
     "label": "十一部门指导意见构建跨部门综合监管机制，涉及虚假宣传与非法行医的线索按行刑衔接处理",
     "ref": "关于进一步加强医疗美容行业监管工作的指导意见 https://www.gov.cn/lianbo/2023-05/05/content_5754184.htm"
    }
   ],
   "scope": "三条途径各有适用条件，赔偿数额、举证责任和所需时间不同；涉及伤残的通常要先做鉴定，调解不成再起诉。",
   "ask": [
    "如果我要走调解，当地的医调委在哪里？",
    "协商达成的协议，有没有法律约束力？",
    "我这种情况，行政投诉和民事诉讼可以同时进行吗？"
   ],
   "status": "verified",
   "first_year": 2002,
   "last_year": 2023,
   "n_evidence": 3
  },
  {
   "id": "compliance-btx-toxic-drug",
   "layer": "endures",
   "domain": "监管",
   "part": "机构",
   "claim": "注射用A型肉毒毒素按毒性药品管理，采购、经营和使用都受指定渠道与专门规定约束。",
   "plain": "2008 年原国家食品药品监督管理局等部门发出通知，将 A 型肉毒毒素列入毒性药品管理。毒性药品在我国实行特殊管理，生产、经营、使用各环节都有专门规定，注射用制剂不能像普通药品那样在任何零售渠道买到。这套要求针对的是毒素本身的毒性，与它被用于医美还是用于治病无关。",
   "evidence": [
    {
     "year": 2008,
     "type": "监管文件",
     "grade": "强",
     "label": "上海市卫生健康委员会转发《关于将A型肉毒毒素列入毒性药品管理的通知》，要求按毒性药品管理执行",
     "ref": "国食药监药化监〔2008〕405号 https://wsjkw.sh.gov.cn/yzgl4/20180815/0012-60884.html"
    },
    {
     "year": 2019,
     "type": "监管文件",
     "grade": "强",
     "label": "《药品管理法》规定医疗用毒性药品实行特殊管理",
     "ref": "中华人民共和国药品管理法 https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/fgs/art/2023/art_b73ec9dabb2d468281d6c994b4bcdaf8.html"
    },
    {
     "year": 2026,
     "type": "监管文件",
     "grade": "强",
     "label": "《药品管理法实施条例》对医疗用毒性药品的生产、经营与使用作出具体管理规定",
     "ref": "中华人民共和国药品管理法实施条例 https://www.gov.cn/zhengce/zhengceku/202601/content_7056256.htm"
    }
   ],
   "scope": "规定针对的是列入毒性药品管理的注射用A型肉毒毒素，其他剂型与用途另有要求。",
   "ask": [
    "这次用的肉毒素是走什么渠道采购的，能不能看采购凭证？",
    "机构有没有毒性药品的储存与使用管理记录？",
    "开封后的剩余药品怎么处理，有没有登记？"
   ],
   "status": "verified",
   "first_year": 2008,
   "last_year": 2026,
   "n_evidence": 3
  },
  {
   "id": "btx-individual-variation",
   "layer": "endures",
   "domain": "肉毒素",
   "part": "面部",
   "claim": "肉毒素的疗效与注射点位、剂量和个体肌肉厚度有关，同一剂量在不同人身上差异明显。",
   "plain": "肉毒素靠弥散到肌肉起作用，肌肉厚、筋膜层次复杂、注射点偏了，效果就不一样。剂量研究显示同样的单位数在不同人身上维持时间从几个月到近一年不等；超声能看到肌肉厚度和血管位置，帮助把剂量和点位个体化。",
   "evidence": [
    {
     "year": 2005,
     "type": "队列研究",
     "grade": "中",
     "label": "剂量对照研究显示20至40U比10U更有效，多数人效果维持3至4个月，个别人可达12个月",
     "ref": "PMID:15871316"
    },
    {
     "year": 2015,
     "type": "系统综述",
     "grade": "强",
     "label": "Meta分析确认肉毒素改善眉间纹的疗效与安全性，个体差异存在",
     "ref": "PMID:26313835"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "综述讨论提高单次剂量对疗效和维持时间的影响",
     "ref": "PMID:34357966"
    },
    {
     "year": 2024,
     "type": "队列研究",
     "grade": "中",
     "label": "超声研究显示咬肌深部肌腱存在个体差异，影响注射点位选择",
     "ref": "PMID:39330849"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "综述主张用超声引导确定咬肌注射的层次与点位",
     "ref": "PMID:39453189"
    }
   ],
   "first_year": 2005,
   "last_year": 2024,
   "n_evidence": 5,
   "scope": "长期注射、已有抗体或解剖结构异常的人差异更大，不能照搬别人的方案。",
   "ask": [
    "我的目标肌肉厚度大概是多少？",
    "这个剂量是按什么定的？",
    "效果不对称时怎么调整？"
   ],
   "status": "verified"
  },
  {
   "id": "btx-onset-duration",
   "layer": "endures",
   "domain": "肉毒素",
   "part": "面部",
   "claim": "注射A型肉毒素后通常两周左右效果充分显现，单次疗效多维持三到四个月，之后需要重复注射。",
   "plain": "肉毒素阻断神经末梢释放乙酰胆碱需要时间，临床观察注射后两周左右效果才充分显现，单次疗效一般维持三到四个月。Cochrane综述纳入65项随机对照试验、近1.5万人，平均疗效持续时间约20周。加大剂量可能延长维持时间，但也会增加弥散和邻近肌肉受累的风险；效果消退后肌肉功能恢复，皱纹会重新出现。",
   "evidence": [
    {
     "year": 2005,
     "type": "队列研究",
     "grade": "中",
     "label": "鱼尾纹剂量反应随机对照试验在注射后第7天已见改善，随访到180天，疗效随剂量增加",
     "ref": "PMID:15841623"
    },
    {
     "year": 2014,
     "type": "系统综述",
     "grade": "强",
     "label": "综述总结肉毒素效果约两周充分显现，单次维持三到四个月，动态纹改善比静态纹明显",
     "ref": "PMID:25077722"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "Cochrane系统综述65项随机对照试验、14919人，平均疗效持续时间约20周",
     "ref": "PMID:34224576"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "综述认为高于说明书剂量的肉毒素可能延长眉间纹疗效，安全性未见明显变差，但研究数量有限",
     "ref": "PMID:34357966"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "中",
     "label": "143人双盲随机对照用三维摄影比较四种A型肉毒素制剂，在第3、30、90、180天随访效果变化",
     "ref": "PMID:40434770"
    }
   ],
   "scope": "个体差异大，长期注射或出现抗体的人维持时间会缩短；增加剂量带来的获益有限，不能靠加量追求更久。",
   "ask": [
    "我这次打多大剂量，预期能维持几个月？",
    "效果一般在第几天开始、什么时候最明显？",
    "如果四个月就恢复原状，是剂量不够还是别的原因？"
   ],
   "status": "verified",
   "first_year": 2005,
   "last_year": 2025,
   "n_evidence": 5
  },
  {
   "id": "btx-neutralizing-antibody",
   "layer": "endures",
   "domain": "肉毒素",
   "part": "面部",
   "claim": "肉毒素的中和抗体与单次剂量、注射间隔和累积注射次数有关；剂量高、间隔短，出现免疫耐受的概率更高。",
   "plain": "反复注射外源蛋白，身体可能产生中和抗体，让同样的剂量越来越不灵。临床上常见的做法是控制单次剂量、把间隔拉开、避免频繁补打；一旦疗效明显下降，需要区分是抗体问题、产品问题还是注射技术问题，不能简单加量。",
   "evidence": [
    {
     "year": 2007,
     "type": "队列研究",
     "grade": "弱",
     "label": "个案报告在美容小剂量、4至5个月间隔下仍出现抗体介导的失效",
     "ref": "PMID:17278332"
    },
    {
     "year": 2009,
     "type": "队列研究",
     "grade": "中",
     "label": "大剂量适应证与更短注射间隔的患者中和抗体比例更高",
     "ref": "PMID:19620852"
    },
    {
     "year": 2013,
     "type": "系统综述",
     "grade": "强",
     "label": "综述把总剂量、加强注射和既往暴露列为免疫原性相关因素",
     "ref": "PMID:23008029"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "综述认为重复注射是中和抗体形成的主要风险因素",
     "ref": "PMID:39459517"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "预测模型显示剂量与治疗间隔等变量可用于评估免疫原性风险",
     "ref": "PMID:39287793"
    }
   ],
   "first_year": 2007,
   "last_year": 2025,
   "n_evidence": 5,
   "scope": "低剂量也可能出现抗体，个体差异大。也有大剂量、长疗程的研究没有观察到剂量与抗体的明确关联，这条的证据并不完全一致。疗效下降不等于都是抗体，需要检测或者换型观察。",
   "ask": [
    "我打的是多少单位、间隔多久一次？",
    "如果效果变差，怎么判断是不是抗体？",
    "换一种肉毒素产品能不能恢复效果？"
   ],
   "status": "verified"
  },
  {
   "id": "btx-hyperhidrosis-bromhidrosis",
   "layer": "endures",
   "domain": "肉毒素",
   "part": "全身",
   "claim": "注射A型肉毒素可减少腋窝和手掌的局部多汗，对腋臭也有改善；效果是暂时的，症状回升后需要重复注射。",
   "plain": "肉毒素阻断汗腺的交感神经末梢释放乙酰胆碱，腋窝多汗的随机对照试验里，注射后汗量下降超过五成、严重程度和生活质量评分同步改善，52周的多中心研究显示中位疗效约197天。腋臭的对照研究也看到异味评分和汗量下降，组织学上大汗腺出现萎缩。效果会随时间消退，青少年腋臭的长期随访里多数人要按异味回升追加注射。",
   "evidence": [
    {
     "year": 2007,
     "type": "队列研究",
     "grade": "中",
     "label": "322例52周多中心双盲随机对照，75U与50U腋下注射后75%达到严重程度两分改善，中位疗效197天",
     "ref": "PMID:17306417"
    },
    {
     "year": 2017,
     "type": "系统综述",
     "grade": "强",
     "label": "50项研究的系统综述认为肉毒素治疗腋窝多汗有中等质量证据和大效应量，其他干预证据较弱",
     "ref": "PMID:29271741"
    },
    {
     "year": 2018,
     "type": "队列研究",
     "grade": "中",
     "label": "62例青少年腋臭随访约2.6年，按异味回升重复注射，疗效时长个体差异大",
     "ref": "PMID:29344685"
    },
    {
     "year": 2019,
     "type": "队列研究",
     "grade": "中",
     "label": "19例腋臭自身对照随机研究，注射侧3个月异味评分与汗量显著低于对照侧，大汗腺出现萎缩",
     "ref": "PMID:30829777"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "8项随机对照试验937人的Meta分析显示肉毒素减少腋窝汗量超过五成，严重程度与生活质量改善，但随访多只到8周",
     "ref": "PMID:33619611"
    }
   ],
   "scope": "手掌、足底多汗的疗效也有证据，但注射疼痛和手部无力更常见；腋窝异味明显时需先排除其他原因。",
   "ask": [
    "我这个多汗是原发还是继发，需要先做哪些检查？",
    "一次注射大概能维持多久，什么时候可以补打？",
    "手掌注射后手部无力或代偿性出汗的风险有多大？"
   ],
   "status": "verified",
   "first_year": 2007,
   "last_year": 2021,
   "n_evidence": 5
  },
  {
   "id": "btx-dilution-diffusion-spread",
   "layer": "endures",
   "domain": "肉毒素",
   "part": "面部",
   "claim": "肉毒素向周围扩散的范围受稀释浓度、注射体积和产品特性影响；浓度低、体积大，通常弥散更广，越难局限在目标肌肉。",
   "plain": "同样单位数的肉毒素，用更多生理盐水稀释、注射更大体积，药液更容易沿组织间隙扩散到邻近肌肉；浓度高、体积小则相对局限。面颊、眼周这类肌肉小、层次浅的部位通常用高浓度小体积，大肌肉用低浓度大体积。但20人自身对照研究显示，五倍稀释差在除皱效果上没有测出差别，说明常规稀释范围内影响不大；扩散还受注射点位、层次和产品特性影响。",
   "evidence": [
    {
     "year": 2007,
     "type": "队列研究",
     "grade": "中",
     "label": "20人自身对照随机研究把五倍浓度差打在同一人鱼尾纹两侧，临床评分和维持时间未测出差异",
     "ref": "PMID:17451579"
    },
    {
     "year": 2012,
     "type": "系统综述",
     "grade": "强",
     "label": "综述认为注射体积、浓度和剂量都影响扩散，不同产品不可互换，部分产品扩散更大、扩散相关不良事件更多",
     "ref": "PMID:23440162"
    },
    {
     "year": 2012,
     "type": "队列研究",
     "grade": "中",
     "label": "额部无汗晕面积比较显示相同剂量与体积下，一种A型肉毒素制剂的扩散面积明显大于另两种，另两种相当",
     "ref": "PMID:22002325"
    },
    {
     "year": 2013,
     "type": "系统综述",
     "grade": "强",
     "label": "综述指出体积和稀释影响药物局部与全身分布，多数局部和远处并发症来自非目标扩散",
     "ref": "PMID:23868503"
    },
    {
     "year": 2020,
     "type": "系统综述",
     "grade": "强",
     "label": "综述认为稀释体积越大、浓度越低，理论扩散范围越大，但这方面的临床研究有限",
     "ref": "PMID:32568126"
    }
   ],
   "scope": "常规稀释范围内差异可能很小；注射点位、层次和产品特性对扩散的影响不亚于稀释，不能只靠调浓度控制效果。",
   "ask": [
    "这次注射用多少毫升稀释、每个点打多少？",
    "我的目标是精细部位还是大肌肉，浓度会怎么选？",
    "如果出现邻近肌肉无力，多久能恢复？"
   ],
   "status": "verified",
   "first_year": 2007,
   "last_year": 2020,
   "n_evidence": 5
  },
  {
   "id": "btx-masseter-dose-response",
   "layer": "endures",
   "domain": "肉毒素",
   "part": "咬肌",
   "claim": "A型肉毒素注射咬肌可缩小咬肌体积；效果与剂量和注射次数有关，停药后体积会逐步回升。",
   "plain": "咬肌缩小是肌肉废用性萎缩的结果，不是把肌肉溶掉。剂量够、按间隔重复注射，缩小幅度更大；停止注射后，随着咀嚼负荷恢复，肌肉体积会慢慢回来一部分，所以把它当成需要维护的项目，更接近实际。",
   "evidence": [
    {
     "year": 2013,
     "type": "系统综述",
     "grade": "强",
     "label": "Cochrane综述当时未找到咬肌注射的随机对照试验，提示证据等级有限",
     "ref": "PMID:24018587"
    },
    {
     "year": 2019,
     "type": "队列研究",
     "grade": "中",
     "label": "50例随访4年，注射3次者咬肌体积缩小约四成，注射2次者约两成半",
     "ref": "PMID:31461011"
    },
    {
     "year": 2019,
     "type": "系统综述",
     "grade": "强",
     "label": "东亚人群咬肌注射综述总结剂量、点位与间隔的常用方案",
     "ref": "PMID:30883483"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "中",
     "label": "随机对照显示肉毒素早期缩小咬肌厚度优于咬合垫，到6个月时效果回落",
     "ref": "PMID:40935351"
    },
    {
     "year": 2026,
     "type": "系统综述",
     "grade": "强",
     "label": "Meta分析显示48U与72U方案均有改善，但剂量反应关系证据仍不足",
     "ref": "PMID:42379083"
    }
   ],
   "first_year": 2013,
   "last_year": 2026,
   "n_evidence": 5,
   "scope": "咬肌肥厚伴严重磨牙或咬合异常的人，单靠注射效果有限，需同时处理病因。",
   "ask": [
    "我这个脸宽是咬肌、骨骼还是脂肪？",
    "计划打几次、间隔多久？",
    "停打以后大概多久会回来，怎么判断？"
   ],
   "status": "verified"
  },
  {
   "id": "btx-scar-evidence-limited",
   "layer": "endures",
   "domain": "肉毒素",
   "part": "面部",
   "claim": "注射A型肉毒素改善面部手术切口瘢痕的证据集中在中小样本随机对照研究；对已形成的瘢痕疙瘩和增生性瘢痕，效果弱于糖皮质激素注射。",
   "plain": "肉毒素减少瘢痕周围肌肉张力，随机对照的Meta分析显示注射后温哥华瘢痕评分、瘢痕宽度和外观评分优于生理盐水，面部和颈部效果更明显。但这些研究多在百例上下、随访几个月，而且和糖皮质激素直接比较时，肉毒素的改善幅度更小。对已经形成的瘢痕疙瘩，现有系统综述里曲安奈德的减容幅度最大，肉毒素只是可选方案之一，不是首选。",
   "evidence": [
    {
     "year": 2019,
     "type": "系统综述",
     "grade": "强",
     "label": "9项随机对照试验的Meta分析显示肉毒素降低温哥华瘢痕评分、缩小瘢痕宽度并提高满意度",
     "ref": "PMID:30903249"
    },
    {
     "year": 2020,
     "type": "系统综述",
     "grade": "强",
     "label": "11项随机对照试验486例的Meta分析显示瘢痕评分和宽度改善，但证据主要来自面部颈部、亚洲人群",
     "ref": "PMID:31155638"
    },
    {
     "year": 2022,
     "type": "系统综述",
     "grade": "强",
     "label": "21项随机对照试验的Meta分析显示肉毒素优于生理盐水，但改善幅度小于糖皮质激素",
     "ref": "PMID:36112846"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "20项研究894例的Meta分析显示面部、头颈部瘢痕改善，上唇和额头更明显",
     "ref": "PMID:37934126"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "12项研究397例的系统综述里，增生性瘢痕和瘢痕疙瘩的减容幅度以曲安奈德最大，肉毒素只是比较方案之一",
     "ref": "PMID:40773601"
    }
   ],
   "scope": "术后早期开始注射、面部切口、亚洲人群的证据更集中；陈旧瘢痕、瘢痕疙瘩和瘢痕体质者需联合其他治疗。",
   "ask": [
    "我这个瘢痕适合在术后多久开始打肉毒素？",
    "和激素注射相比，肉毒素的预期改善差多少？",
    "如果已经形成瘢痕疙瘩，先做哪种治疗更合适？"
   ],
   "status": "verified",
   "first_year": 2019,
   "last_year": 2025,
   "n_evidence": 5
  },
  {
   "id": "ipl-any-skin-season",
   "layer": "fails",
   "domain": "光电",
   "part": "面部",
   "claim": "光子嫩肤任何肤质、任何季节都能做。",
   "plain": "强脉冲光是宽谱光，参数要按肤色、病变类型和近期日晒调整。深肤色人群黑色素吸收更多能量，操作不当容易出现灼伤和色素沉着；刚暴晒过或正在用光敏药物的人，风险更高。季节本身不是禁忌，但夏季紫外线强，术后防晒做不到位会影响效果。",
   "evidence": [
    {
     "year": 2001,
     "type": "队列研究",
     "grade": "中",
     "label": "亚洲人光子嫩肤研究提示需按肤色调整参数",
     "ref": "PMID:11442612"
    },
    {
     "year": 2007,
     "type": "指南",
     "grade": "强",
     "label": "欧洲激光皮肤病学会指南给出血管激光与强脉冲光的适应证与注意事项",
     "ref": "PMID:17558762"
    },
    {
     "year": 2008,
     "type": "队列研究",
     "grade": "中",
     "label": "强脉冲光脱毛相关并发症包括灼伤、色素改变等",
     "ref": "PMID:18654911"
    },
    {
     "year": 2013,
     "type": "系统综述",
     "grade": "强",
     "label": "深肤色激光与光疗综述强调色素改变风险与参数个体化",
     "ref": "PMID:24098905"
    },
    {
     "year": 2015,
     "type": "指南",
     "grade": "强",
     "label": "欧洲指南更新血管激光与强脉冲光的治疗规范",
     "ref": "PMID:25931003"
    }
   ],
   "first_year": 2001,
   "last_year": 2015,
   "n_evidence": 5,
   "scope": "光敏性疾病、近期暴晒、妊娠期和使用光敏药物的人，需要推迟或调整方案。",
   "ask": [
    "我的肤色分型和近期日晒情况适合现在做吗？",
    "参数会按我的情况调整吗？",
    "术后怎么防晒和保湿？"
   ],
   "status": "verified",
   "rev_year": 2015
  },
  {
   "id": "laser-permanent-hair-removal",
   "layer": "fails",
   "domain": "光电",
   "part": "全身",
   "claim": "激光脱毛能根除毛发，以后不用再治疗。",
   "plain": "激光做的是长期毛发减少，不是根除。生长期毛囊被破坏后，休止期毛囊还会进入生长期；激素变化、部位和肤色都会影响效果，操作指南明确要求用长期毛发减少这个说法，不承诺毛发不再生长。反常性多毛也有报道，面部和颈部治疗后毛发反而增多。",
   "evidence": [
    {
     "year": 2008,
     "type": "指南",
     "grade": "强",
     "label": "激光与强脉冲光毛发减少指南明确要求使用长期毛发减少一词，不承诺毛发不再生长",
     "ref": "PMID:18688107"
    },
    {
     "year": 2013,
     "type": "系统综述",
     "grade": "强",
     "label": "激光脱毛综述认为诊室设备可提供长期毛发减少，但需要多次治疗",
     "ref": "PMID:23332016"
    },
    {
     "year": 2019,
     "type": "系统综述",
     "grade": "强",
     "label": "家用低能量设备通过诱导毛囊进入退行期起效，与专业设备直接破坏毛囊的机制不同",
     "ref": "PMID:30681170"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "激光和光疗后反常性多毛的系统综述与Meta分析估计发生率约3%，面部和颈部更高",
     "ref": "PMID:34057666"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "脱毛方法综述指出除电解外，所有方法都是暂时性的，包括激光和强脉冲光",
     "ref": "PMID:34524781"
    }
   ],
   "scope": "毛发颜色浅、激素异常或治疗间隔不足时，效果更短；把长期减少理解成不再生长，会错过维持治疗。",
   "ask": [
    "这个部位大概能减少多少，多久需要补做？",
    "我的毛发颜色和激素情况影响效果吗？",
    "做完后会不会出现反常性多毛？"
   ],
   "status": "verified",
   "first_year": 2008,
   "last_year": 2021,
   "n_evidence": 5,
   "rev_year": 2021
  },
  {
   "id": "picosecond-always-better-qs",
   "layer": "fails",
   "domain": "光电",
   "part": "面部",
   "claim": "皮秒激光一定比调Q好。",
   "plain": "皮秒和调Q都是选择性光热或光声作用，优势取决于色素颜色、深度、波长和肤色。头对头研究里，755纳米皮秒在部分黑蓝色文身和太田痣上清除率更高、次数更少；但1064纳米黑文身的动物实验中两者无显著差异，皮秒也有色沉报告。把脉宽当成全面优势，忽略了波长和适应证。",
   "evidence": [
    {
     "year": 2020,
     "type": "队列研究",
     "grade": "中",
     "label": "56例分面对照显示755纳米皮秒在太田痣清除率、次数和疼痛上优于调Q",
     "ref": "PMID:30885760"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "77项研究的系统综述认为皮秒激光在文身、色素、嫩肤和瘢痕上安全有效，证据等级因适应证而异",
     "ref": "PMID:32282094"
    },
    {
     "year": 2022,
     "type": "队列研究",
     "grade": "弱",
     "label": "大鼠文身模型显示1064纳米皮秒与纳秒激光对黑文身清除无显著差异",
     "ref": "PMID:35289435"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "中",
     "label": "99例回顾性研究显示1064纳米点阵皮秒治黄褐斑比低能量调Q起效更快，但存在色沉",
     "ref": "PMID:41841366"
    },
    {
     "year": 2026,
     "type": "队列研究",
     "grade": "中",
     "label": "30例随机分半对照显示755纳米皮秒对黑蓝色文身清除率高于纳秒，但色沉更多",
     "ref": "PMID:41729109"
    }
   ],
   "scope": "皮秒在部分色素和文身上有优势；深肤色、黄褐斑和需要大面积治疗时，调Q仍是有效选择，要看波长和反应。",
   "ask": [
    "我的色素适合皮秒还是调Q？",
    "两种设备的波长和脉宽分别是什么？",
    "皮秒的色沉风险比调Q高吗？"
   ],
   "status": "verified",
   "first_year": 2020,
   "last_year": 2026,
   "n_evidence": 5,
   "rev_year": 2021
  },
  {
   "id": "home-device-equals-medical",
   "layer": "fails",
   "domain": "光电",
   "part": "面部",
   "claim": "家用美容仪和医美设备效果一样。",
   "plain": "家用设备受安全限制，单脉冲能量和冷却能力都低于医用设备。家用强脉冲光主要靠低能量诱导毛囊进入休止期，医用设备靠更高能量破坏毛囊；家用设备的证据多是小样本、短随访，部分产品在脱毛上接近医用强脉冲光，但抗衰、紧致和瘢痕治疗达不到同等能量，不能一概而论。",
   "evidence": [
    {
     "year": 2010,
     "type": "系统综述",
     "grade": "强",
     "label": "三款家用强脉冲光设备的输出参数差异明显，家用设备缺少统一的国际标准",
     "ref": "PMID:20625788"
    },
    {
     "year": 2015,
     "type": "系统综述",
     "grade": "强",
     "label": "家用激光和光类设备的综述指出家用强脉冲光和LED效果有限，样本小、随访短",
     "ref": "PMID:25705949"
    },
    {
     "year": 2019,
     "type": "系统综述",
     "grade": "强",
     "label": "家用设备与专业设备在单脉冲能量和生物学机制上不同，低能量主要诱导毛囊进入退行期",
     "ref": "PMID:30681170"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "中",
     "label": "84例随机分侧对照显示某款家用强脉冲光在脱毛上与医用强脉冲光效果接近",
     "ref": "PMID:40106027"
    }
   ],
   "scope": "个别家用设备在脱毛上接近医用强脉冲光；紧致、抗衰和瘢痕治疗仍以医用设备为主，家用产品要看能量和适应证。",
   "ask": [
    "这个家用仪器的能量密度是多少？",
    "它有没有随机对照研究，随访多久？",
    "我想解决的问题适合家用还是医用设备？"
   ],
   "status": "verified",
   "first_year": 2010,
   "last_year": 2025,
   "n_evidence": 4,
   "rev_year": 2019
  },
  {
   "id": "laser-spot-one-session",
   "layer": "fails",
   "domain": "光电",
   "part": "面部",
   "claim": "激光祛斑一次就能干净。",
   "plain": "色斑类型不同，治疗次数差别很大。黄褐斑做低能量调Q激光通常要六到十次，一年后复发率可达五成以上；剥脱性点阵激光单用治疗黄褐斑并不优于其他激光，还可能出现色沉。雀斑、晒斑次数可能少一些，但也要按反应调整，一次干净的说法忽略了复发和色素沉着。",
   "evidence": [
    {
     "year": 2011,
     "type": "系统综述",
     "grade": "强",
     "label": "色素性病变激光治疗综述按病种给出不同治疗间隔和参数，多数需要多次治疗",
     "ref": "PMID:21492309"
    },
    {
     "year": 2016,
     "type": "队列研究",
     "grade": "中",
     "label": "34例黄褐斑做6至10次低能量调Q激光后改善，一年后58.8%复发",
     "ref": "PMID:27349828"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "14项随机对照试验的Meta分析显示剥脱性点阵激光单用治疗黄褐斑不优于其他激光",
     "ref": "PMID:38379033"
    },
    {
     "year": 2026,
     "type": "系统综述",
     "grade": "强",
     "label": "黄褐斑激光与光疗综述指出复发和炎症后色素改变是常见风险",
     "ref": "PMID:41020517"
    }
   ],
   "scope": "雀斑、晒斑可能一到数次明显改善；黄褐斑、颧部褐青色痣和炎症后色沉需要多次治疗并长期防晒。",
   "ask": [
    "我的色斑是什么类型，预计几次？",
    "一次能做到什么程度，会不会复发？",
    "做完色沉或反黑怎么处理？"
   ],
   "status": "verified",
   "first_year": 2011,
   "last_year": 2026,
   "n_evidence": 4,
   "rev_year": 2026
  },
  {
   "id": "energy-device-no-downtime",
   "layer": "fails",
   "domain": "光电",
   "part": "面部",
   "claim": "射频和聚焦超声类紧肤项目做完没有恢复期，随做随走。",
   "plain": "这类项目靠热作用刺激胶原，术后常见短暂红斑、水肿和触痛，少数人会出现水疱、脂肪萎缩或神经刺激症状。所谓没有恢复期，多指不需要住院和切开，不等于当天可以正常社交和运动；并发症一旦发生，恢复期可能以周计。",
   "evidence": [
    {
     "year": 2018,
     "type": "队列研究",
     "grade": "中",
     "label": "微聚焦超声治疗后出现水肿、萎缩和皮肤坏死等严重不良事件的病例系列",
     "ref": "PMID:29154457"
    },
    {
     "year": 2020,
     "type": "队列研究",
     "grade": "中",
     "label": "调查显示激光与能量设备术前术后措施缺乏统一标准，恢复期管理不一致",
     "ref": "PMID:31840388"
    },
    {
     "year": 2026,
     "type": "队列研究",
     "grade": "中",
     "label": "美国FDA数据中射频微针并发症包括脂肪流失、炎症反应和烧伤",
     "ref": "PMID:41886649"
    },
    {
     "year": 2026,
     "type": "系统综述",
     "grade": "强",
     "label": "射频微针系统综述记录红斑、水肿等术后反应与恢复时间",
     "ref": "PMID:41947517"
    }
   ],
   "first_year": 2018,
   "last_year": 2026,
   "n_evidence": 4,
   "scope": "能量设置过高、同一部位重复治疗或有自身免疫病的人，恢复期更长、风险更高。",
   "ask": [
    "这次治疗的能量和发数是多少？",
    "术后常见反应有哪些、持续多久？",
    "出现水疱或凹陷怎么处理？"
   ],
   "status": "verified",
   "rev_year": 2026
  },
  {
   "id": "antiaging-rf-at-18",
   "layer": "fails",
   "domain": "光电",
   "part": "面部",
   "claim": "抗老越早开始越好，十八岁就该做射频紧肤。",
   "plain": "射频紧肤针对的是皮肤松弛和胶原流失，十八岁通常没有这类适应证。年轻皮肤做能量项目也不是没有风险，射频微针就有脂肪萎缩、烧伤的报告。更合理的做法是按皮肤状态而不是年龄决定是否治疗，先做好防晒和基础护理。",
   "evidence": [
    {
     "year": 2023,
     "type": "系统综述",
     "grade": "强",
     "label": "年轻成人肉毒素美容治疗的综述建议个体化并降低剂量，未支持普遍提前干预",
     "ref": "PMID:36445847"
    },
    {
     "year": 2026,
     "type": "队列研究",
     "grade": "中",
     "label": "美国FDA数据显示射频微针并发症包括脂肪流失与烧伤",
     "ref": "PMID:41886649"
    },
    {
     "year": 2026,
     "type": "系统综述",
     "grade": "强",
     "label": "射频微针系统综述的疗效证据来自有适应证人群，未按年龄分层",
     "ref": "PMID:41947517"
    }
   ],
   "first_year": 2023,
   "last_year": 2026,
   "n_evidence": 3,
   "scope": "有特殊皮肤问题的人可能需要早期干预，但应由医生按具体情况判断，不能按年龄一刀切。",
   "ask": [
    "我的皮肤状态需要做射频吗？",
    "这个年龄做这类项目的证据有多少？",
    "不做的话，有哪些更基础的方案？"
   ],
   "status": "unverified",
   "rev_year": 2026
  },
  {
   "id": "thread-lift-replace-facelift",
   "layer": "fails",
   "domain": "手术",
   "part": "面部",
   "claim": "埋线提升可以替代面部拉皮手术。",
   "plain": "拉皮手术切除多余皮肤、收紧筋膜层，效果按年计；埋线只是用倒刺线抓住组织，靠异物反应形成支撑，系统评价显示多数研究提升效果有限、维持时间短。两者解决的是不同量级的问题，埋线更适合轻中度松弛或作为过渡。",
   "evidence": [
    {
     "year": 2010,
     "type": "队列研究",
     "grade": "中",
     "label": "29例埋线后出现并发症与早期复发，提示效果不持久",
     "ref": "PMID:20100265"
    },
    {
     "year": 2018,
     "type": "系统综述",
     "grade": "强",
     "label": "系统综述认为多数埋线研究提升效果有限，阳性研究多由厂商资助",
     "ref": "PMID:29481392"
    },
    {
     "year": 2019,
     "type": "系统综述",
     "grade": "强",
     "label": "综述列出埋线的线材相关并发症与再手术风险",
     "ref": "PMID:30893160"
    },
    {
     "year": 2019,
     "type": "队列研究",
     "grade": "中",
     "label": "内镜面中部提升的长期随访显示手术提升的维持时间以年计",
     "ref": "PMID:31621793"
    },
    {
     "year": 2023,
     "type": "撤稿",
     "grade": "强",
     "label": "声称埋线长期有效的论文被撤稿，相关证据可信度下降",
     "ref": "PMID:36762403"
    }
   ],
   "first_year": 2010,
   "last_year": 2023,
   "n_evidence": 5,
   "scope": "皮肤量明显多余、筋膜松弛严重的人，埋线难以达到拉皮的效果，强行做还可能变形。",
   "ask": [
    "我的松弛程度适合埋线还是手术？",
    "埋线效果预计能维持多久？",
    "如果以后再做拉皮，埋线会影响手术吗？"
   ],
   "status": "verified",
   "rev_year": 2023
  },
  {
   "id": "liposuction-weight-loss",
   "layer": "fails",
   "domain": "手术",
   "part": "全身",
   "claim": "抽脂可以减肥。",
   "plain": "抽脂能去掉局部皮下脂肪，大容量抽脂后BMI会暂时下降，但这不是减重治疗。动物研究显示脂肪切除后体重和体脂会回升；人体随机研究显示抽脂后内脏脂肪代偿性增加，胰岛素敏感性和心血管风险没有改善。把它当减肥手段，既容易反弹，也会忽略真正影响代谢的饮食和运动。",
   "evidence": [
    {
     "year": 2010,
     "type": "队列研究",
     "grade": "中",
     "label": "随机对照显示手术切除大网膜脂肪并未改善肥胖者的胰岛素敏感性和心血管风险",
     "ref": "PMID:20457158"
    },
    {
     "year": 2012,
     "type": "队列研究",
     "grade": "中",
     "label": "36例随机试验显示抽脂后未运动组内脏脂肪增加约10%，能量消耗下降",
     "ref": "PMID:22539589"
    },
    {
     "year": 2017,
     "type": "系统综述",
     "grade": "强",
     "label": "12项研究364例的系统综述显示大容量抽脂后BMI下降，代谢和心血管指标改善不一致",
     "ref": "PMID:28737560"
    },
    {
     "year": 2019,
     "type": "系统综述",
     "grade": "强",
     "label": "64项动物研究的范围综述显示脂肪切除后体重和体脂多在12至14周内回升",
     "ref": "PMID:31361090"
    },
    {
     "year": 2020,
     "type": "系统综述",
     "grade": "强",
     "label": "综述指出抽脂后脂肪会在特定部位优先重新堆积，只有保持能量负平衡才能避免",
     "ref": "PMID:31652224"
    }
   ],
   "scope": "局部轮廓塑形是抽脂的主要用途；体重明显超标或代谢异常的人，需要先做减重和代谢管理。",
   "ask": [
    "抽脂能减掉多少体重，会反弹吗？",
    "术后内脏脂肪和代谢指标会怎么变？",
    "我需要先减重再做抽脂吗？"
   ],
   "status": "verified",
   "first_year": 2010,
   "last_year": 2020,
   "n_evidence": 5,
   "rev_year": 2020
  },
  {
   "id": "younger-surgery-faster-better",
   "layer": "fails",
   "domain": "手术",
   "part": "面部",
   "claim": "年轻做手术恢复更快、效果更好。",
   "plain": "把年龄当成恢复快慢和效果好坏的主要变量，证据不足。11300例面部提升的队列里，年龄没有进入主要并发症的独立风险因素；4238例瘢痕分析反而显示年龄越小，增生性瘢痕风险越高。鼻整形还要等面部发育基本完成，青少年手术的适应证与心理成熟度需要单独评估。",
   "evidence": [
    {
     "year": 2016,
     "type": "队列研究",
     "grade": "中",
     "label": "11300例面部提升的前瞻性队列显示主要风险因素为男性、BMI和联合手术，年龄未列入独立预测因素",
     "ref": "PMID:26578747"
    },
    {
     "year": 2017,
     "type": "系统综述",
     "grade": "强",
     "label": "儿童鼻部手术时机的综述指出多数术者主张等鼻部发育完成，也有研究认为早期手术不影响发育",
     "ref": "PMID:28509670"
    },
    {
     "year": 2018,
     "type": "系统综述",
     "grade": "强",
     "label": "青少年整形手术的系统综述指出该人群的安全性和适应证研究很少，需按术式分别评估",
     "ref": "PMID:29878991"
    },
    {
     "year": 2023,
     "type": "队列研究",
     "grade": "中",
     "label": "4238例甲状腺术后瘢痕分析显示年轻年龄与增生性瘢痕风险升高相关",
     "ref": "PMID:37880850"
    },
    {
     "year": 2026,
     "type": "队列研究",
     "grade": "中",
     "label": "541例面部提升的回顾显示各年龄组主要和次要并发症均无差异，75岁以上也未增加风险",
     "ref": "PMID:42045665"
    }
   ],
   "scope": "缺少按年龄分层的恢复时间与效果对照研究；现有证据只能说明年龄不是效果优势，青少年仍需评估发育、瘢痕和适应证。",
   "ask": [
    "这个术式在我这个年龄的证据有多少？",
    "我的瘢痕体质和发育情况需要评估吗？",
    "恢复期大概多久，和年龄关系大吗？"
   ],
   "status": "unverified",
   "first_year": 2016,
   "last_year": 2026,
   "n_evidence": 5,
   "rev_year": 2018
  },
  {
   "id": "upper-blepharoplasty-permanent-shape",
   "layer": "fails",
   "domain": "手术",
   "part": "眼周",
   "claim": "上睑成形做完就永久定型，不用再管。",
   "plain": "上睑的形态会随年龄继续变化，皮肤松弛、脂肪移位和瘢痕软化的过程都在术后继续。埋线法线结松脱后皱襞会变浅或消失，切开法也可能因为皮肤再度松弛而变窄或不对称。公开的随访与修复文献里，再手术并不罕见，把术后形态当成不会变的结果，容易忽略复查和后续调整。",
   "evidence": [
    {
     "year": 2018,
     "type": "队列研究",
     "grade": "中",
     "label": "连续埋线法重睑术的术式报告，讨论线结固定与皱襞维持的关系",
     "ref": "PMID:30191281"
    },
    {
     "year": 2020,
     "type": "系统综述",
     "grade": "强",
     "label": "亚洲重睑术并发症综述，列出不对称、皱襞变浅与需要修复的情形",
     "ref": "PMID:33368082"
    },
    {
     "year": 2022,
     "type": "队列研究",
     "grade": "中",
     "label": "不同固定方式的重睑术对比，随访皱襞形态与稳定性",
     "ref": "PMID:34896040"
    },
    {
     "year": 2023,
     "type": "系统综述",
     "grade": "强",
     "label": "亚洲上睑成形修复的综述，说明修复原因与手术要点",
     "ref": "PMID:36396250"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "中",
     "label": "七年投诉资料分析，反映重睑术后常见的形态与不对称问题",
     "ref": "PMID:39998431"
    }
   ],
   "scope": "多数人术后多年形态稳定，是否再手术取决于松弛程度与个人预期；埋线法与切开法的远期稳定性不同。",
   "ask": [
    "这个术式几年后皱襞变浅的概率有多大？",
    "如果不对称或者变窄，修复的难度和费用怎么算？",
    "术后需要多久复查一次？"
   ],
   "status": "verified",
   "first_year": 2018,
   "last_year": 2025,
   "n_evidence": 5,
   "rev_year": 2023
  },
  {
   "id": "fat-graft-90-percent",
   "layer": "fails",
   "domain": "手术",
   "part": "面部",
   "claim": "自体脂肪填充的存活率可以达到九成以上。",
   "plain": "系统评价汇总的客观测量结果显示，面部脂肪移植的平均保留率在五成左右，个体和部位差异很大。九成以上的说法多来自医生主观判断、短期随访，或把肿胀期体积当成存活，缺少三维体积或影像学测量支撑。",
   "evidence": [
    {
     "year": 2014,
     "type": "队列研究",
     "grade": "中",
     "label": "长期客观测量显示保留率约三成至五成，年龄与受区条件影响结果",
     "ref": "PMID:25028738"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "Meta分析汇总面部脂肪移植平均保留率47%，95%置信区间41%至53%",
     "ref": "PMID:31940073"
    },
    {
     "year": 2023,
     "type": "系统综述",
     "grade": "强",
     "label": "Meta分析比较不同面部畸形的脂肪移植效果，保留率差异明显",
     "ref": "PMID:37837945"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "中",
     "label": "五年随访显示保留率与体重变化相关，常需再次移植",
     "ref": "PMID:39938464"
    }
   ],
   "first_year": 2014,
   "last_year": 2025,
   "n_evidence": 4,
   "scope": "不同受区、处理方式和测量方法会改变数字，任何单一存活率都不适合直接套用。",
   "ask": [
    "这个存活率是怎么测出来的？",
    "我的受区条件大概在什么水平？",
    "需要几次移植才能达到目标？"
   ],
   "status": "verified",
   "rev_year": 2023
  },
  {
   "id": "nonincisional-permanent-face-shape",
   "layer": "fails",
   "domain": "手术",
   "part": "面部",
   "claim": "不开刀也能让脸型定型，不用再维护。",
   "plain": "填充剂、肉毒素和埋线都会随时间消退：透明质酸维持几个月到一年多，肉毒素按月起算，埋线多数在一年内减弱。不可降解的注射材料确实存在，但肉芽肿、感染和取出困难让它不被当成常规选项；骨骼和咬合层面的脸型改变仍要靠手术。所谓定型，多是把多次维护说成了一次完成。",
   "evidence": [
    {
     "year": 2014,
     "type": "系统综述",
     "grade": "强",
     "label": "不可降解的液态硅胶注射后的肉芽肿、感染和血管阻塞可在数年后出现，处理困难",
     "ref": "PMID:25536128"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "透明质酸填充剂的综述显示维持时间取决于交联度、浓度和流变学，均会逐步降解",
     "ref": "PMID:34992400"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "674例非手术鼻整形的系统综述显示透明质酸效果维持8至14个月",
     "ref": "PMID:33660013"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "1126例的系统综述显示骨性颏成形与假体植入是改变下颌轮廓的手术方式，各有并发症",
     "ref": "PMID:40666078"
    }
   ],
   "scope": "短期轮廓调整可以靠注射或埋线，需要每年维护；不可降解材料带来的并发症可能比多次维护更难处理。",
   "ask": [
    "这个效果能维持多久，需要几次维护？",
    "如果用了不可降解材料，以后还能取出吗？",
    "我的脸型问题在骨骼、脂肪还是肌肉？"
   ],
   "status": "verified",
   "first_year": 2014,
   "last_year": 2025,
   "n_evidence": 4,
   "rev_year": 2025
  },
  {
   "id": "lower-blepharoplasty-once-for-all",
   "layer": "fails",
   "domain": "手术",
   "part": "眼周",
   "claim": "眼袋手术做完就不会再长，一次解决。",
   "plain": "手术解决的是当时的脂肪膨出与皮肤松弛，改变不了随年龄继续发生的软组织下垂和骨质吸收。脂肪切除过多的人，若干年后面中部出现凹陷，反而需要再填。修复手术在眼周并不少见，术式选择和技术细节对远期结果影响很大，把一次手术当成终点，容易做出过度切除的决定。",
   "evidence": [
    {
     "year": 2016,
     "type": "系统综述",
     "grade": "强",
     "label": "经结膜下睑成形术综述，说明适应证选择与远期效果的关系",
     "ref": "PMID:27499473"
    },
    {
     "year": 2024,
     "type": "队列研究",
     "grade": "中",
     "label": "经结膜脂肪复位的回顾研究，讨论脂肪处理方式与再手术的关系",
     "ref": "PMID:37220233"
    },
    {
     "year": 2024,
     "type": "队列研究",
     "grade": "中",
     "label": "眶骨膜上脂肪复位联合中面部提升的长期结果报告",
     "ref": "PMID:38353810"
    },
    {
     "year": 2026,
     "type": "队列研究",
     "grade": "中",
     "label": "经皮入路下睑成形中脂肪复位与深层脂肪切除的技术与结果",
     "ref": "PMID:41051496"
    }
   ],
   "scope": "术后维护得当、衰老进程慢的人，效果可以维持很多年；是否再手术取决于外观变化与个人预期，不是固定年限。",
   "ask": [
    "这个方案会切掉多少脂肪，切多了以后怎么办？",
    "大概几年后可能需要再处理，取决于什么？",
    "如果不做手术，先做填充会有什么问题？"
   ],
   "status": "verified",
   "first_year": 2016,
   "last_year": 2026,
   "n_evidence": 4,
   "rev_year": 2016
  },
  {
   "id": "implant-lifetime-no-replacement",
   "layer": "fails",
   "domain": "手术",
   "part": "全身",
   "claim": "硅胶假体可以终身不换，做完不用再管。",
   "plain": "硅胶假体没有统一的更换年限，但终身不换也不成立。美国99993例的长期随访里，初次隆胸7年再手术率11.7%，包膜挛缩是最常见原因；单中心15至19年随访的修复率约29.8%。破裂、包膜挛缩和罕见的假体相关间变性大细胞淋巴瘤风险随年限累积，随访要按症状和影像安排，不能一次手术就结束。",
   "evidence": [
    {
     "year": 2019,
     "type": "队列研究",
     "grade": "中",
     "label": "美国FDA上市后研究99993例显示初次隆胸7年再手术率11.7%，包膜挛缩7.2%",
     "ref": "PMID:30222598"
    },
    {
     "year": 2022,
     "type": "队列研究",
     "grade": "中",
     "label": "84例15至19年随访显示总修复率29.8%，就医者满意度仍较高",
     "ref": "PMID:34677578"
    },
    {
     "year": 2023,
     "type": "系统综述",
     "grade": "强",
     "label": "美国假体相关间变性大细胞淋巴瘤的系统综述估计有纹理假体人群风险约1比913",
     "ref": "PMID:37616552"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "中",
     "label": "133例修复手术的回顾显示包膜挛缩和破裂是医疗原因修复的主要问题",
     "ref": "PMID:40670655"
    }
   ],
   "scope": "没有症状的人不一定需要按固定年限取出；但破裂、包膜挛缩、疼痛或影像异常时，需要评估取出或更换。",
   "ask": [
    "我的假体是什么材料、什么表面？",
    "随访用什么影像，多久做一次？",
    "出现破裂或包膜挛缩时怎么处理？"
   ],
   "status": "verified",
   "first_year": 2019,
   "last_year": 2025,
   "n_evidence": 4,
   "rev_year": 2023
  },
  {
   "id": "ha-dissolve-no-risk",
   "layer": "fails",
   "domain": "注射填充",
   "part": "面部",
   "claim": "玻尿酸既然能被溶解，注射玻尿酸就没有风险。",
   "plain": "能被溶解不等于没有风险。玻尿酸可能堵血管造成皮肤坏死甚至失明，也可能出现迟发结节、感染和过敏；溶解酶本身有过敏和局部反应，溶解过程也有风险。真正的安全来自适应证判断、解剖熟悉、无菌操作和急救能力。",
   "evidence": [
    {
     "year": 2012,
     "type": "队列研究",
     "grade": "中",
     "label": "面部填充后视网膜动脉阻塞病例显示玻尿酸可导致严重视力损害",
     "ref": "PMID:22835509"
    },
    {
     "year": 2015,
     "type": "队列研究",
     "grade": "中",
     "label": "迟发结节发生率约0.5%，多在注射后数月出现",
     "ref": "PMID:26166260"
    },
    {
     "year": 2020,
     "type": "系统综述",
     "grade": "强",
     "label": "系统综述汇总玻尿酸填充相关视力丧失病例，风险不可忽视",
     "ref": "PMID:31822960"
    },
    {
     "year": 2022,
     "type": "队列研究",
     "grade": "中",
     "label": "7659例注射填充回顾分析记录感染、血管并发症等严重事件",
     "ref": "PMID:35170541"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "系统综述汇总玻尿酸填充的不良事件谱，严重事件虽少见但存在",
     "ref": "PMID:37563436"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "综述指出透明质酸酶本身也可能引起过敏，急救需综合处理",
     "ref": "PMID:38231537"
    }
   ],
   "first_year": 2012,
   "last_year": 2024,
   "n_evidence": 6,
   "scope": "有血管病史、凝血异常、免疫疾病或既往填充史的人风险更高，需要个体化评估。",
   "ask": [
    "这个部位的主要血管在哪里？",
    "机构有没有透明质酸酶和急救设备？",
    "出现迟发结节的处理流程是什么？"
   ],
   "status": "verified",
   "rev_year": 2024
  },
  {
   "id": "biodegradable-no-residue",
   "layer": "fails",
   "domain": "注射填充",
   "part": "面部",
   "claim": "可降解填充材料会在体内降解干净，不留下残留。",
   "plain": "可降解材料的降解速度和完全程度因材料而异。聚左旋乳酸类要靠巨噬细胞慢慢清除，过程可持续一两年，期间可能形成结节或肉芽肿；聚己内酯降解更慢。所谓降解干净是材料设计的理想状态，不等于每个人都不留痕迹。",
   "evidence": [
    {
     "year": 2008,
     "type": "队列研究",
     "grade": "弱",
     "label": "组织病理显示填充物颗粒可在注射后长期存在并引起肉芽肿反应",
     "ref": "PMID:18442665"
    },
    {
     "year": 2009,
     "type": "队列研究",
     "grade": "弱",
     "label": "聚左旋乳酸注射后出现迟发皮下结节",
     "ref": "PMID:19207329"
    },
    {
     "year": 2009,
     "type": "队列研究",
     "grade": "中",
     "label": "聚左旋乳酸相关迟发肉芽肿平均潜伏期约19个月，部分反复发作",
     "ref": "PMID:19797889"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "综述比较各类填充物降解途径，永久性材料未见降解证据",
     "ref": "PMID:39649762"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "系统综述显示胶原刺激类填充物均可引起异物肉芽肿，非降解材料发生率更高、潜伏期更长",
     "ref": "PMID:41132036"
    }
   ],
   "first_year": 2008,
   "last_year": 2025,
   "n_evidence": 5,
   "scope": "注射层次过浅、剂量过大或反复注射的人更容易出现结节和残留，需要影像或病理确认。",
   "ask": [
    "这个材料大概多久降解完？",
    "出现结节时怎么判断是残留还是肉芽肿？",
    "能不能用影像看到材料分布？"
   ],
   "status": "verified",
   "rev_year": 2025
  },
  {
   "id": "ha-rhinoplasty-low-risk",
   "layer": "fails",
   "domain": "注射填充",
   "part": "鼻部",
   "claim": "玻尿酸隆鼻是低风险项目。",
   "plain": "鼻部血管丰富，鼻背动脉、角动脉与眼动脉存在吻合，填充物误入血管可能造成皮肤坏死甚至失明。大样本回顾里鼻部注射后出现皮肤坏死和感染的病例虽少但确有发生；把鼻部当低风险部位，容易低估解剖风险和急救要求。",
   "evidence": [
    {
     "year": 2012,
     "type": "队列研究",
     "grade": "中",
     "label": "面部填充导致视网膜动脉阻塞的病例分析包含鼻部注射",
     "ref": "PMID:22835509"
    },
    {
     "year": 2020,
     "type": "队列研究",
     "grade": "中",
     "label": "5000例鼻部注射回顾中记录感染与局部皮肤坏死",
     "ref": "PMID:32097303"
    },
    {
     "year": 2020,
     "type": "系统综述",
     "grade": "强",
     "label": "系统综述汇总玻尿酸填充相关视力丧失病例",
     "ref": "PMID:31822960"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "非手术鼻整形的并发症综述列出血管与皮肤坏死风险",
     "ref": "PMID:34587355"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "更新的系统综述总结鼻部注射的技术、结局与并发症",
     "ref": "PMID:38862661"
    }
   ],
   "first_year": 2012,
   "last_year": 2024,
   "n_evidence": 5,
   "scope": "既往做过鼻整形、鼻部有瘢痕或血管变异的人风险更高，需影像或超声评估。",
   "ask": [
    "鼻部注射用什么层次和工具？",
    "出现过皮肤发白或视力异常吗？",
    "机构有没有处理血管栓塞的预案？"
   ],
   "status": "verified",
   "rev_year": 2024
  },
  {
   "id": "hyaluronidase-single-shot",
   "layer": "fails",
   "domain": "注射填充",
   "part": "面部",
   "claim": "打一针溶解酶就能把透明质酸填充剂全部溶干净。",
   "plain": "不同产品对溶解酶的抵抗差别很大，体外研究里完全溶解同样体积的填充物，需要的酶量从几个单位到一百多个单位不等，交联度高、颗粒大的产品更耐药。血管并发症还要靠影像定位、反复给药和大剂量冲洗，一次注射常常不够。用量不足会残留，用量过大又增加局部反应和过敏风险。",
   "evidence": [
    {
     "year": 2018,
     "type": "共识",
     "grade": "强",
     "label": "专家共识按发生时间对填充并发症分类，并强调透明质酸酶在血管并发症中的紧急使用",
     "ref": "PMID:29305643"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "弱",
     "label": "体外研究测定22种透明质酸填充剂完全溶解所需的最低单次酶量，差异达数十倍",
     "ref": "PMID:40261260"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "系统综述汇总83例血管并发症，给药延迟与恢复慢、恢复不全相关",
     "ref": "PMID:41200269"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "弱",
     "label": "比较不同来源透明质酸酶对透明质酸的降解能力，降解效率存在差异",
     "ref": "PMID:40583609"
    },
    {
     "year": 2026,
     "type": "队列研究",
     "grade": "弱",
     "label": "实验研究显示透明质酸酶可以逆转填充效果，同时不破坏正常皮肤结构",
     "ref": "PMID:42136041"
    }
   ],
   "scope": "注射量小、材料敏感的人可能一次就够；血管并发症和耐药产品通常需要追加剂量或影像引导。",
   "ask": [
    "我打的产品大概需要多少单位的溶解酶？",
    "一次没溶干净的话，隔多久可以再打？",
    "怎么判断是溶完了还是还有残留？"
   ],
   "status": "verified",
   "first_year": 2018,
   "last_year": 2026,
   "n_evidence": 5,
   "rev_year": 2025
  },
  {
   "id": "sculptra-cosmetic-grade",
   "layer": "fails",
   "domain": "注射填充",
   "part": "面部",
   "claim": "童颜针、少女针属于护肤品级别。",
   "plain": "这类材料是注射用的医疗器械，不是化妆品。化妆品按法规只能涂擦、喷洒于体表，不得宣称医疗作用；童颜针、少女针要注射进真皮或皮下，属于侵入性医疗行为，必须在医疗机构由医师操作，风险和监管等级都远高于护肤品。",
   "evidence": [
    {
     "year": 2002,
     "type": "监管文件",
     "grade": "强",
     "label": "《医疗美容服务管理办法》把注射等侵入性方法界定为医疗美容",
     "ref": "卫生部令第19号 https://www.gov.cn/zhengce/2002-01/22/content_5713757.htm"
    },
    {
     "year": 2009,
     "type": "队列研究",
     "grade": "中",
     "label": "聚左旋乳酸注射后可出现迟发肉芽肿，需按注射类材料的相关风险处理",
     "ref": "PMID:19797889"
    },
    {
     "year": 2020,
     "type": "监管文件",
     "grade": "强",
     "label": "《化妆品监督管理条例》把化妆品限定为涂擦、喷洒等表面使用的日用化学工业产品",
     "ref": "国令第727号 https://www.gov.cn/zhengce/content/2020-06/29/content_5522593.htm"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "系统综述显示胶原刺激类注射填充物均可引起异物肉芽肿",
     "ref": "PMID:41132036"
    }
   ],
   "first_year": 2002,
   "last_year": 2025,
   "n_evidence": 4,
   "scope": "外用含同类成分的护肤品是另一回事，但不能因为名字相近就当成同一类产品。",
   "ask": [
    "这个产品是药品、医疗器械还是化妆品？",
    "注射的层次和剂量是多少？",
    "出现结节时怎么处理？"
   ],
   "status": "verified",
   "rev_year": 2025
  },
  {
   "id": "postop-immediate-activities",
   "layer": "fails",
   "domain": "注射填充",
   "part": "面部",
   "claim": "术后立刻可以化妆、运动、喝酒。",
   "plain": "注射和激光都会留下针孔或创面，术后一段时间内皮肤屏障不完整，化妆、出汗和酒精都可能增加感染、肿胀和淤青的风险。不同项目的恢复窗口不一样，术后护理是疗效和并发症管理的一部分，不是可有可无的形式。",
   "evidence": [
    {
     "year": 2016,
     "type": "系统综述",
     "grade": "强",
     "label": "综述指出无菌操作和减少组织创伤是预防填充物感染的关键",
     "ref": "PMID:27152101"
    },
    {
     "year": 2020,
     "type": "队列研究",
     "grade": "中",
     "label": "调查显示能量设备术前术后措施缺乏统一标准，术后护理直接影响恢复",
     "ref": "PMID:31840388"
    },
    {
     "year": 2020,
     "type": "系统综述",
     "grade": "强",
     "label": "共识建议用规范的操作与术后管理降低注射并发症",
     "ref": "PMID:32201935"
    },
    {
     "year": 2025,
     "type": "指南",
     "grade": "强",
     "label": "专家共识为深肤色人群的非剥脱能量项目给出术前、术中、术后分阶段护理方案",
     "ref": "PMID:39829119"
    }
   ],
   "first_year": 2016,
   "last_year": 2025,
   "n_evidence": 4,
   "scope": "无创的光电项目恢复窗口较短，但也要看能量和个体反应，不能一概而论。",
   "ask": [
    "这个项目术后多久可以化妆和运动？",
    "喝酒会不会增加淤青？",
    "出现异常红肿时怎么联系处理？"
   ],
   "status": "verified",
   "rev_year": 2025
  },
  {
   "id": "filler-treats-dark-circles",
   "layer": "fails",
   "domain": "注射填充",
   "part": "眼周",
   "claim": "打玻尿酸可以治黑眼圈。",
   "plain": "填充只对结构型有效，也就是凹陷投下的阴影。色素型是皮肤本身的色素沉着，填充没有作用；血管型是皮肤薄、静脉透出，填充有时能遮盖，也可能因为丁达尔现象让颜色更明显。把黑眼圈当成一个能靠一针解决的问题，是把三类不同的成因混成了一类。",
   "evidence": [
    {
     "year": 2016,
     "type": "系统综述",
     "grade": "强",
     "label": "眶周色素沉着综述，把色素、血管与结构因素分开，治疗方向不同",
     "ref": "PMID:26962392"
    },
    {
     "year": 2020,
     "type": "系统综述",
     "grade": "强",
     "label": "基于证据的眶周色素沉着诊断与治疗综述，填充只占其中一类手段",
     "ref": "PMID:34078228"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "眶周色素沉着治疗系统综述，多数干预证据质量偏低，需要按型选择",
     "ref": "PMID:32740208"
    },
    {
     "year": 2022,
     "type": "系统综述",
     "grade": "强",
     "label": "泪沟填充迟发并发症综述，丁达尔现象与变色是已知问题",
     "ref": "PMID:34666405"
    }
   ],
   "scope": "结构型为主的黑眼圈，填充确实能改善；混合型需要联合方案，单纯填充可能只解决一部分。",
   "ask": [
    "我的黑眼圈是色素、血管还是结构为主？",
    "如果打填充，出现丁达尔现象的概率有多大？",
    "除了填充，还有哪些针对我这个类型的选择？"
   ],
   "status": "verified",
   "first_year": 2016,
   "last_year": 2022,
   "n_evidence": 4,
   "rev_year": 2022
  },
  {
   "id": "fat-safer-than-ha",
   "layer": "fails",
   "domain": "注射填充",
   "part": "面部",
   "claim": "自体脂肪取自自己身上，所以比透明质酸填充剂安全。",
   "plain": "自体脂肪没有排异问题，但注射本身的风险并不更低。脂肪颗粒进入血管可以造成栓塞，面部脂肪注射后出现失明和脑梗的病例在文献里反复报告；脂肪没有对应的溶解酶，堵住血管只能靠扩血管和对症处理。安全取决于操作和解剖层次，不取决于材料从哪里来。",
   "evidence": [
    {
     "year": 2017,
     "type": "队列研究",
     "grade": "弱",
     "label": "病例报告与文献回顾记录面部脂肪注射后的眼部并发症，个别病例视力部分恢复",
     "ref": "PMID:28233134"
    },
    {
     "year": 2022,
     "type": "系统综述",
     "grade": "强",
     "label": "系统综述与Meta分析汇总面部脂肪移植后的眼部并发症",
     "ref": "PMID:35650299"
    },
    {
     "year": 2023,
     "type": "队列研究",
     "grade": "弱",
     "label": "病例报告与文献回顾记录面部脂肪注射后致命的脑脂肪栓塞",
     "ref": "PMID:37602257"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "系统综述与Meta分析评估面部脂肪注射后的脑部并发症",
     "ref": "PMID:39093359"
    }
   ],
   "scope": "需要大量填充、受区条件差的人，脂肪移植的量和层次风险更高；两种材料各有适应证，不能互相替代。",
   "ask": [
    "脂肪打进去以后如果堵了血管，有没有办法溶解？",
    "这个部位一次打多少毫升，分几层打？",
    "出现视力变化或剧烈头痛时怎么处理？"
   ],
   "status": "verified",
   "first_year": 2017,
   "last_year": 2024,
   "n_evidence": 4,
   "rev_year": 2024
  },
  {
   "id": "eye-area-injection-low-risk-claim",
   "layer": "fails",
   "domain": "注射填充",
   "part": "眼周",
   "claim": "眼周打针恢复快、剂量小，所以没什么风险。",
   "plain": "剂量小不等于风险小。眶周皮肤薄、血管吻合丰富、淋巴回流慢，同样剂量的材料在这里更容易出现丁达尔现象、迟发水肿、结节，误入血管还可能影响视力。恢复快说的是表面看不出切口，不代表并发症轻。这个部位的处理难度和后果，都比面颊高一档。",
   "evidence": [
    {
     "year": 2020,
     "type": "系统综述",
     "grade": "强",
     "label": "眶下注射并发症综述，指出该区域并发症类型与面部其他部位不同",
     "ref": "PMID:33794721"
    },
    {
     "year": 2022,
     "type": "系统综述",
     "grade": "强",
     "label": "泪沟填充迟发并发症的系统综述，结节与水肿是主要问题",
     "ref": "PMID:34666405"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "眶周透明质酸填充并发症综述，认为该区域需要更保守的策略",
     "ref": "PMID:40963300"
    },
    {
     "year": 2026,
     "type": "系统综述",
     "grade": "强",
     "label": "泪沟解剖与临床管理综述，强调术前评估与并发症处理预案",
     "ref": "PMID:42150047"
    }
   ],
   "scope": "确实有相当一部分人注射顺利、恢复快，这属于结果而不属于风险评估；既往注射史和皮肤条件会明显改变风险。",
   "ask": [
    "这个部位最常见的并发症是什么，出现了怎么处理？",
    "剂量小是不是就不需要备溶解酶？",
    "如果出现迟发水肿，多久能消退？"
   ],
   "status": "verified",
   "first_year": 2020,
   "last_year": 2026,
   "n_evidence": 4,
   "rev_year": 2026
  },
  {
   "id": "filler-migration-everywhere",
   "layer": "fails",
   "domain": "注射填充",
   "part": "面部",
   "claim": "透明质酸填充剂打进去会自己在脸上到处游走，打在哪个部位都留不住。",
   "plain": "注射后材料确实可能沿组织间隙有少量移位，尤其在皮肤薄、层次浅、剂量大的部位，但这是技术和解剖层面的问题，不是材料本身会跑。影像随访里材料大多留在注射区域，远隔部位出现填充物属于少见报告；把移位说成常态，会误导对剂量和层次的选择。",
   "evidence": [
    {
     "year": 2021,
     "type": "队列研究",
     "grade": "弱",
     "label": "磁共振可以用来随访填充剂的位置和存留时间，材料大多留在注射区域",
     "ref": "PMID:33002985"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "影像综述总结各类填充材料在面部的分布形态",
     "ref": "PMID:34881333"
    },
    {
     "year": 2026,
     "type": "队列研究",
     "grade": "中",
     "label": "三维磁共振测量显示填充剂在注射区域形成可测量的体积，部分产品还会膨胀",
     "ref": "PMID:42396227"
    },
    {
     "year": 2026,
     "type": "系统综述",
     "grade": "强",
     "label": "综述认为移位和过度填充与解剖知识、注射技术和病例选择有关，不是产品固有特性",
     "ref": "PMID:42499804"
    }
   ],
   "scope": "皮肤很薄、层次过浅、一次注射量过大的人，移位风险更高；少数病例报告过远隔部位出现材料。",
   "ask": [
    "这个部位打完后材料大概会留在哪一层？",
    "剂量怎么控制才能减少移位？",
    "如果以后在别处摸到硬块，怎么判断是不是填充物？"
   ],
   "status": "verified",
   "first_year": 2021,
   "last_year": 2026,
   "n_evidence": 4,
   "rev_year": 2026
  },
  {
   "id": "filler-then-no-energy",
   "layer": "fails",
   "domain": "注射填充",
   "part": "面部",
   "claim": "注射过填充剂以后，就不能再做激光和射频这类光电项目。",
   "plain": "同一天做和隔一段时间做，都是临床上常见的组合。共识建议同一天治疗时先做光电再注射，避免注射后按压；小样本随访里同日做低能量点阵激光和注射没有出现相关不良事件。真正需要留意的是能量参数、治疗顺序和注射层次，不是一句不能做。",
   "evidence": [
    {
     "year": 2019,
     "type": "共识",
     "grade": "强",
     "label": "共识建议同日联合治疗时先做光电再注射，避免注射后按压",
     "ref": "PMID:31073742"
    },
    {
     "year": 2021,
     "type": "队列研究",
     "grade": "中",
     "label": "两年半的回顾性随访未发现同日低能量点阵激光与注射联合治疗的相关不良事件",
     "ref": "PMID:33742533"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "中",
     "label": "对照研究评估675纳米激光与透明质酸填充联合治疗的安全性与效果",
     "ref": "PMID:40583534"
    }
   ],
   "scope": "刚注射完、局部还在肿胀或有血管并发症迹象时，应先观察；剥脱性高能量治疗也要按具体情况安排间隔。",
   "ask": [
    "这两项治疗建议隔多久做？",
    "同一天做的话，先做哪一项？",
    "做完光电后按压注射部位会不会有影响？"
   ],
   "status": "verified",
   "first_year": 2019,
   "last_year": 2025,
   "n_evidence": 3,
   "rev_year": 2019
  },
  {
   "id": "water-light-not-medical",
   "layer": "fails",
   "domain": "皮肤管理",
   "part": "面部",
   "claim": "水光针属于生活美容，不属于医疗行为。",
   "plain": "水光针是把透明质酸等物质注射进真皮，属于侵入性操作，按现行规定属于医疗美容，必须在取得医疗机构执业许可证的机构、由具备资质的医师实施。生活美容机构只能做清洁、护理等非侵入性项目，开展注射属于违规。",
   "evidence": [
    {
     "year": 2002,
     "type": "监管文件",
     "grade": "强",
     "label": "《医疗美容服务管理办法》把注射等侵入性方法界定为医疗美容，须在医疗机构由主诊医师实施",
     "ref": "卫生部令第19号 https://www.gov.cn/zhengce/2002-01/22/content_5713757.htm"
    },
    {
     "year": 2008,
     "type": "队列研究",
     "grade": "中",
     "label": "中胚层注射后分枝杆菌脓肿暴发，提示以无创名义开展的注射同样有感染风险",
     "ref": "PMID:18200353"
    },
    {
     "year": 2010,
     "type": "队列研究",
     "grade": "中",
     "label": "美容注射相关分枝杆菌感染暴发被报道",
     "ref": "PMID:19840199"
    },
    {
     "year": 2020,
     "type": "监管文件",
     "grade": "强",
     "label": "《化妆品监督管理条例》把化妆品限定为涂擦、喷洒等表面使用，不得宣称医疗作用",
     "ref": "国令第727号 https://www.gov.cn/zhengce/content/2020-06/29/content_5522593.htm"
    },
    {
     "year": 2021,
     "type": "监管文件",
     "grade": "强",
     "label": "《医疗美容广告执法指南》要求生活美容机构不得开展医疗美容宣传，发现即通报卫健部门",
     "ref": "市场监管总局公告2021年第37号 https://www.gov.cn/zhengce/zhengceku/2021-11/04/content_5648772.htm"
    }
   ],
   "first_year": 2002,
   "last_year": 2021,
   "n_evidence": 5,
   "scope": "只做表面涂抹、无创导入的项目不属于医疗美容；一旦突破皮肤屏障，性质就变了。",
   "ask": [
    "这个项目算医疗美容还是生活美容？",
    "操作的人有没有医师资质？",
    "机构有没有对应的诊疗科目？"
   ],
   "status": "verified",
   "rev_year": 2021
  },
  {
   "id": "acid-peel-all-acne-marks",
   "layer": "fails",
   "domain": "皮肤管理",
   "part": "面部",
   "claim": "刷酸能去掉各种痘印。",
   "plain": "痘印分红色、褐色和凹陷性瘢痕，化学剥脱对浅表色素和部分浅层瘢痕有帮助，对冰锥型、车厢型和滚动型凹陷瘢痕作用有限。Cochrane系统综述认为现有研究质量低，没有哪种干预可以作为痘印的一线方案；深肤色人群刷酸后出现炎症后色素沉着的风险更高。",
   "evidence": [
    {
     "year": 2008,
     "type": "指南",
     "grade": "强",
     "label": "化学剥脱指南把适应证限定为浅表性痤疮瘢痕和色素性问题，并列出禁忌证",
     "ref": "PMID:18688104"
    },
    {
     "year": 2016,
     "type": "系统综述",
     "grade": "强",
     "label": "Cochrane综述纳入24项试验，认为痘印治疗缺少高质量证据，不支持任何干预作为一线",
     "ref": "PMID:27038134"
    },
    {
     "year": 2016,
     "type": "系统综述",
     "grade": "强",
     "label": "美容操作后炎症后色素沉着的综述指出亚洲人和有黄褐斑史者风险更高",
     "ref": "PMID:29452657"
    },
    {
     "year": 2023,
     "type": "系统综述",
     "grade": "强",
     "label": "痘印综述把凹陷性瘢痕分为冰锥、车厢和滚动三型，不同术式证据强弱不同",
     "ref": "PMID:38059974"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "68项随机对照试验的网状Meta分析显示联合方案排名靠前，单用剥脱并非最优",
     "ref": "PMID:41081097"
    }
   ],
   "scope": "浅表色素和轻度粗糙可以改善；凹陷性瘢痕、活动期痤疮和深肤色人群需要联合方案并先控制炎症。",
   "ask": [
    "我的痘印是色素还是凹陷瘢痕？",
    "刷酸之外还需要配合什么治疗？",
    "我的肤色刷酸后色沉风险有多高？"
   ],
   "status": "verified",
   "first_year": 2008,
   "last_year": 2025,
   "n_evidence": 5,
   "rev_year": 2025
  },
  {
   "id": "needle-free-water-light-dermis",
   "layer": "fails",
   "domain": "皮肤管理",
   "part": "面部",
   "claim": "无针水光不用针，也能把营养送进真皮。",
   "plain": "皮肤角质层是主要屏障，分子量小于500道尔顿、偏脂溶的物质才容易透过去；透明质酸分子量大，高分子量透明质酸基本停在角质层，低分子量也只能进入浅层。高压喷射类无针设备确实能把少量材料送入真皮浅层，但深度随压力变化，剂量和层次跟注射水光不是一回事；电穿孔、超声类导入的作用更浅。",
   "evidence": [
    {
     "year": 2008,
     "type": "系统综述",
     "grade": "强",
     "label": "透皮给药综述指出第一代透皮系统只适合小分子、脂溶性、低剂量药物",
     "ref": "PMID:18997767"
    },
    {
     "year": 2016,
     "type": "队列研究",
     "grade": "中",
     "label": "拉曼光谱显示20至300 kDa透明质酸可穿过角质层，1000至1400 kDa高分子量透明质酸不能透过",
     "ref": "PMID:25877232"
    },
    {
     "year": 2016,
     "type": "队列研究",
     "grade": "弱",
     "label": "尸体研究显示无针喷射在6巴和8.5巴下穿透深度分别约2.3毫米和8.9毫米，深度随压力变化",
     "ref": "PMID:27075398"
    },
    {
     "year": 2019,
     "type": "系统综述",
     "grade": "强",
     "label": "微针透皮综述指出分子量小于500道尔顿才易透皮，多肽和核酸等大分子需要微针等物理方式",
     "ref": "PMID:30348022"
    },
    {
     "year": 2023,
     "type": "队列研究",
     "grade": "中",
     "label": "人体试验显示外用透明质酸主要停留在角质层，重复使用可在角质层累积",
     "ref": "PMID:36549259"
    }
   ],
   "scope": "高压喷射设备能把少量材料送入真皮浅层，但覆盖范围和剂量有限；透明质酸填充和深层补水仍以注射为主，不能按无针宣传等同。",
   "ask": [
    "这个无针设备是喷射、电穿孔还是超声？",
    "用的透明质酸分子量多大？",
    "能送到多深，有没有检测数据？"
   ],
   "status": "verified",
   "first_year": 2008,
   "last_year": 2023,
   "n_evidence": 5,
   "rev_year": 2019
  },
  {
   "id": "skincare-cannot-replace-procedures",
   "layer": "fails",
   "domain": "皮肤管理",
   "part": "面部",
   "claim": "护肤品能替代医美。",
   "plain": "护肤品能改善角质层状态、肤色和细纹，维A酸类也有长期证据；但面部老化还涉及脂肪垫下移、筋膜松弛和骨性改变，这些层面外用成分到不了。综述明确，软组织下垂和容量缺失仍以手术为标准处理；把日常护肤当成医美替代，会耽误对适应证的判断。",
   "evidence": [
    {
     "year": 2008,
     "type": "系统综述",
     "grade": "强",
     "label": "透皮给药综述指出角质层限制大多数成分的吸收，只有特定理化性质的小分子能有效透皮",
     "ref": "PMID:18997767"
    },
    {
     "year": 2016,
     "type": "队列研究",
     "grade": "中",
     "label": "拉曼光谱显示高分子量透明质酸不能穿过角质层",
     "ref": "PMID:25877232"
    },
    {
     "year": 2023,
     "type": "系统综述",
     "grade": "强",
     "label": "中面部老化综述显示脂肪垫下移和骨性改变参与面部老化",
     "ref": "PMID:36700849"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "面部抗衰药物与非手术治疗的综述认为软组织下垂和容量缺失仍以手术为标准处理",
     "ref": "PMID:39314107"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "外用抗光老化网状Meta分析显示外用成分改善细纹和色素，观察终点集中在皮肤表面",
     "ref": "PMID:40707570"
    }
   ],
   "scope": "肤色、细纹和屏障问题可以靠护肤改善；松弛、容量缺失和轮廓改变需要光电、注射或手术，具体方案由医生按解剖层次判断。",
   "ask": [
    "我的问题是皮肤质地还是软组织下垂？",
    "护肤能做到什么程度，哪些需要治疗？",
    "如果先做护肤观察，多久复评一次？"
   ],
   "status": "verified",
   "first_year": 2008,
   "last_year": 2025,
   "n_evidence": 5,
   "rev_year": 2025
  },
  {
   "id": "medical-mask-not-superior",
   "layer": "fails",
   "domain": "皮肤管理",
   "part": "面部",
   "claim": "医用面膜比普通面膜好很多。",
   "plain": "所谓医用面膜多指按医疗器械注册的敷料，注册适用范围是创面护理，不是日常护肤；普通面膜按化妆品管理。两者在保湿和舒缓上的差别，公开的头对头研究很少。敷料在激光术后有随机试验支持，但日常拿来当护肤品，效果和普通保湿面膜接近，长时间敷还可能增加干燥和红斑。",
   "evidence": [
    {
     "year": 2014,
     "type": "队列研究",
     "grade": "中",
     "label": "随机临床研究显示撕拉式面膜的保湿和紧致效果是短期的",
     "ref": "PMID:24750029"
    },
    {
     "year": 2020,
     "type": "监管文件",
     "grade": "强",
     "label": "《化妆品监督管理条例》把化妆品限定为涂擦、喷洒等表面使用，不得宣称医疗作用",
     "ref": "国令第727号 https://www.gov.cn/zhengce/content/2020-06/29/content_5522593.htm"
    },
    {
     "year": 2021,
     "type": "监管文件",
     "grade": "强",
     "label": "《医疗器械监督管理条例》规定医疗器械按风险分类管理，注册证载明适用范围",
     "ref": "国令第739号 https://www.gov.cn/zhengce/content/2021-03/18/content_5593739.htm"
    },
    {
     "year": 2024,
     "type": "队列研究",
     "grade": "中",
     "label": "随机对照显示面膜敷用短于25分钟可暂时提高角质层含水量，超过25分钟反而增加干燥和红斑",
     "ref": "PMID:38951050"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "中",
     "label": "双盲随机试验显示含泛醇的敷料能改善非剥脱激光术后的红斑和水分丢失",
     "ref": "PMID:40613435"
    }
   ],
   "scope": "激光、剥脱等术后按医嘱使用敷料有证据；日常护肤选择妆字号面膜即可，重点在成分和耐受，不在字号。",
   "ask": [
    "这个面膜是医疗器械还是化妆品？",
    "它的注册适用范围写的是什么？",
    "术后用和日常用，需要区分吗？"
   ],
   "status": "verified",
   "first_year": 2014,
   "last_year": 2025,
   "n_evidence": 5,
   "rev_year": 2021
  },
  {
   "id": "license-equals-safety",
   "layer": "fails",
   "domain": "监管",
   "part": "全身",
   "claim": "机构有医疗机构执业许可证就等于操作安全。",
   "plain": "许可证只说明机构具备开展医疗美容的资格，具体项目还要看诊疗科目备案、操作者有没有主诊医师资格、产品是否合规。有证的机构同样会出现严重并发症，文献里的感染、血管栓塞和坏死并不只发生在无证场所。",
   "evidence": [
    {
     "year": 2002,
     "type": "监管文件",
     "grade": "强",
     "label": "《医疗美容服务管理办法》要求机构有许可证，同时要求项目备案和主诊医师负责制",
     "ref": "卫生部令第19号 https://www.gov.cn/zhengce/2002-01/22/content_5713757.htm"
    },
    {
     "year": 2020,
     "type": "队列研究",
     "grade": "中",
     "label": "合法与非法填充物对比研究显示合法产品也可能出现血管并发症",
     "ref": "PMID:32418301"
    },
    {
     "year": 2022,
     "type": "队列研究",
     "grade": "中",
     "label": "7659例注射填充回顾分析记录严重不良事件",
     "ref": "PMID:35170541"
    },
    {
     "year": 2024,
     "type": "系统综述",
     "grade": "强",
     "label": "系统综述显示玻尿酸填充的严重不良事件在规范操作下仍会发生",
     "ref": "PMID:37563436"
    }
   ],
   "first_year": 2002,
   "last_year": 2024,
   "n_evidence": 4,
   "scope": "许可证是必要条件，不是充分条件；人员资质、项目备案和急救能力要单独核对。",
   "ask": [
    "这个项目在机构的诊疗科目里备案了吗？",
    "操作者的主诊医师资格是什么？",
    "机构的并发症处理和转诊流程是什么？"
   ],
   "status": "verified",
   "rev_year": 2024
  },
  {
   "id": "compliance-consent-shields-liability",
   "layer": "fails",
   "domain": "监管",
   "part": "机构",
   "claim": "只要签了知情同意书，机构就对治疗结果不再承担责任。",
   "plain": "知情同意书证明的是告知义务履行过，不等于责任归零。民法典规定医务人员未尽说明义务造成损害的应承担赔偿责任；即便签了字，如果诊疗行为本身违反诊疗规范，或者存在隐匿、拒绝提供病历等情形，责任仍可能成立。实务里看的是告知是否充分、操作是否合规，签字本身两个方向都不足以定论。",
   "evidence": [
    {
     "year": 2002,
     "type": "监管文件",
     "grade": "强",
     "label": "第十九条规定实施治疗前必须书面告知适应症、禁忌症、医疗风险和注意事项并取得签字同意",
     "ref": "卫生部令第19号 https://www.gov.cn/zhengce/2002-01/22/content_5713757.htm"
    },
    {
     "year": 2018,
     "type": "监管文件",
     "grade": "强",
     "label": "《医疗纠纷预防和处理条例》要求医疗机构就病情、措施、风险等向就医者说明并取得书面同意",
     "ref": "国令第701号 https://www.gov.cn/zhengce/content/2018-08/31/content_5318057.htm"
    },
    {
     "year": 2020,
     "type": "监管文件",
     "grade": "强",
     "label": "民法典规定医务人员未尽说明义务造成损害的应承担赔偿责任，并列举推定医疗机构有过错的情形",
     "ref": "中华人民共和国民法典第七编第六章 https://szb.suqian.gov.cn/sqsz/fgwj/202411/b574f99304434c1faa823b8701d5f84f.shtml"
    },
    {
     "year": 2021,
     "type": "监管文件",
     "grade": "强",
     "label": "医师法规定医师应当向就医者说明病情与医疗措施并取得同意",
     "ref": "中华人民共和国医师法 https://wjw.jiangsu.gov.cn/art/2023/2/27/art_49492_10770673.html"
    }
   ],
   "scope": "签字不能一概免除责任，也不能反推机构一定有过错；责任成立与否要看告知内容与诊疗行为本身。",
   "ask": [
    "这份同意书上写明了哪些具体风险和替代方案？",
    "告知是口头还是书面，有没有给我留一份？",
    "如果出现同意书上没写的并发症，怎么处理？"
   ],
   "status": "verified",
   "first_year": 2002,
   "last_year": 2021,
   "n_evidence": 4,
   "rev_year": 2021
  },
  {
   "id": "price-equals-safety",
   "layer": "fails",
   "domain": "监管",
   "part": "全身",
   "claim": "医美项目价格越贵越安全。",
   "plain": "安全取决于产品是否合规、操作者有没有资质、解剖层次判断和急救能力，这些和价格没有对应关系。监管处罚的案例里，收费不低的机构同样会因为夸大功效、使用未获批产品被罚；把价格当安全指标，容易忽略更关键的资质和适应证问题。",
   "evidence": [
    {
     "year": 2020,
     "type": "队列研究",
     "grade": "中",
     "label": "合法与非法填充物对比研究显示不良反应更多与产品和操作者资质相关",
     "ref": "PMID:32418301"
    },
    {
     "year": 2021,
     "type": "监管文件",
     "grade": "强",
     "label": "《医疗美容广告执法指南》把对安全性、功效作保证性承诺列为重点打击情形",
     "ref": "市场监管总局公告2021年第37号 https://www.gov.cn/zhengce/zhengceku/2021-11/04/content_5648772.htm"
    },
    {
     "year": 2025,
     "type": "监管文件",
     "grade": "强",
     "label": "市场监管总局违法广告典型案例中，医疗美容机构因宣称功效与实际不符被处罚",
     "ref": "市场监管总局2025年7月违法广告典型案例 https://www.samr.gov.cn/zt/ndzt/2025n/zhzznjsjzwhgpjzsczx/gzdt/art/2025/art_efdde550581749589b4704357045660b.html"
    },
    {
     "year": 2026,
     "type": "系统综述",
     "grade": "强",
     "label": "专家共识指出很多现行建议缺少高质量证据，安全性判断不能靠单一指标",
     "ref": "PMID:42696333"
    }
   ],
   "first_year": 2020,
   "last_year": 2026,
   "n_evidence": 4,
   "scope": "高价项目可能包含更好的设备或服务，但这不等于风险更低，仍需按资质和适应证判断。",
   "ask": [
    "这个价格里包含哪些具体项目？",
    "用的产品和设备有没有正规注册？",
    "操作者的资质和急救预案是什么？"
   ],
   "status": "verified",
   "rev_year": 2026
  },
  {
   "id": "unlicensed-practitioner-skills",
   "layer": "fails",
   "domain": "监管",
   "part": "机构",
   "claim": "没有执业证的「老师」只要技术好，做注射也没问题。",
   "plain": "医疗美容服务属于医疗活动，操作者必须是在医疗机构执业、具备相应资格的医师。没有执业资格的人实施注射，性质上是非法行医，技术好坏不改变这个定性。真出了事，血管栓塞和过敏反应的处置需要急救能力和药品储备，这些不是熟练度能替代的。",
   "evidence": [
    {
     "year": 2002,
     "type": "监管文件",
     "grade": "强",
     "label": "医疗美容服务管理办法要求医疗美容项目由具备资格的医师在取得许可的医疗机构内实施",
     "ref": "卫生部令第19号 https://www.gov.cn/zhengce/2002-01/22/content_5713757.htm"
    },
    {
     "year": 2008,
     "type": "监管文件",
     "grade": "强",
     "label": "A型肉毒毒素按毒性药品管理，使用者须为具备资质的医师并按规定开具处方",
     "ref": "国食药监办〔2008〕405号 https://wsjkw.sh.gov.cn/yzgl4/20180815/0012-60884.html"
    },
    {
     "year": 2023,
     "type": "监管文件",
     "grade": "强",
     "label": "十一部门指导意见要求清理无证行医，并强化行刑衔接",
     "ref": "关于进一步加强医疗美容行业监管工作的指导意见 https://www.gov.cn/lianbo/2023-05/05/content_5754184.htm"
    }
   ],
   "scope": "医师的执业范围也有边界，取得执业资格不等于可以做所有项目，跨范围执业仍属违规。",
   "ask": [
    "你的医师执业证书能给我看一下吗？",
    "你的执业范围包含这个项目吗？",
    "如果出现血管栓塞，这里有什么急救设备和药品？"
   ],
   "status": "verified",
   "first_year": 2002,
   "last_year": 2023,
   "n_evidence": 3,
   "rev_year": 2023
  },
  {
   "id": "any-project-under-license",
   "layer": "fails",
   "domain": "监管",
   "part": "机构",
   "claim": "机构只要注册了医疗美容，什么项目都能做。",
   "plain": "执业许可只是第一层，具体能做什么还受诊疗科目和项目分级管理约束。医疗美容项目按风险分为不同级别，不同级别的机构可开展的范围不同，超出范围执业属于违规。另外，麻醉、输血、急救等配套能力也决定了某些项目能不能安全开展，这些不在许可证的字面上。",
   "evidence": [
    {
     "year": 2002,
     "type": "监管文件",
     "grade": "强",
     "label": "医疗美容服务管理办法要求按核准的诊疗科目开展项目，并实行主诊医师负责制",
     "ref": "卫生部令第19号 https://www.gov.cn/zhengce/2002-01/22/content_5713757.htm"
    },
    {
     "year": 2018,
     "type": "监管文件",
     "grade": "强",
     "label": "医疗纠纷预防和处理条例要求医疗机构具备与诊疗活动相适应的场所、设备与人员",
     "ref": "国务院令第701号 https://www.gov.cn/zhengce/content/2018-08/31/content_5318057.htm"
    },
    {
     "year": 2023,
     "type": "监管文件",
     "grade": "强",
     "label": "十一部门指导意见要求细化审批标准、把好行业准入关口，并把诊疗活动纳入综合监管重点事项",
     "ref": "关于进一步加强医疗美容行业监管工作的指导意见 https://www.gov.cn/lianbo/2023-05/05/content_5754184.htm"
    }
   ],
   "scope": "项目分级的具体归属以现行目录与地方规定为准，同一名称的项目在不同机构可能对应不同级别；急救与麻醉能力需要单独确认。",
   "ask": [
    "这个项目在你们的诊疗科目范围内吗，属于几级项目？",
    "如果术中出现意外，你们的急救和转诊流程是什么？",
    "这里有没有麻醉科或者对应的抢救条件？"
   ],
   "status": "verified",
   "first_year": 2002,
   "last_year": 2023,
   "n_evidence": 3,
   "rev_year": 2023
  },
  {
   "id": "compliance-business-license-enough",
   "layer": "fails",
   "domain": "监管",
   "part": "机构",
   "claim": "生活美容机构只要办了营业执照，就可以开展注射类医美项目。",
   "plain": "营业执照解决的是经营主体登记，医疗美容属于医疗活动，要另取得《医疗机构执业许可证》并在核准的诊疗科目内开展。《医疗美容服务管理办法》第二十三条规定，未取得许可证并经登记机关核准医疗美容诊疗科目的，不得开展医疗美容服务；2023 年十一部门指导意见明确生活美容机构不得开展医疗美容。注射用的针剂还要按医疗器械或药品管理。",
   "evidence": [
    {
     "year": 2002,
     "type": "监管文件",
     "grade": "强",
     "label": "第二十三条规定未取得《医疗机构执业许可证》并经核准医疗美容诊疗科目的，不得开展医疗美容服务",
     "ref": "卫生部令第19号 https://www.gov.cn/zhengce/2002-01/22/content_5713757.htm"
    },
    {
     "year": 2021,
     "type": "监管文件",
     "grade": "强",
     "label": "医疗器械使用单位应具备相应条件并执行进货查验，使用的器械应经注册或备案",
     "ref": "国令第739号 https://www.gov.cn/zhengce/content/2021-03/18/content_5593739.htm"
    },
    {
     "year": 2023,
     "type": "监管文件",
     "grade": "强",
     "label": "十一部门指导意见明确生活美容机构不得开展医疗美容服务",
     "ref": "关于进一步加强医疗美容行业监管工作的指导意见 https://www.gov.cn/lianbo/2023-05/05/content_5754184.htm"
    }
   ],
   "scope": "已取得医疗机构许可但超出核准科目开展的，同样属于超范围执业，与有没有营业执照无关。",
   "ask": [
    "给我操作的场所有《医疗机构执业许可证》吗？",
    "执照上的经营范围写的是生活美容还是医疗美容？",
    "给我注射的针剂是什么注册证号，能不能现场查？"
   ],
   "status": "verified",
   "first_year": 2002,
   "last_year": 2023,
   "n_evidence": 3,
   "rev_year": 2023
  },
  {
   "id": "medical-not-pure-consumption",
   "layer": "fails",
   "domain": "监管",
   "part": "机构",
   "claim": "医美属于普通消费，出了问题按消费者权益保护法退一赔三就够了。",
   "plain": "医美兼具医疗属性和消费属性，但监管口径已经明确，医疗美容服务属于医疗活动，要遵守卫生健康行业的准入规定。争议怎么定性要看具体情形，涉及诊疗行为的按医疗损害处理，涉及虚假宣传和欺诈的可以适用消费者权益保护的规定，两者并不互斥。把医美当成普通消费，容易忽略医疗行为本身的过错认定规则。",
   "evidence": [
    {
     "year": 2018,
     "type": "监管文件",
     "grade": "强",
     "label": "医疗纠纷预防和处理条例按医疗损害责任处理诊疗活动中的争议，明确协商、调解与诉讼的路径",
     "ref": "国务院令第701号 https://www.gov.cn/zhengce/content/2018-08/31/content_5318057.htm"
    },
    {
     "year": 2021,
     "type": "监管文件",
     "grade": "强",
     "label": "《医疗美容广告执法指南》把医疗美容广告定性为医疗广告，按医疗广告的规则管理",
     "ref": "市场监管总局公告2021年第37号 https://www.gov.cn/zhengce/zhengceku/2021-11/04/content_5648772.htm"
    },
    {
     "year": 2023,
     "type": "监管文件",
     "grade": "强",
     "label": "十一部门指导意见明确规定医疗美容服务属于医疗活动，必须遵守卫生健康有关行业准入的法律法规",
     "ref": "关于进一步加强医疗美容行业监管工作的指导意见 https://www.gov.cn/lianbo/2023-05/05/content_5754184.htm"
    }
   ],
   "scope": "具体案件适用哪部法律，取决于争议焦点是诊疗过错还是虚假宣传与欺诈，实务中存在不同判法，不能一概而论。",
   "ask": [
    "这次争议的性质是诊疗过错，还是宣传与承诺不实？",
    "如果按医疗损害处理，需要做哪一类鉴定？",
    "哪些情形可以同时主张消费欺诈？"
   ],
   "status": "verified",
   "first_year": 2018,
   "last_year": 2023,
   "n_evidence": 3,
   "rev_year": 2023
  },
  {
   "id": "deregistration-no-liability",
   "layer": "fails",
   "domain": "监管",
   "part": "机构",
   "claim": "机构注销了，出了问题就找不到人赔。",
   "plain": "机构注销不等于责任消失。诊疗行为造成的损害，责任主体可以是机构，也可以是具体实施诊疗的医师；机构注销后，还可以向举办者、出资人追责，涉及非法行医的走刑事路径。病历、收费记录、支付凭证和聊天记录都要留存，这些是确定责任主体的关键。",
   "evidence": [
    {
     "year": 2018,
     "type": "监管文件",
     "grade": "强",
     "label": "医疗纠纷预防和处理条例规定病历资料的管理与查阅复制，为事后追责留下证据基础",
     "ref": "国务院令第701号 https://www.gov.cn/zhengce/content/2018-08/31/content_5318057.htm"
    },
    {
     "year": 2021,
     "type": "监管文件",
     "grade": "强",
     "label": "《医疗美容广告执法指南》要求发现无证机构及时通报卫生健康部门，形成跨部门线索流转",
     "ref": "市场监管总局公告2021年第37号 https://www.gov.cn/zhengce/zhengceku/2021-11/04/content_5648772.htm"
    },
    {
     "year": 2023,
     "type": "监管文件",
     "grade": "强",
     "label": "十一部门指导意见要求登记管理、资质审核与行刑衔接贯通，防止机构通过注销逃避监管",
     "ref": "关于进一步加强医疗美容行业监管工作的指导意见 https://www.gov.cn/lianbo/2023-05/05/content_5754184.htm"
    }
   ],
   "scope": "责任主体的认定要看诊疗行为由谁实施、费用由谁收取，证据不足时维权难度会明显上升；跨地区追责成本更高。",
   "ask": [
    "诊疗行为是机构做的，还是某个医生个人做的？",
    "收费凭证上的收款方是谁？",
    "如果机构注销，我的病历还能从哪里调取？"
   ],
   "status": "verified",
   "first_year": 2018,
   "last_year": 2023,
   "n_evidence": 3,
   "rev_year": 2023
  },
  {
   "id": "compliance-only-litigation",
   "layer": "fails",
   "domain": "监管",
   "part": "机构",
   "claim": "医美出了纠纷，只能到法院起诉才能解决。",
   "plain": "医疗纠纷的处理途径不止诉讼。医疗纠纷预防和处理条例列了双方自愿协商、申请人民调解、申请行政调解和提起诉讼几条路，还要求医疗机构建立投诉接待与纠纷处理机制。诉讼是最后一条，周期与举证成本最高，多数纠纷在协商或调解阶段处理。",
   "evidence": [
    {
     "year": 2018,
     "type": "监管文件",
     "grade": "强",
     "label": "条例规定医疗纠纷可以通过双方自愿协商、申请人民调解、申请行政调解和提起诉讼等途径解决",
     "ref": "国令第701号 https://www.gov.cn/zhengce/content/2018-08/31/content_5318057.htm"
    },
    {
     "year": 2018,
     "type": "监管文件",
     "grade": "强",
     "label": "国务院令第701号公布《医疗纠纷预防和处理条例》，自2018年10月1日起施行",
     "ref": "国令第701号 国务院公报 https://www.gov.cn/gongbao/content/2018/content_5323086.htm"
    },
    {
     "year": 2020,
     "type": "监管文件",
     "grade": "强",
     "label": "民法典医疗损害责任章规定医疗机构及其医务人员的赔偿责任与举证规则",
     "ref": "中华人民共和国民法典第七编第六章 https://szb.suqian.gov.cn/sqsz/fgwj/202411/b574f99304434c1faa823b8701d5f84f.shtml"
    }
   ],
   "scope": "协商与调解达成的协议不排除后续诉讼；涉及伤残或死亡的，鉴定与诉讼仍可能是必要路径。",
   "ask": [
    "机构内部有没有投诉接待和纠纷处理的对接人？",
    "可以申请医患纠纷人民调解吗，去哪里申请？",
    "走协商的话，和解协议里哪些内容要写清楚？"
   ],
   "status": "verified",
   "first_year": 2018,
   "last_year": 2020,
   "n_evidence": 3,
   "rev_year": 2020
  },
  {
   "id": "compliance-records-withheld",
   "layer": "fails",
   "domain": "监管",
   "part": "机构",
   "claim": "病历是机构内部资料，就医者要求查阅复制时可以不给。",
   "plain": "医疗纠纷预防和处理条例规定就医者有权查阅、复制属于病历的全部资料，医疗机构应当提供。民法典进一步规定，隐匿或者拒绝提供与纠纷有关的病历资料，推定医疗机构有过错。病历既是诊疗记录，也是纠纷里的关键证据，扣着不给对机构不利。",
   "evidence": [
    {
     "year": 2018,
     "type": "监管文件",
     "grade": "强",
     "label": "第十六条规定就医者有权查阅、复制属于病历的全部资料，医疗机构应当提供",
     "ref": "国令第701号 https://www.gov.cn/zhengce/content/2018-08/31/content_5318057.htm"
    },
    {
     "year": 2020,
     "type": "监管文件",
     "grade": "强",
     "label": "民法典规定隐匿或者拒绝提供与纠纷有关的病历资料，推定医疗机构有过错",
     "ref": "中华人民共和国民法典第七编第六章 https://szb.suqian.gov.cn/sqsz/fgwj/202411/b574f99304434c1faa823b8701d5f84f.shtml"
    },
    {
     "year": 2021,
     "type": "监管文件",
     "grade": "强",
     "label": "医师法禁止隐匿、伪造、篡改或者擅自销毁病历等医学文书及有关资料",
     "ref": "中华人民共和国医师法 https://wjw.jiangsu.gov.cn/art/2023/2/27/art_49492_10770673.html"
    }
   ],
   "scope": "查阅复制按规定的程序和时限办理；涉及第三方隐私的内容可能作技术处理，但不影响本人查阅。",
   "ask": [
    "我要复印全部病历，包括病程记录和手术记录，流程怎么走？",
    "复印一般要多久，费用怎么算？",
    "如果机构拖着不给，我可以向哪个部门反映？"
   ],
   "status": "verified",
   "first_year": 2018,
   "last_year": 2021,
   "n_evidence": 3,
   "rev_year": 2021
  },
  {
   "id": "compliance-counterfeit-online-products",
   "layer": "fails",
   "domain": "监管",
   "part": "机构",
   "claim": "网上买到或代购来的注射类产品，与正规渠道的正品没有差别。",
   "plain": "注射类填充剂属于医疗器械，肉毒素属于药品，都要经批准注册或审批才能生产、进口和销售。药品管理法要求药品取得批准证明文件，未取得批准证明文件进口、销售的属于违法；医疗器械未经注册或备案不得使用。代购渠道的运输与储存往往脱离冷链要求，真伪也不能靠包装和价格判断。",
   "evidence": [
    {
     "year": 2019,
     "type": "监管文件",
     "grade": "强",
     "label": "药品管理法要求药品取得批准证明文件，并对未取得批准证明文件进口、销售药品以及假药、劣药作出规定",
     "ref": "中华人民共和国药品管理法 https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/fgs/art/2023/art_b73ec9dabb2d468281d6c994b4bcdaf8.html"
    },
    {
     "year": 2021,
     "type": "监管文件",
     "grade": "强",
     "label": "医疗器械监督管理条例要求医疗器械经注册或备案，使用单位应执行进货查验",
     "ref": "国令第739号 https://www.gov.cn/zhengce/content/2021-03/18/content_5593739.htm"
    },
    {
     "year": 2026,
     "type": "监管文件",
     "grade": "强",
     "label": "《药品管理法实施条例》对药品进口与经营环节的管理作出具体规定",
     "ref": "中华人民共和国药品管理法实施条例 https://www.gov.cn/zhengce/zhengceku/202601/content_7056256.htm"
    }
   ],
   "scope": "个人自用少量携带与经营销售的定性不同；有没有注册证可以查，真伪不能靠包装分辨。",
   "ask": [
    "这个针剂的医疗器械注册证号或药品批准文号是多少？",
    "能不能现场在药监部门网站上查到这支产品？",
    "产品是怎么运输和储存的，有没有冷链记录？"
   ],
   "status": "verified",
   "first_year": 2019,
   "last_year": 2026,
   "n_evidence": 3,
   "rev_year": 2026
  },
  {
   "id": "ad-claims-legal-effect",
   "layer": "fails",
   "domain": "监管",
   "part": "机构",
   "claim": "广告里写的效果和承诺，是有法律效力的，做不到就可以按广告赔。",
   "plain": "广告里的效果描述本身不是合同条款，但虚假宣传和保证性承诺是违法的，会被市场监管部门查处。就医者主张赔偿，通常要走欺诈或者医疗损害的路径，需要证明宣传内容不实、自己因此作出决定并受到损害。把广告当成合同直接索赔，多数情况下走不通。",
   "evidence": [
    {
     "year": 2021,
     "type": "监管文件",
     "grade": "强",
     "label": "《医疗美容广告执法指南》把对诊疗效果作保证性承诺、使用就医者形象作对比列为重点打击情形",
     "ref": "市场监管总局公告2021年第37号 https://www.gov.cn/zhengce/zhengceku/2021-11/04/content_5648772.htm"
    },
    {
     "year": 2023,
     "type": "监管文件",
     "grade": "强",
     "label": "十一部门指导意见要求对虚假宣传保持高压，并把线索纳入综合监管",
     "ref": "关于进一步加强医疗美容行业监管工作的指导意见 https://www.gov.cn/lianbo/2023-05/05/content_5754184.htm"
    },
    {
     "year": 2026,
     "type": "监管文件",
     "grade": "强",
     "label": "市场监管总局公布的违法广告典型案例中，医美机构因虚构销量、冒用审查文号等被处罚",
     "ref": "市场监管总局2026年违法广告典型案例 https://www.samr.gov.cn/xw/zj/art/2026/art_b7802ad0a4dc407ea1b10a8a53a5792f.html"
    }
   ],
   "scope": "宣传内容被认定构成欺诈的，可以按消费者权益保护的规定主张赔偿；这需要证据，光凭一句口头承诺通常不够。",
   "ask": [
    "广告里这句话，能不能写进术前告知和病历？",
    "如果效果没达到，机构按什么标准处理？",
    "这条宣传有没有经过医疗广告审查？"
   ],
   "status": "verified",
   "first_year": 2021,
   "last_year": 2026,
   "n_evidence": 3,
   "rev_year": 2026
  },
  {
   "id": "btx-self-injection",
   "layer": "fails",
   "domain": "肉毒素",
   "part": "全身",
   "claim": "肉毒素可以自行购买、在家注射。",
   "plain": "A型肉毒毒素在我国按毒性药品管理，只能由具备资质的医师在医疗机构使用。自行购买来源不明的产品，剂量、稀释和注射层次都无法保证，可能出现眼睑下垂、吞咽困难、过敏甚至中毒；一旦出事，抢救和追溯都很困难。",
   "evidence": [
    {
     "year": 2002,
     "type": "监管文件",
     "grade": "强",
     "label": "《医疗美容服务管理办法》要求医疗美容项目由具备资格的医师在医疗机构实施",
     "ref": "卫生部令第19号 https://www.gov.cn/zhengce/2002-01/22/content_5713757.htm"
    },
    {
     "year": 2008,
     "type": "监管文件",
     "grade": "强",
     "label": "《关于将A型肉毒毒素列入毒性药品管理的通知》要求按毒性药品管理",
     "ref": "国食药监办〔2008〕405号 https://wsjkw.sh.gov.cn/yzgl4/20180815/0012-60884.html"
    },
    {
     "year": 2014,
     "type": "系统综述",
     "grade": "强",
     "label": "系统综述记录肉毒素美容注射的不良事件，包括上睑下垂等",
     "ref": "PMID:24575858"
    },
    {
     "year": 2016,
     "type": "系统综述",
     "grade": "强",
     "label": "Meta分析显示肉毒素面部注射有头痛、眼睑下垂等不良反应",
     "ref": "PMID:27495260"
    },
    {
     "year": 2022,
     "type": "系统综述",
     "grade": "强",
     "label": "综述强调注射者需熟悉局部解剖与药物作用，才能减少严重并发症",
     "ref": "PMID:34341857"
    }
   ],
   "first_year": 2002,
   "last_year": 2022,
   "n_evidence": 5,
   "scope": "任何声称可以邮寄、代购或上门注射肉毒素的渠道，都不符合药品和医疗管理规定。",
   "ask": [
    "这个产品有没有正规的药品批准信息？",
    "注射的人有没有医师资质？",
    "出现吞咽困难或呼吸困难时去哪处理？"
   ],
   "status": "verified",
   "rev_year": 2022
  },
  {
   "id": "btx-overdose-facial-palsy",
   "layer": "fails",
   "domain": "肉毒素",
   "part": "面部",
   "claim": "肉毒素打多了会面瘫，而且不可逆。",
   "plain": "肉毒素的作用是暂时的，药物代谢后神经肌肉接头功能恢复，不会把神经烧坏。面部注射后常见的并发症是上睑下垂、眉下垂和表情不对称，35项临床研究、8787人的安全性综述里这些事件都自行恢复；上睑下垂多在注射后3到14天出现，随药效消退而恢复。面神经麻痹不是美容注射的典型后果，真正的风险来自剂量过大、层次错误或产品来源不明。",
   "evidence": [
    {
     "year": 2004,
     "type": "系统综述",
     "grade": "强",
     "label": "综述梳理肉毒素美容注射的并发症与处理，强调多数反应与注射技术和剂量有关",
     "ref": "PMID:15158548"
    },
    {
     "year": 2014,
     "type": "系统综述",
     "grade": "强",
     "label": "35项临床研究8787人的安全性综述记录上睑下垂2.5%、眉下垂3.1%、眼部感觉异常3%，均自行恢复",
     "ref": "PMID:24575858"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "综述指出肉毒素相关上睑下垂多在注射后3至14天出现，随药效消退自行恢复，可部分用药逆转",
     "ref": "PMID:34378298"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "Cochrane系统综述显示肉毒素疗效平均持续约20周，作用可逆",
     "ref": "PMID:34224576"
    },
    {
     "year": 2022,
     "type": "系统综述",
     "grade": "强",
     "label": "24项研究4268次注射的Meta分析显示总体并发症率16%，多为头痛、局部反应和面部神经肌肉症状，程度轻且短暂",
     "ref": "PMID:35178552"
    }
   ],
   "scope": "剂量过大、颈部或下面部注射、使用来源不明的产品时，吞咽困难和呼吸困难等全身反应风险更高，需要立即处理。",
   "ask": [
    "这次注射的剂量和点位是怎么定的？",
    "如果出现上睑下垂或表情不对称，多久会恢复？",
    "出现吞咽困难或呼吸困难时应该去哪里处理？"
   ],
   "status": "verified",
   "first_year": 2004,
   "last_year": 2022,
   "n_evidence": 5,
   "rev_year": 2022
  },
  {
   "id": "btx-brand-unit-conversion",
   "layer": "fails",
   "domain": "肉毒素",
   "part": "面部",
   "claim": "不同品牌的A型肉毒素单位可以按相同数值直接换算。",
   "plain": "各品牌的单位是各自的效价单位，不是统一的国际单位。检测显示同样标注100单位的产品，实际神经毒素蛋白含量差别明显；临床换算研究给出的两种常用制剂比例在1比2.5到1比3之间，另一种与前者接近1比1。按相同单位数换品牌，可能剂量不足或过量，需要医生按产品、部位和既往反应重新定。",
   "evidence": [
    {
     "year": 2012,
     "type": "队列研究",
     "grade": "中",
     "label": "53人随机半脸对照比较两种A型肉毒素制剂，在所用剂量下疗效无显著差异，提示换品牌要按比例调整",
     "ref": "PMID:22231417"
    },
    {
     "year": 2016,
     "type": "系统综述",
     "grade": "强",
     "label": "综述认为含复合蛋白的制剂与另一种制剂的换算比例约3比1或更低，不含复合蛋白的制剂与前一种约1比1",
     "ref": "PMID:26959061"
    },
    {
     "year": 2016,
     "type": "系统综述",
     "grade": "强",
     "label": "4项随机对照试验的系统综述认为两种制剂的换算比例在1比2.5到1比3之间时安全性和疗效相当",
     "ref": "PMID:27110585"
    },
    {
     "year": 2018,
     "type": "队列研究",
     "grade": "弱",
     "label": "实验室检测显示三种制剂每瓶150kDa神经毒素含量不同，效价单位不可互换",
     "ref": "PMID:30551641"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "综述指出三种A型肉毒素制剂在分子结构、扩散、免疫原性和剂量等效性上均不同，不是同一种药",
     "ref": "PMID:33797747"
    }
   ],
   "scope": "换品牌时还要考虑既往注射史、是否产生抗体和注射部位；有抗体的人换品牌未必能恢复效果，需要医生评估。",
   "ask": [
    "这次换品牌，剂量是按什么比例折算的？",
    "我之前的注射记录需要提供给医生吗？",
    "如果换品牌后效果变差，怎么判断是剂量还是抗体问题？"
   ],
   "status": "verified",
   "first_year": 2012,
   "last_year": 2021,
   "n_evidence": 5,
   "rev_year": 2021
  },
  {
   "id": "btx-all-wrinkle-types",
   "layer": "fails",
   "domain": "肉毒素",
   "part": "面部",
   "claim": "肉毒素能解决所有类型的皱纹，包括已经定型的静态纹和光老化。",
   "plain": "肉毒素放松的是肌肉，对动态纹效果最好；已经定型的静态纹来自真皮胶原流失和光老化，单靠肉毒素改善有限。综述明确，动态纹的改善比静态纹明显，眉间纹、鱼尾纹和额纹的证据最充分；鼻唇沟、木偶纹和面颊松弛通常要联合透明质酸填充剂、光电或能量设备。把肉毒素当万能除皱，容易在静态纹上反复加量，反而增加表情僵硬和上睑下垂的风险。",
   "evidence": [
    {
     "year": 2014,
     "type": "系统综述",
     "grade": "强",
     "label": "综述指出皱纹由真皮萎缩和肌肉反复收缩形成，肉毒素对动态纹的改善明显优于静态纹",
     "ref": "PMID:25077722"
    },
    {
     "year": 2016,
     "type": "共识",
     "grade": "强",
     "label": "国际共识推荐透明质酸填充剂与肉毒素联合用于上面部、中面部和下面部，按解剖与衰老原因分别处理",
     "ref": "PMID:27119917"
    },
    {
     "year": 2021,
     "type": "系统综述",
     "grade": "强",
     "label": "Cochrane系统综述纳入65项随机对照试验，疗效评价集中在眉间纹等皱纹的动态改善",
     "ref": "PMID:34224576"
    },
    {
     "year": 2023,
     "type": "系统综述",
     "grade": "强",
     "label": "综述把肉毒素的适应证写为眉间、额部、眶周、鼻部和口周的动态皱纹，肌肉肥大等属于另外的用途",
     "ref": "PMID:36828397"
    },
    {
     "year": 2025,
     "type": "系统综述",
     "grade": "强",
     "label": "综述讨论生物刺激剂与肉毒素、填充剂和能量设备联合，说明容量与质地问题需要其他手段",
     "ref": "PMID:39719485"
    }
   ],
   "scope": "动态纹、上面部皱纹获益最明确；静态纹、光老化、容量缺失需要联合治疗，单靠增加肉毒素剂量不会解决。",
   "ask": [
    "我脸上的纹哪些是动态纹、哪些是静态纹？",
    "这些静态纹适合填充、光电还是联合治疗？",
    "如果只打肉毒素，预期能改善到什么程度？"
   ],
   "status": "verified",
   "first_year": 2014,
   "last_year": 2025,
   "n_evidence": 5,
   "rev_year": 2025
  },
  {
   "id": "btx-calf-thinning",
   "layer": "fails",
   "domain": "肉毒素",
   "part": "全身",
   "claim": "打肉毒素能瘦小腿，腿围变细以后可以长期保持。",
   "plain": "肉毒素打在小腿腓肠肌上，能让肌肉暂时萎缩、腿围小幅下降，三维CT和超声看到的也是肌肉厚度与围度的变化。但这种缩小幅度有限，研究里6个月最大腿围只降不到1厘米，而且皮下脂肪和比目鱼肌会代偿性增厚，腿型不一定跟着变。效果会随肌肉负荷恢复而消退，需要反复注射；骨骼和脂肪造成的小腿粗，打肉毒素没有用。",
   "evidence": [
    {
     "year": 2018,
     "type": "队列研究",
     "grade": "中",
     "label": "对小腿肥大者注射后用三维CT随访，观察到腓肠肌体积与形态变化",
     "ref": "PMID:29616159"
    },
    {
     "year": 2019,
     "type": "队列研究",
     "grade": "中",
     "label": "27人个体化100至300单位注射，最大腿围3个月降0.33厘米、6个月降0.67厘米，作者认为改善的是轮廓而非缩小体积",
     "ref": "PMID:31555873"
    },
    {
     "year": 2020,
     "type": "系统综述",
     "grade": "强",
     "label": "综述认为小腿肉毒素注射是新兴方法，近期副作用少，但最佳剂量、适应证和长期影响尚未确定",
     "ref": "PMID:31977500"
    },
    {
     "year": 2024,
     "type": "队列研究",
     "grade": "中",
     "label": "34人自身对照研究显示腓肠肌厚度和腿围下降，但皮下脂肪与比目鱼肌出现代偿性增厚，长期可能影响效果",
     "ref": "PMID:38064673"
    },
    {
     "year": 2024,
     "type": "队列研究",
     "grade": "中",
     "label": "50例随访6个月，各脂肪厚度组对腿围改善的满意度都低，提示腿围变化不等于腿型满意",
     "ref": "PMID:37220391"
    }
   ],
   "scope": "肌肉型小腿才可能有效；脂肪型、骨骼型或合并静脉问题的人效果有限。注射后过度行走或运动可能加重代偿和不适。",
   "ask": [
    "我的小腿粗是肌肉、脂肪还是骨骼？",
    "预期腿围能降多少，维持多久？",
    "需要打几次，间隔多久，停打以后会恢复吗？"
   ],
   "status": "verified",
   "first_year": 2018,
   "last_year": 2024,
   "n_evidence": 5,
   "rev_year": 2020
  },
  {
   "id": "btx-three-sessions-permanent",
   "layer": "fails",
   "domain": "肉毒素",
   "part": "咬肌",
   "claim": "打三次瘦脸针就定型，以后不用再打。",
   "plain": "肉毒素的作用是暂时的，药物代谢后神经肌肉接头恢复，肌肉会按咀嚼负荷重新变厚。研究显示效果在几个月后开始回落，长期维持需要按间隔重复注射；也有人因为抗体或注射技术问题越打越不灵，更谈不上定型。",
   "evidence": [
    {
     "year": 2007,
     "type": "队列研究",
     "grade": "弱",
     "label": "小剂量美容注射后出现抗体介导的疗效失效，说明效果并不稳定",
     "ref": "PMID:17278332"
    },
    {
     "year": 2013,
     "type": "系统综述",
     "grade": "强",
     "label": "Cochrane综述未找到高质量随机对照证据支持咬肌注射的长期定型效果",
     "ref": "PMID:24018587"
    },
    {
     "year": 2025,
     "type": "队列研究",
     "grade": "中",
     "label": "随机对照显示6个月时咬肌厚度差异消失，提示效果回落",
     "ref": "PMID:40935351"
    },
    {
     "year": 2026,
     "type": "系统综述",
     "grade": "强",
     "label": "Meta分析认为现有证据不足以确定最佳方案，需要更长随访",
     "ref": "PMID:42379083"
    }
   ],
   "first_year": 2007,
   "last_year": 2026,
   "n_evidence": 4,
   "scope": "少数人因为咀嚼减少、体重下降，回落会慢一些；也有小样本研究报告两三次注射后缩小维持到第四年，但样本小、随访方式不统一，没法当成通例。",
   "ask": [
    "这次效果大概能维持多久？",
    "停打之后体积会回到什么程度？",
    "如果效果变差，是剂量问题还是抗体问题？"
   ],
   "status": "verified",
   "rev_year": 2026
  }
 ]
}